WELCOME TO THE 93rd MEETING OF
THE COUNCIL OF RESEARCH
ADVOCATES.
AS ALWAYS THANK YOU SO MUCH FOR
BEING HERE AND TAKING THE TIME
FROM WHAT I KNOW ARE BUSY DAYS.
YOU GUYS ARE WEARING MANY HATS.
IT'S ALWAYS SO GREAT TO BE IN
PERSON.
WE WORKED HARD TO SEE EVERYONE
TODAY SO THANK YOU.
I THINK WE HAVE A GREAT DAY
AHEAD OF US AND JOINED BY
DR. RATHMELL FOR UPDATES AND
JOINED BY NCI'S NEW DEPUTY
DIRECTOR DR. KIBBE.
WE'LL HAVE UPDATES AND THEN THIS
AFTERNOON TWO MORE SCIENTIFIC
DISCUSSIONS WE'LL HAVE.
WE'LL BE JOINED BY STAFF BY NIH
TO HIGHLIGHT A NEW INITIATIVE
THE NIH ADVANCING EQUITY AND
HEALTH INITIATIVE.
IT'S A LOT OF WORDS AND A
NETWORK AND A PRESENTATION ON
NCI'S PROGRAM.
WE'LL HAVE CANCER RESEARCHERS.
I'LL TURN IT OVER TO ANNIE TO
GET US UNDERWAY.
WE HAVE A YOUM MEMBERS AND
INTRODUCING YOU IN A FEW MINUTES
>> SO WELCOME EVERYBODY.
I ECHO AMY'S EXCITEMENT.
IT'S GREAT WHEN WE'RE IN PERSON
AS COMMITTEE MEMBERS I WANT TO
REMIND YOU MUST ABSENT YOURSELF
DURING SPECIFIC DISCUSSIONS
WILDFIRE YOU'RE PARTICIPATION ON
A PRODUCT, PROGRAM OR OTHER
MATTER WOULD CONSTITUTE A
CONFLICT OF INTEREST OR CREATE
THE APPEARANCE OF ONE.
IT IS INCUMBENT UPON YOU TO
ADVISE THE EXECUTIVE SECRETARY
AND ABSTAIN FROM ANY
PARTICIPATION AND DISCUSSION OR
ACTION REGARDING THAT MATTER.
IN LIGHT OF THE CURRENT POLICIES
GOVERNING CONCEPT OF INTEREST
BASED ON FINANCIAL HOLDINGS OF
SPECIAL GOVERNMENT EMPLOYEES
INCLUDING ALL MEMBERS OF THIS
COMMITTEE WE MUST DEPEND ON YOU
TO VOLUNTARILY ACCEPT YOURSELF
DURING DISCUSSIONS ON MATTERS
THAT CAN CONCEIVABLY IMPACT THE
STATUS OF THOSE HOLDINGS.
WE TRUST YOUR JUDGMENT IN THESE
INSTANCES.
BY LAW A QUORUM IS REQUIRED AND
SIX MUST BE PRESENT TO VOICE
THEIR VOTES.
NEW MEMBERS NOT CURRENT MEMBERS
OF ANOTHER NCI ADVISORY BOARD
ARE NOT VOTING UNTIL THEY HAVE
BEEN CLEARED BY THE NCI ETHICS
PROCESS AND THE OFFICE OF HUMAN
RESOURCES.
MEMBERS OF THE PUBLIC WHO MAY
WISH TO EXPRESS VIEWS DURING
ITEMS DISCUSSED DURING THEY WILL
MEETING MAY WRITE THE EXECUTIVE
SECRETARY WITHIN 10 DAYS AND ANY
WRITTEN COMMENTS WILL BE RECEIVE
CAREFUL CONSIDERATION.
I'M PLEASED WE'RE HERE IN PERSON
AND IT'S MY PLEASURE TO WELCOME
NEW MEMBERS AND I'LL ASK YOU TO
PLEASE TAKE A FEW MOMENTS TO
INTRODUCE YOURSELF.
FIRST WE HAVE KATIE COLEMAN.
I AM A PATIENT AND PATIENT
ADVOCACY I HAVE RARE KIDNEY
CANCER AND EACH I'M HONORED TO
JOIN.
>> WE HAVE AMANDA.
>> I CO-FOUNDED A NONPROFIT AND
WE'RE FOCUSSED LARGELY OR DATA
SHARING AND INFRASTRUCTURE TO BE
ABLE TO COLLABORATE AND WE LOOK
AT CANCERS AND RARE DISEASES AND
I CAME INTO THIS AREA.
>> ONLINE WE HAVE ANDREE A
>> I'M ANDREA HUTTON I'VE BEEN
LIVING WITH METASTATIC BREAST
CANCER SINCE 2009.
AND IN WRITING A BOOK ON MY
EXPERIENCE I BECAME AWARE AND
INTERESTED IN ALL THE ADVOCACY
OPPORTUNITIES.
I'M A BOARD MEMBER WITH THE
METASTATIC BREAST CANCER
ALLIANCE AND HAVE BEEN DELIGHTED
TO WORK WITH DOD AND DO OTHER
RESEARCH GRANTS WITH THE
PROJECTS AND EXCITED TO BE HERE
THOUGH I'M NOT THERE I LOOK
FORWARD TO MEETING YOU ALL AT
ANOTHER TIME.
>> WE'RE SO DELIGHTED YOU COULD
JOIN VIRTUALLY AND LOOK FORWARD
TO MEETING YOU IN PERSON NEXT
TIME.
THANK YOU FOR JOINING.
>> AND I WILL BE NEXT UP IS OUR
DIRECTOR'S UPDATE.
BEFORE WE DO THAT I WANT TO
REMIND YOU WHEN SPEAKING TURN ON
YOUR MIKE AND BRING IT CLOSE TO
YOU SO WE CAN HEAR YOU AND THE
MINUTES CAN BE RECORDED IN THE
PACKETS ARE THE BIOS FROM MANY
SPEAKERS.
WE'LL GET A CONDENSED FORM BUT
ENCOURAGE YOU TO READ FURTHER ON
THE GREAT SPEAKERS WE HAVE
TODAY.
WOW, WE'RE AHEAD OF SCHEDULE.
THIS IS GREAT.
SO NEXT UP I AM ALWAYS SO HAPPY
TO HAVE DR. RATHMELL HERE TO
GIVE US HER DIRECTOR'S UPDATE.
AS YOU KNOW SHE HAS BEEN
DIRECTOR OF NCI NINE MONTHS.
IT'S LIKE THE BABY.
SO A LOT HAS HAPPENED AND WE'RE
VERY EXCITED ABOUT HOW TO ENGAGE
ADVOCATES AND I'LL TURN IT OVER
TO HER.
>> GREAT.
SO IT'S REALLY GOOD TO BE HERE
AND I ECHO I'M GLAD TO DO THUS
THIS IN PERSON.
IT MEANS MORE TO HAVE THE FACE
TO FACE INTERACTIONS AND LOOK
FORWARD TO HEARING MORE ON THE
TOPICS WE'LL RUN THROUGH TODAY.
MY DIRECTOR'S REPORT WILL START
WITH WHAT WE COVERED, THREE NEW
MEMBERS AND I HEARD AMANDA'S
WRITING A BOOK?
NO, ANDREA.
SO A PLUG FOR KATIE COLEMAN'S
BOOK IS LAUNCHING -- COMING IN
NOVEMBER.
SO WELCOME WE REALLY VALUE YOUR
VOICES AND APPRECIATE YOU'RE
HERE SO I WOULD SAY TO NEW
MEMBERS, DON'T HESITATE TO ASK
QUESTIONS.
EVERYTHING IS FAIR GAME.
THERE ARE NO QUESTIONS THAT IF
YOU'RE WONDERING, SOMEONE ELSE
IS WONDERING TOO.
ALL RIGHT.
I CAN TALK MORE ABOUT THE NEW
MEMBERS.
KNOWN OF THE THING I KNOW HOW TO
DO ARE MAKING IT GO.
EXCEPT FOR THAT.
OKAY.
MAGIC.
THIS IS THE OUTLINE OF THE TALK
TODAY.
WE JUST MET LAST SUMMER BUT
THERE'S BEEN A LOT OF ACTIVITY.
THE SUMMER WAS REALLY BUSY.
I HAD RECENT NEWS AND UPDATES.
WE LIKE TO TALK ABOUT BUDGET
HERE.
THAT'S ONE OF THE MAJOR TOPICS
OF CONVERSATION IS WHERE WE'RE
GOING WITH BUCKET AND I'M GOING
TO TALK MOSTLY ABOUT THE BYPASS
BUDGET.
THE BUDGET WE GIVE TO THE
PRESIDENT TO SAY WHAT IT IS WE
NEED AS AN ORGANIZATION.
WE'LL TALK ABOUT RESEARCH AND
PROGRAM HIGHLIGHTS AND I WANT TO
SAVE TIME FOR DISCUSSION.
SO FIRST OF ALL, WHAT DID WE DO
THIS SUMMER IN TERMS OF BUSY
SUMMERTIME.
THERE WAS A LOT OF DIFFERENT
VISITS.
AS YOU HEARD NINE MONTHS IN I'M
STILL GETTING TO KNOW THE PLACE
AND THE PLACE IS NOT BETHESDA
AND SHADY GROVE BUT CANCER
RESEARCH ALL OVER THE UNITED
STATES.
THERE WERE A FAIR NUMBER OF
VISITS.
I'M TRYING TO PRIORITIZE.
ONE GETTING TO KNOW THE CANCER
CENTER NETWORK, ALSO GETTING TO
KNOW THE NEEDS OF DIFFERENT
PARTS OF THE LANDSCAPE OF THE
UNITED STATES AND PRIORITIZING
INTERACTS WITH TRAINEES.
TO ME THAT'S A VERY IMPORTANT
PART AND ALSO OUR COMMUNITY
ACCESS PROGRAM SO THE NCORP IS
THE FLAGSHIP AND A NETWORK OF
MANY COMMUNITY ONCOLOGY PROGRAMS
THAT REACHES OVER 2,000 SITES TO
TAKE CLINICAL TRIALS INTO
COMMUNITY AREAS.
SO I WENT TO KANSAS.
I HAD AN AMAZING VISIT TO THE
KANSAS CANCER CENTER AND SHOWN
THE DIRECTOR ON THE LEFT AND THE
GROUP DO INTENSIVE WORK AROUND
DRUG DEVELOPMENT TO PATIENTS AND
HAVE AN NCORP SITES IN THE
MIDWEST.
A FEDERATED SYSTEM THAT IS
REMARKABLE AND VERY IMPRESSIVE.
I ALSO VISITED AN NCORP SITE IN
NEW YORK.
COMPLETELY DIFFERENT OF ISSUES.
THOUGH THE GEOGRAPHY IS SMALL.
THIS WAS IN THE BRONX DEALING
WITH DOZENS OF LANGUAGES.
PEOPLE THAT HAVE COME FROM A
DIFFERENT COUNTRY PEOPLE WITH
DIFFERENT VALUES AND NORMS.
THE HEALTH CARE SYSTEM IS
COMPLICATED FOR EVERYBODY BUT
UNDERSTAND IF YOU DON'T
UNDERSTAND THE RULES AND
LANGUAGE?
THAT ADDED LEVEL OF COMPLICATION
FACTORS INTO THE DECISIONS THEY
MAKE AND YET THEY HAD A RECORD
NUMBER OF CLINICAL TRIALS AND
PILOTING LARGE NUMBER OF
INNOVATION TO REACH THE PATIENTS
THEY SERVE.
AND MEETING TRAINEES.
I DID THAT AT KANSAS I'LL PLUG
COUNCIL ONE MORE SECOND.
SENATOR MORAN INVITED US AND
HIGHLIGHTED HOW MUCH OUR
LEGISLATORS ARE REALLY INVESTED
IN THE CANCER RESEARCH THAT
HAPPENS IN THE UNITED STATES AND
IN THEIR COMMUNITY WE INVITED
HIM TO MEET WITH STUDENTS.
I WANT TO SPEND AN UNSTRUCTURED
HOUR WITH POSTDOCTORAL TRAINEES
AND HE JOINED AND GOT TO HEAR
WHAT THEIR ANXIETIES ARE AND
WHAT THEY'RE EXCITED ABOUT AND
THEIR RESEARCH.
IT WAS INCREDIBLE.
REALLY VALUABLE.
I WENT TO THE UNIVERSITY OF
CHICAGO AND THEIR CANCER CENTER
SERVES THE SOUTH SIDE AND A
DIFFERENT SET OF EXPERTISE.
THEY INVITED ME FOR A TRAINING
DAY AND HIGHLIGHTED TRAINING
PROGRAMS AND WERE JOINED BY
SENATOR DURBIN ALSO A MAJOR
ADVOCATE AND I WILL SAY THAT THE
KINDS OF INNOVATION HAPPENING IN
TRAINING ARE AMAZING.
I'M GOING TO HIGHLIGHT A PROGRAM
NOT CURRENTLY FUNDED BY THE NCI.
THEY'RE PARTNERS WITH LOCAL
COMMUNITY COLLEGES RECOGNIZING
THE WORKFORCE FOR CLINICAL
TRIALS IS ACTUALLY WAY TOO
SMALL.
THIS IS A NATIONWIDE PROBLEM WE
DON'T HAVE ENOUGH SKILLED
INDIVIDUALS WHO WANT TO GO INTO
THE WORK OF DOING CLINICAL
TRIALS.
PEOPLE WHO DO SCREENING, DATA
COLLECTION, INFORMING PATIENTS
ABOUT SIDE EFFECTS AND RISKS.
THEY'RE PARTNER WITH PEOPLE
GETTING ASSOCIATES DEGREES AND
THEY WERE FANTASTIC.
THESE KINDS OF HIGHLIGHTS SHOW
WHAT'S GOING ON IN THE CANCER
CENTER WORLD.
IN ADDITION TO PROGRAMS WE
SUPPORT AND FOR MIDDLE AND HIGH
SCHOOL AND GRADUATE AND
POSTDOCTORAL STUDENTS AND
CLINICAL TRAINING.
I WENT TO A NATIONAL CONFERENCE.
PEOPLE PURSUING COMBINED DEGREES
LIVING AT THE INTERSECTION
BETWEEN BASIC SCIENCE AND
CLINICAL MEDICINE HIGHLIGHT THE
REAL POWER IN PUTTING THOSE
THINGS TOGETHER AND THAT'S HOW
WE GET THE TRANSLATION OF BASIC
DISCOVERY AND MET STUDENTS WITH
INDIANA AND FROM ALL OVER THE
COUNTRY.
REALLY ENER GETTIC AND EXCITED
ABOUT THE FUTURE GOOD ENERGETIC
AND CANCER RESEARCH IS WHERE
THEY GO.
I ALSO SPENT TIME GETTING TO
KNOW OUR COLLABORATIONS.
WE HAVE A COLLABORATION WITH THE
W.H.O.
THEY CAME DO RE-ESTABLISH THE
CENTER AND MET WITH HOME TO AND
OUR CENTER FOR GLOBAL HEALTH.
WE ALSO WE'RE A PART OF THE
QUAD.
I DON'T KNOW IF YOU'RE FAMILIAR
WITH THE QUAD INITIATIVE.
THIS IS A COLLABORATION OF THE
UNITED STATES, JAPAN, INDIA AND
AUSTRALIA TO TAKE ON THE HARDEST
PROBLEMS.
CANCER FITS INTO THOSE PROBLEMS.
THOSE ARE THEE COUNTRIES I'VE
BEEN REALLY WORKING HARD TO
DEVELOP THE RELATIONSHIP WITH WE
MET WITH THE U.S. AMBASSADOR TO
AUSTRALIA AND ALSO WITH THE
AUSTRALIAN AMBASSADOR AND MY
COUNTERPART WITH THE STRUCTURE
IN AUSTRALIA AND THE PICTURE
THERE ON THE RIGHT AND ALSO WITH
JAPAN.
THE PICTURE ON THE BOTTOM RIGHT
IS WHEN THE NATIONAL CANCER
CENTER MEMBERS WERE DOING A TOUR
OF THE UNITED STATES AND VISITED
WITH US AND WE GOT TO TALK ABOUT
WHERE OUR PRIORITIES ARE.
A LOT OF INTEREST IN CANCER
GENOMICS TO SHARE EXPERTISE IN.
THEN THEY INVITED ME TO THEIR
AMBASSADOR AND BLEND MY
INTERESTS.
THEY HAVE AN ANNUAL EVENT TO
BRING TRAINEES FROM JAPAN WHO
ARE TRAINING IN BIO MEDICAL
SCIENCE IN THE UNITED STATES
TOGETHER TO TALK ABOUT THE
ISSUES AND HOW THEY'RE
SUPPORTED.
THEY WERE ALL TOGETHER AT THE
JAPANESE EMBASSY AND IT WAS A
FANTASTIC MENTORSHIP
INTERACTION.
SO THAT IS WHAT I DID THIS
SUMMER.
'FEW OTHER THINGS INTERACTIONS
WITH THE WHITE HOUSE HAVE BEEN
BUSY.
THE OFFICE OF MANAGEMENT AND
BUDGET IS PEOPLE WHO WRITE THE
BUDGET SO WE REALLY WANT TO HAVE
A GOOD RELATIONSHIP AND GET TO
KNOW THEM.
WE GOT TO MEET WITH THEIR
EXAMINERS WHEN THEY CAME TO THE
NIH AND TALK ABOUT WHAT THE
MOONSHOT PROJECTS WERE.
THE INTEREST THERE WAS PIQUED SO
WE BROUGHT THEM BACK LATER TO
VISIT OUR FREDERICK NATIONAL LAB
AND SEE THE AMAZING WORK
HAPPENING THERE SO THEY HAVE A
VISUAL ON ABOUT WHAT IT IS WE'RE
DOING IN THE CANCER RESEARCH
ARENA.
WE ALSO WORK WITH HHS.
SO WITH THE HHS SECRETARY AND
WITH THE DEPUTY CIRCUMSTANCED.
I MEET WITH HER TO UPDATE HER ON
ALL THE S WE HAVE ONGOING AND
BROUGHT UP AGAIN THE FREDERICK
NATIONAL LABORATORY.
SOMETHING WE SHOULD PROBABLY
TALK A LITTLE BIT MORE AND MAKE
SURE YOU'RE UP TO SPEED ON WITH
THIS AMAZING FEDERALLY FUNDED
RESEARCH CENTER CAN DO.
WE BROUGHT HER IN AND DID A
WHOLE OVERVIEW OF WHAT THE
FREDERICK NATIONAL LABORATORIES
CAN DO AS WELL SHOWCASING WHAT
WE DO TAKING BASING SCIENCE
DISCOVERY TO PATIENT CARE.
IT WAS AN EYE OPENING EXPERIENCE
AND TO ALLOW THOSE
COMMUNICATIONS TO BE MORE CLEAR.
I THINK I TOLD YOU WE WERE
PLANNING AN ANNUAL RETREAT AND
DECIDED TO MIX IT UP A LITTLE
BIT.
WE BROUGHT TOGETHER OUR SENIOR
LEADERS AS WELL THE CHAIRS OF
OUR BOARDS.
SO ANNIE WAS THERE WITH A GOOD
OPPORTUNITY TO THINK ABOUT WHERE
CAN THE NCI WORK TOGETHER TO
MOVE SOME THINGS FORWARD AND WE
DID SOME PREPRE WORK AND SPENT
TIME WRESTLING WITH THINGS THAT
ARE ALREADY MOVING WELL VERSUS
THINGS THAT REALLY NEED A PUSH
BECAUSE WE CAN'T DO EVERYTHING
BUT WE CAN DO SOME THINGS REALLY
WELL IF WE'RE ALL COORDINATED.
WE LANDED ON A BUNCH OF
DIFFERENT TOPICS.
I WILL SAY AT ONE POINT IN THE
DAY, THE FOCUS WAS ENTIRELY ON
REBUILDING TRUST AND
COMMUNICATION AND REACHING OUT
TO COMMUNITY.
I HAVE A WORKING GROUP THAT IS
TACKLING THAT RIGHT NOW SO WE
CAN MOVE FORWARD ON WHAT IT IS
THAT IS SOME OF THAT BAUER
BARRIER AND HOW DO WE OVERCOME
DISINFORMATION OR DISBELIEF IN
WHAT SCIENCE DOES?
IT'S HARD FOR US, I WILL SAY.
PEOPLE GO INTO SCIENCE BECAUSE
THAT'S OUR STRUCTURED TRUTH.
WE SEARCH FOR TRUTH BY COMPARING
KNOWN AND UNKNOWN AND MAKING
THOSE KINDS OF INVESTMENTS.
WHEN IT'S NOT BEEN BELIEVED THAT
MAKES US WE'RE NOT COMMUNICATING
WELL.
WE'RE NOT EXPRESSING WHAT IT IS
AND THE SCIENCE BRINGS TO THE
TABLE AND WHERE IT HAS
LIMITATIONS AND WHERE IT'S
SOMETHING PEOPLE SHOULD
UNDERSTAND.
SORRY, THAT WAS AN INTERESTING
DIVERGENCE IN THE DAY.
I ALSO WANT TO PLUG HAVING
ADVOCATES IN THE ROOM.
WE HAD TWO ASKING US QUESTIONS
AND HELPING GUIDE THE
DISCUSSION.
WE HAD A LOT OF TOPIC.
I'LL HAVE MORE SPECIFIC
ANNOUNCEMENTS LATER IN THE FALL
ABOUT THINGS WE'RE DOING.
EARLY ONSET CANCERS GOT A LOT OF
ATTENTION AND IS A MAJOR AREA
THAT IS ALSO BEING UNMET.
THERE'S THINGS HAPPENING.
THEY'RE HAPPENING IN ALL KINDS
OF AREAS AND EVERYBODY'S WORKING
ON THEIR OWN AND COULD WE BRING
THEM A LITTLE BIT CLOSER
TOGETHER AND ALSO IN AREAS OF
OBESITY AND CANCER, IMMUNOLOGY,
THE NEED FOR VACCINES FOR MORE
CANCERS AND ARTIFICIAL
INTELLIGENCE.
ALL THESE TOPICS ROSE TO THE
TOP.
SO WE'LL BE KIND OF COALESCES
SOME OF OUR BIGGER EFFORTS
AROUND THESE AREAS.
I WANT TO HIGHLIGHT SENIOR
LEADERSHIP UPDATE.
THE ONE MOST RELEVANT TO THIS
GROUP IS PETER GARRETT.
HE WAS JUST SWORN IN A COUPLE
WEEKS AGO AS DIRECTOR FOR THE
NEW CENTER FOR EXTERNAL AFFAIRS.
THIS IS A RE-ORGANIZATION THAT
STARTED UNDER DR. BERTAGNOLLI
AND THE GOAL IS TO REALLY BRING
TOGETHER ALL OF THE POWER WE
HAVE AROUND ADVOCACY,
COMMUNICATIONS AND MEDIA
RELATIONS AND OUR WORK IN
LEGISLATIVE BRANCHS.
NOT AT ALL TO UPSET THE IDENTITY
OR ECONOMY OF THE GROUPS BUT TO
ELEVATE.
SO HE WILL BE COMING AND MEETING
WITH YOU IN THE FUTURE.
WE WEREN'T SURE WHEN HE'D GET
SWORN IN.
IT SORT OF HAPPENS AND THEN YOU
GET SWORN IN AND SO IT HAPPENED
A COUPLE WEEKS AGO.
I'M REALLY EXCITED ABOUT NOT
HAVING AN ADVOCACY GROUP THAT
KIND OF IS IN THE CORNER AND WE
TAKE NOTES AND WORK WITH THAT
BUT HAVING YOU ALL AT THE TABLE
AND REALLY PUSHING ALONG WITH
WHAT WE SAY IN OUR
COMMUNICATIONS AND WHAT WE DO
WITH OUR LEGISLATIVE GROUP AND
THE PROACTIVE WORK THAT WE CAN
ALL DO TOGETHER.
THAT'S HIS NEW ROLE.
AMBER LOWRY WAS OUR ACTING
DEPUTY DIRECTOR FOR MANAGEMENT
AND OFFICER.
ALSO JUST SWORN IN A COUPLE
WEEKS AGO.
WE'RE EXCITED TO HAVE HER
PERMANENTLY ON BOARD.
WE HAVE A NEW DEPUTY FOR DATA
SCIENCE AND STRATEGY.
SO WARREN KIBBE WAS HERE FOR A
LONG TIME BEFORE AS A DIRECTOR.
HE WAS AN ACTING DEPUTY BEFORE
HE WAS RECRUITED TO ACADEMIA AND
SPENT ABOUT 10 YEARS AND BROUGHT
HIM BACK TO A DEPUTY LEVEL ROLE
AND YOU'LL HEAR FROM HIM TO HEAR
WHERE DATA SCIENCE IS.
I ALSO ENCOURAGE YOU TO ALWAYS
FOLLOW OUR CANCER DATA SCIENCE
PULSE LOG TO KNOW WHERE WE ARE.
THERE'S SOMETHING NEW IN DATA
SCIENCE LITERALLY EVERY DAY.
I DON'T HAVE A MEETING SO IT
DOESN'T SAY AND WHAT ABOUT A.I.
AND WHERE CAN A.I. HELP US OR
WHAT CAN WE DO WITH DIFFERENT
SOURCES.
HAVING SOMEBODY WHO KNOWS THE
DATA SCIENCE WORLD AT THESE
TABLES IS -- I CAN'T TELL YOU
HOW GOOD IT'S BEEN THAT WARREN
IS IN THE ROOM WITH US.
LOOKING FORWARD TO HEARING FROM
HIM LATER TODAY.
FUN PART, BUDGET.
THE ANNUAL PLAN JUST PUBLISHED
LAST WEEK SO TOES FRESH AND OUT
ON THE WEBSITE.
I DO ENCOURAGE YOU AND TOOK
EFFORT INTO HOW DO WE TELL THE
WHITE HOUSE AND THE PUBLIC WHAT
IT IS WE'RE DOING AND WHAT WE
NEED TO BE ABLE TO BE SUCCESSFUL
IN A VERY CONCISE FORMAT.
I LOVE CONCISE OVER LONG BUT WE
DO IT IN DIFFERENT WAYS.
WE TELL STORIES AND HAVE TABLES
AN DATA AND THEN ASUNE A SET OF
PRIORITIES.
THE STORIES HIGHLIGHT THE
IMPORTANT INITIATIVES GOING ON.
WE CAN TELL 1,000 DIFFERENT
STORIES BUT THESE STORIES I
THINK SPEAK TO WHAT IT IS WE'RE
HERE TO DO.
THE FIRST IS A STORY ABOUT A MAN
NAME JUSTIN WHO HAD
NON-HODGKIN'S LYMPHOMA AND CAME
TO THE NCI TO RESOURCE A VERY
NEW THERAPEUTIC REGIMENT AND
THAT WAS THREE YEARS AGO.
AND HE'S NOW DISEASE FREE AND
WORKS IN THE WILDLIFE AREA AND
IS A FORESTER AND THIS IS WHAT
WE WANT.
IT'S A SUCCESS STORY THAT WE'RE
LOOKING FOR WHICH IS NOW
LAUNCHED A BIGGER TRIAL.
THIS CAN BE MORE AVAILABLE AND
IN A WIDER VARIETY OF
APPRECIATES SO WE KNOW WHO WILL
RESPOND AND WHEN DO WE USE IT
APPROPRIATELY.
THIS IS THE BREAD AND BUTTER AND
WHAT PEOPLE THINK OF WHEN THEY
THINK OF CANCER RESEARCH.
UNDERSTANDING THE BIOLOGY OF THE
TUMOR, DEVELOPING A NOVEL
THERAPEUTIC AND GIVING IT TO A
PATIENT TO GET BETTER.
DONE.
WE DO A LOT OF OTHER THINGS DO
-- TOO.
WE WANTED TO HIGHLIGHT A
TRAINEE.
THERE'S A THOUSAND STORIES OF
TRAINEES AND SUCCESSES AND THE
WAY THE TRAINING THEY GET UP
DIFFERENT WAYS.
WE HIGHLIGHT A STORY OF AN IN
OUR MOONSHOT SCHOLAR PROGRAM.
SO THAT'S A WHITE HOUSE
CO-FUNDED INITIATIVE TO BRING
MORE PEOPLE FROM DIVERSE
BACKGROUNDS INTO THE RESEARCH
FUNDED POOLS.
SHE HAS AN EXCITING STORY.
SHE'S VERY SUCCESSFULLY TAKING
HOW WE DO PRE CANCER TREATMENT
IN RESEARCH SETTINGS AND IT'S A
COMBINATION OF BIOLOGY ALONG
WITH OUTREACH AND COMMUNITY
ENGAGEMENT.
A NICE PROJECT.
SHE HIGHLIGHTS HOW THAT TRAINING
HELPS MAKE HER MORE SUCCESSFUL
IN HER SPACE.
AND THEN WE WANTED TO DO GOOD
SCIENCE.
SCIENCE THAT HIGHLIGHTS THE
TRANSLATIONAL IMPACT YOU CAN
BRING TOGETHER AND TELL THE
STORY ABOUT A NEW TOOL THAT
ALLOWS A SURGEON TO TREAT TUMORS
WITH LIGHT UNSURGERY.
THE MORE WE CAN MAKE SURGEONS
MORE CAPABLE OF DOING SURGERY,
BETTER OUTCOMES FOR PATIENTS.
IT'S BETTER SURGERIES AND BETTER
UNDERSTANDING WHERE THE TUMORS
ARE AT THE TIME THE SURGEONS ARE
GOING IN.
WE DON'T WANT THEM GOING IN
BLIND.
THIS IS LATE STAGE MEDICINE.
TUMORS GLOW AND YOU CAN SEE IT
SO REALLY EXCITING WORK.
SO WHAT DOES IT TAKE TO DO THIS
WORK?
IT TAKES REAL MONEY.
SO OUR CURRENT APPROPRIATION FOR
FY24 WAS $7.2 BILLION WHICH
SOUNDS LIKE A LOT OF MONEY.
TO OUT IT IN PERSPECTIVE, I
THINK THERE WERE FIVE BIO TECH
COMPANIES THAT WERE BOUGHT FOR
MORE THAN $7 BILLION LAST YEAR.
WHEN YOU THINK ABOUT WE FUND ALL
THE CANCER CENTERS, ALL THESE
TRAINEES ALL AROUND THE COUNTRY,
CLINICAL TRIALS IN OVER 2,000
SITES, ALL OF OUR INTRAMURAL
PROGRAMS.
ALL THE INFRASTRUCTURE WORK AND
WE DO THAT FOR $7 BILLION.
IT'S THE BEST INVESTMENT THE
GOVERNMENT MADE, 100%.
IT GROWS OUR ECONOMY, IT CREATES
A SKILLED WORKFORCE AND MAKES
PEOPLE HEALTHY.
IT'S A NO-BRAINER EXCEPT THEY
KEEP WANTING TO GIVE US JUST A
FEW MORE PENNIES EVERY YEAR.
WE CAN'T DO IT FOR THE SAME
AMOUNT.
INFLATION INCREASES OUR COSTS.
PEOPLE'S SALARIES GO UP.
WE CAN'T DOING THE WORK WITHOUT
A BIG INFUSION.
IN NY25, PRESIDENT BIDEN
PROPOSED A BUDGET OF ALMOST $9.3
BILLION.
OUR FY25 PROPOSED A FURTHER
INCREASE OF $2.1 BILLION FOR A
GRANT TOLD OF $11.5 BILLION
ROUNDING UP.
THAT IS WHAT WAS PUT IN LAST
YEAR FOR THE YEAR STARTING
OCTOBER 1.
IT'S WE DON'T KNOW WHAT WE'RE
DOING TO GET FOR FY25.
YOU CAN WATCH THE NEWS AND TRY
TO GUESS.
I DON'T KNOW WHEN WE'LL KNOW.
WE PROBABLY WON'T KNOW NEXT WEEK
IS MY GUESS.
SO WE'VE HAD TO SAY WHAT DO WE
THINK WE'LL NEED FOR FY26?
YOU CAN SEE THE GAP GETTING
BIGGER AND BIGGER AND PUT IN
$11,466 AND WE'RE DOING A LOT TO
STREAMLINING, BEING EFFICIENT,
RUNNING A BUSINESS THE WAY WE'D
EXPECT BUT IT'S GOING TO BE DARN
HARD TO DO ON 7.2.
OUR REQUEST WAS FOR 11.46.
WE'LL SEE WHAT HAPPENS.
WHEN YOU TELL THE WORLD WHAT
WOULD WE DO IF WE HAD MORE.
SO FIRST SOME OF OUR PROJECTS
LIVE ON SHOE STRINGS AND WE WANT
TO DO CLINICAL TRIALS ON A
BROADER PART OF THE COUNTRY AND
WE HAVE STUDIES DO AND WE HAVE
TO TACKLE THE EMERGENCE OF EARLY
ONSET CANCER.
THAT'S A NEW AREA.
THIS IS CANCERS BETWEEN THE AGES
OF 20 AND 50.
WHAT DO WE DOUGH IN THE FOLLOW
UP PERIOD WHEN SOMEONE GETS
CANCERS IN THEIR 30s.
IT AFFECT THE WHOLE BODY.
HISTORICALLY THAT'S BEEN TOO
HARD.
YOU CAN ONLY STUDY THE CANCER
CELLS OR IMMUNE CELLS OR BLOOD
VESSELS THEY MAY BE TRACKING
THROUGH.
NOW WE HAVE THE ABILITY TO BE
ABLE TO LOOK AT THEM ALL IN
AGGREGATE AND UNDERSTAND HOW
THINGS ARE AFFECTED BY THE
NERVOUS SYSTEM AND DIGESTIVE
SYSTEM AND BIOMEDICAL.
AND WHAT CACHES AS THEY GET.
AND WHAT HAPPENS IF PATIENTS
CAN'T AFFORD TO GET THE THERAPY
THEY NEED.
THIS IS HEALTH POLICY WORK
RESEARCH.
WE STUDY AND ABOUT WHAT ARE THE
S TO DRIVE FINANCIAL TOXICITY?
WHERE ARE THERE OPPORTUNITIES
THAT CAN ALLEVIATE AND BRING
CANCER TREATMENTS IN WAYS THAT
ARE AFFORDABLE TO A DIFFERENT
GROUP OF PATIENTS.
SO WE'RE INVESTING IN DOING THAT
KIND OF RESEARCH SO IT CAN HELP
INFORM POLICY.
AND EXPANDING THE UTILITY OF
CANCER TARGETING VACCINES.
THIS IS ON THE LIST BECAUSE
WE'VE SEEN WITH HPV WHAT WE CCA
DO TO PREVENT AND ENHANCE
IMMUNOTHERAPIES AND TREATING
CANCERS.
RIGHT NOW WE HAVE THERAPIES AND
INFILTRATING LYMPHOCYTES AND THE
NEXT WAVE WILL BE IN THE
VACCINES.
AND WE GOT $7.3 MILLION AND
THERE WAS A CUT THIS YEAR TO
7.2.
READING THE NEWS IT'S AN
INCREASE IN THE BASE $120
MILLION INCREASE IN THE BASE BUT
THE CARES ACT FUNDING THAT
FUNDED THE MOONSHOT WENT DOWN BY
MORE THAN THAT SO IT'S
EFFECTIVELY A $96 MILLION
DECREASE FOR OUR BUDGET SO
THAT'S WHAT WE'RE WORKING WITH
TODAY.
YOU CAN SEE ON THE LEFT WHAT THE
PROPOSED PROFESSIONAL JUDGMENT
FOR BYPASS BUDGET NUMBERS ARE.
IN FY23 WE GOT 7.9 AND THEN WE
GOT 7.2 AND WE PROPOSED 11.4.
THIS IS THE GAP I'M TALKING
ABOUT.
HERE'S WHERE WE ARE PROPOSING
11.4 AND WAITING TO SEE WHAT
HAPPENS FOR '25 AND '26.
WITH THE MONEY WE HAVE WE HAVE
THE ABILITY TO MAKE DECISIONS
AND PRIORITIZE WHERE WE CAN'T
FUND EVERYBODY.
OUR PRIORITY IS EARLY STAGE
INVESTIGATORS MAKING SURE WE'RE
KEEPING THEM IN THE PIPELINE.
THIS IS A FIVE-YEAR BUMP AND THE
PAY LINE IS 10% OF GRANTS GET
FUNDED THAT WOULD BE 16
PERCENTILE IF YOU'RE AN EARLY
STAGE INVESTIGATOR.
LAST YEAR THE PAY LINE WAS 12%
WITH A 17% BUMP.
WE DECIDED WE DIDN'T WANT TO
HURT THE EARLY STAGE
INVESTIGATORS AND KEPT THEM AT
17 THOUGH FOR ESTABLISHED
INVESTIGATORS WE DROPPED IT TO
10.
TEN IS SORT OF AVERAGE SO I
COULD SLEEP AT LEAST AT NIGHT
AND SORT OF WHAT THEY MAY BE
USED TO AND I WAS ONE OF THEM.
10 IS HARD BUT IS A NUMBER YOU
UNDERSTAND.
9 AND 8 ARE NOT.
PEOPLE DROP OUT AT 9 AND 8.
FUNDING AT 17 FOR THE EARLY
STAGE INVESTIGATORS WERE
WELCOMING THEM AND GIVING THEM
THE FIRST CHANCE.
THE DOT WITH THE 19 WHICH COULD
BE HIGHER, ANYWAY, NOT QUITE TO
SCALE THERE SHOWS THE PAY LINE
IT DOESN'T MATTER IF YOU'RE
BETTER IT WILL BE FUNDED AND WE
HAVE THE ABILITY TO PULL GRANTS
AFTERWARDS THIS TIME OF YEAR
MORE DOLLARS COME IN FROM GRANTS
UNDER SPENT AND WE'RE PROJECTING
TO 19% FOR THE EARLY STAGE
INVESTIGATORS.
I'M GLAD TO HAVE A NUMBER LIKE
THAT.
WE HAD A DEEP DIVE INTO OUR
BUDGET WITH OUR FINANCIAL
OFFICER AND THIS IS AVAILABLE
ONLINE AND IT'S ENTERTAINING
BUDGET AND REALLY INFORMATIVE.
BUT ANYTIME YOU WANT TO LOOK WE
WANT TO MAKE THE INFORMATION
AVAILABLE.
OKAY.
I WANT TO SAY A COUPLE THINGS
ABOUT THE NATIONAL CANCER PLAN
WE TALKED ABOUT THIS BUT I'M
CONSIDERING BRINGING THE
NATIONAL CANCER PLAN BACK ON TOP
OF EVERYONE'S MIND.
WE USED A PLAN TO COORDINATE OUR
EFFORTS ACROSS THE HEALTH CENTER
GOALS, PREVENT CANCERS, DEVELOP
EFFECTIVE THERAPIES AND DELIVER
OPTIMAL CARE AND ACCELERATING
THOSE, MAXIMIZING DATA UTILITY
AND ELIMINATING INEQUITY AND
CREATE WORKFORCE READY TO GO AND
ENGAGING EVERY PERSON AND USING
DISCOVERY SCIENCE TO FUEL THE
WAY FORWARD.
SO RIGHT NOW FOR THE NEXT THREE
MONTHS SEPTEMBER, OCTOBER,
NOVEMBER WE'RE HIGHLIGHTING ONE
GOAL AND THE GOAL WE'RE
OPTIMIZING IS I'D ENCOURAGE YOU
TO LOOK AT THE SOCIAL MEDIA AND
LINKEDIN AND LOOK AT EARLY STAGE
INVESTIGATORS OR WORKFORCE
DEVELOPMENT IS A FOCUS AREA FOR
US.
AND IT'S GOOD TIMES.
WHAT WE DO TO PRIORITIZE THE
WORKFORCE SO JUST A FEW
EXAMPLES.
WE JUST PUBLISHED A CANCER BLOG.
I ENCOURAGE TO FOLLOW IT.
IT'S UP TO DATE AND WELL DONE
AND KIND OF HIGH LEVEL BUT GOOD
FOR A BOARD TO KNOW ALL THE
THINGS WE DO.
THIS IS HIGHLIGHTING A UNIQUE
GRANT PROGRAM CALLED THE R16 AND
THEY'RE MORE UP AND COMING IN
THEIR RESEARCH AND PROVIDE AN
R01 FUNDING FOR INVESTIGATORS
WITH THE STIPULATION PART OF
THAT MONEY IS MEANT FOR TRAINING
AND DEVELOP UNDERGRADUATES IN
THE SCIENCE FIELD.
SO WE HAD A RETREAT AND TO THE
R15 INVESTIGATORS AND THE WORK
THEY'RE DOING WITH
UNDERGRADUATES IS FEN NOMMAL.
PHENOMENAL AND SO WE TALKED TO
OTHER GROUPS THAT MIGHT WANT TO
SORT US AND THE AMERICAN CANCER
SOCIETY STEPPED UP AND FUND A
SIMILAR TYPE OF AWARD THROUGH
OUR RO1 FOR EARLY CAREER
INVESTIGATORS OFTEN THE SAME
PEOPLE.
WHEN I STARTED I HAD AN RO1 AND
HCS AND PUT DOLLARS TO A
CATALYST AWARD TO ADD MORE OF
THEIR EARLY CAREER INVESTIGATORS
INCLUDING INVESTIGATORS FROM THE
PAY LINE FROM A COUPLE POINTS.
SO WE'RE REALLY GRATEFUL AND I
THINK THIS IS THE WHOLE CANCER
RESEARCH SYSTEM.
IT'S NOT JUST ABOUT NCI BUT
GETTING PEOPLE IN THE WORKFORCE
HOWEVER, THAT HAPPENS IS GOOD TO
GO.
ON THE WORKFORCE THE CANCER
PANEL JUST LAST WEEK DID A
PUBLIC MEETING ON WORKFORCE.
SO WE'LL GET A REPORT ON THAT IN
HOPEFULLY A COUPLE MONTHS.
AND I THINK WELL APPENDED, OPEN
TO THE PUBLIC.
PEOPLE ARE REALLY INTERESTED IN
HOW WE CONTINUE TO DEVELOP A
WORKFORCE.
ALL RIGHT.
QUICK HIGHLIGHTS.
IT'S GOOD TIMES ALL OVER THE
PLACE WHEN WE HAVE TO PICK
SCIENCE.
WE PICK WHATEVER THIS IS THREE
THINGS, FOUR THINGS THAT WE
COULD PICK FROM 10,000 DIFFERENT
COOL THINGS.
I'LL POINT OUT THAT T CELL
RECEPTOR THERAPY FOR GLAU KE QUO
MA IS A REEL THING, FDA
APPROVED, UNHEARD OF.
THEY DIDN'T CHANGE FOR SARCOMA
AND NOW THERE'S IMMUNOTHERAPIES
TO DETECT IT.
AND TREATMENT FOR ENDOMETRIAL
CANCER AND REALIZED HOW LITTLE
OUR PORTFOLIO WAS AND PUT A
SUPPLEMENT OUT TO GET MORE
PEOPLE STUDYING ENDOMETRIAL
CANCER.
WE THINK WHERE WE CAN GRAB ON
AND SEEING THE IMMUNE CHECKPOINT
INHIBITORS CAN HAVE ACTIVITY AND
NEED TO NOW KNOW WHEN, WHY,
WHERE, HOW AND HAVE SCIENTISTS
DO THAT.
THE KRAS IS AN ONCA GENE WE'VE
BEEN PUSHING FOR INHIBITORS THAT
TARGET MUTATION.
REALLY AMAZING.
AND THEN I THINK WHAT'S MOST
EXCITING AND POPULATION SCIENCE
SIDE IS LOOKING AT CANCER
SCREENING AND THE BIG QUESTION
IS IT'S VERY EXPENSIVE TO SCREEN
PATIENTS FOR CANCER AND IS IT
BENEFICIAL.
EVERYONE WHO HAD CANCER CAUGHT
EARLY WOULD SAY YES BUT ON A
POPULATION WIDE BASIS IT MAKES
SENSE ECONOMICALLY AND IT'S MUCH
LESS THAN THE NUMBER THAN WE
WOULD SPEND IN THREE YEARS OF
CANCER TREATMENT.
SO THE ANSWER IS EASY, ECONOMIC
WIN CANCER SCREENING.
SO IT'S A GOOD PAPER.
URGE YOU TO TAKE A LOOK AT IT OR
THERE'S A BLOG.
SO I GUESS YOU GUYS WERE THE
ONES WHO I SAID AT THE END HOW
DO I MAKE SURE I'M GETTING WHAT
I NEED FROM THE BOARD AND YOU
SAID THERE'S DIFFERENT
QUESTIONS.
I'M DOING THIS WITH ALL MY
BOARDS.
IT'S BEEN INCREDIBLY EFFECTIVE.
IN THE ARENA OF EARLY ONSET
CANCER.
I WOULD ASK WHAT ARE YOU HEARING
IN THE COMMUNITY ARE THESE
TRENDS, BEFORE DRIVERS AND
EMERGING NEEDS?
WHAT WOULD YOU LIKE TO SEE FROM
US?
WE WOULD LOVE TO KNOW AND WE'LL
BE HEARING A LOT ABOUT
ARTIFICIAL INTELLIGENCE IN A
MINUTE AND THE STATE OF
SCIENCE -- WHAT ELEMENTS OF DATA
SCIENCE DO YOU THINK ARE RIPE
FOR THE COMMUNITY.
BRING THE SCIENCE FICTIONE THING
FOR A.I. AND BRING IT SO PEOPLE
KNOW AND USE AND TRUST WHAT
WE'RE DOING.
AND THAT'S IT.
I'LL BE HAPPY TO TAKE QUESTIONS.
>> THANK YOU, DR. RATHMELL.
IT'S SO EXCITING TO HEAR HOW
MUCH YOU'VE BEEN GETTING OUT
THERE AND ALL THE DIFFERENT WAYS
AS WELL AS THE NEW DEVELOPMENT
THAT HAPPENED OVER THE SUMMER.
WE THINK IT'S A TIME FOR GOING
ON VACATION, AND WE'RE EXCITED
TO HEAR ALL THAT.
I JUST WANT TO POINT OUT ON THE
ENDOMETRIAL CANCER VACCINE I
BELIEVE SOME OF THOSE APPROACHES
CAME FROM A CLINICAL TRIAL
PLANNING MEETING AND IT'S JUST I
REVIEWED SOME.
IT'S SO EXCITING TO SEE IT TO
FROM GOING TO PEOPLE AND THEN
GETTING APPROVED.
SO HARD WORK OF PUSHING THINGS
THROUGH THE NCI.
ON YOUR -- COULD WE SEE THE
QUESTIONS AGAIN?
SO EARLY ONSET CANCER, I
UNDERSTAND WE HEARD A LOT ABOUT
AYA AND THEIR OUTCOMES ARE A
LITTLE BIT WORSE THAN ADULTS AND
PEDS.
HOW IS THE DEFINITION OF EARLY
ONSET CANCER DIFFERENT FROM AYA
AND IS THERE OPPORTUNITY TO
LEARN FROM THAT GROUP THAT'S
EMERGING LAST 10 YEARS OR SO
I'VE BEEN HEARING ABOUT IT.
IS THERE SXRANGS SO WE DON'T
HAVE TO REINVENT THE WHEEL?
>> THOSE ARE GREAT QUESTIONS.
AND I'LL START WITH THE
DEFINITION BECAUSE I'LL JUST SAY
AS WE'RE PUTTING THIS TOGETHER I
SAT DOWN WITH LEADERS AND TALKED
ABOUT THINGS AND THE NUMBER ONE
THING IS WE DON'T HAVE A GOOD
DEFINITION SO I HAVE A COMMITTEE
OUT THERE GIVING US A
DEFINITION.
HOPEFULLY IN A COUPLE WEEKS
WE'LL HAVE A DEFINITION OF WHERE
WE'RE PUTTING OUR RESOURCE.
IT DOESN'T MEAN IT'S DEFINITION
FOR THE CANCER.
IN MY WORKING MODEL THIS IS
DIFFERENT THAN WHAT WE
TRADITIONALLY CALL THE AYA
THOUGH THERE'S HUGE OVERLAP
THERE.
AYA KIND OF GREW OUT OF
PEDIATRICS AND OFTEN PEDIATRIC
TUMORS HAPPEN INTO ADULTHOOD.
THIS THE RECOGNITION WAS LATER
ADULT TUMORS SHOWING UP IN
PEOPLE.
THE CLASSIC IS COLORECTAL RISE
THE MEDIAN AGE FOR COLORECTAL
CANCER USED TO BE 60s AND IS
EDGING DOWN WITH NOTABLE PEOPLE
IN THEIR 40s AND EVEN 30s COMING
UP WITH COLORECTAL CANCER BUT
IT'S NOT JUST COLORECTAL CANCER.
SOME DATA SUGGESTS EARLY ONSET
BREAST CANCER IS RISING AT A
RATE THAT IS QUITE STRIKING AND
WHEN YOU HAVE A GOOD NUMBER
PERCENTAGE MORE THAT'S A REAL
NUMBER OF PEOPLE.
>> I'M GUESSING IT'S COLLECTED
FOR MUTATION CARRIERS AND PEOPLE
ALREADY AT HIGH RISK.
WE'RE SEEING PEOPLE NOT IN THE
POPULATION AND SOME OF THESE
CANCERS APPEAR TO BE MORE
AGGRES
AGGRESSIVE.
>> WE NEED ALL THESE PEOPLE
TALKING TOGETHER.
I THINK THERE'S SOME CANCERS
MORE AGGRESSIVE AND SOME LESS
AGGRESSIVE THAN THEIR
COUNTERPARTS.
SO WE NEED TO UNDERSTAND THAT.
I THINK WE NEED TO UNDERSTAND
THE MUTATION PROFILE HAPPENING
THE SAME OR HAPPENING EARLIER OR
DIFFERENT DRIVERS WITH DIFFERENT
EXPOSURES?
WE DON'T KNOW ANY OF THAT.
THERE'S HUGE BIOLOGY AND IF
CANCER IS LESS AGGRESSIVE WHEN
YOU GET IT AT 40 THAN 60 IS
STILL AN ISSUE.
THERE'S STILL REAL THINGS TO
STUDY ABOUT OUTCOME AND
SURVIVORSHIP ISSUES.
>> KATIE?
I'VE SEEN ABOUT SURVIVORSHIP AND
NAVIGATING THE DIFFERENT
RESOURCES AVAILABLE TO PATIENTS
AND AND A HALF FWATING WHILE ON
TREATMENT THERE'S DIFFERENT HURD
RALES AND NETWORKING AS WELL AS
SURVIVORSHIP AFTERWARDS AFTER
DIAGNOSIS.
THAT'S THE ONE PREVALENT THING
I'VE HEARD.
>> THAT'S A HUGE AREA OF UNMET
NEED.
WE DON'T REALLY KNOW ALL THE
RIGHT THINGS TO OFFER PEOPLE
ESPECIALLY BECAUSE IT'S BEEN NOT
PART OF THE ONCOLOGISTS SORT OF
WORRIES.
BUT IT NEED TO BE NOW.
AND EFFECTS ON FAMILIES AND
COMMUNITIES AND THERE'S A LOT WE
CAN LEARN.
>> THERE'S PATHOLOGY AND THE
ANALYSIS IS ACTUALLY NOW MORE
ACCURATE AND EFFECTIVE AND THE
REAL BENEFIT OF ARTIFICIAL IN
TELL AGAINST WILL COME WHEN IT'S
USED TO ANALYZE THE ENTIRE PODDY
OF INFORMATION ABOUT THE PATIENT
THAT'S THE BIOMARKERS, HISTORY,
COMORBID, GENETICS ETCETERA.
AND BE ABLE TO THEN DIRECT
TOWARD THE MOST OPTIMAL
TREATMENT OF MANY MANY
TREATMENTS AVAILABLE FOR THAT
PARTICULAR PATIENT AND TO DO
THAT THAT WILL REQUIRE MASSIVE
ANALYSIS AND COST HUNDREDS OF
THOUSANDS OF MILLIONS.
MY QUESTION I'M GETTING TO IS
ARE THEY COLLECTING THIS AND
HELPING TO PREPARE ANALYSIS AND
I'D LIKE TO HEAR WHERE YOU SEE
THAT GOING.
>> DEFINITELY.
TO ME THIS IS GOING TO BE THE
FUTURE OF REALLY PERSONALIZED
MEDICINE.
WHEN IT'S ALL OF YOUR
INFORMATION, BIOLOGICAL,
GENETIC, EVERYTHING GOING INTO
CREATING A PLAN.
THERE ARE ALREADY PIECES COMING
OUT SUMMER AND LATE SPRING THAT
TOOK THE INFORMATION AND A
PATIENT'S RECORD USING A.I.
TOOLS TO PREDICT WHO WOULD
RESPOND BETTER TO CHEMO OR
IMMUNOTHERAPY.
AND THAT WAS MUCH BETTER THAN
WHAT DOCTORS ARE ABLE TO DO.
WE'LL HAVE TO BE ABLE TO LET GO
AND TRUST WHEN THESE THINGS WORK
AND EVEN THESE COOL ALGORITHMS
AREN'T QUITE OUT THERE BUT
THEY'LL BE COMING VERY SOON.
IN TERMS OF THE PASSIVE AMOUNTS
OF DATA NEEDED.
WE'RE PULLING THE DATA INTO
THINGS LIKE DATA FABRICS AND
MULTIPLE TRIALS AND MULTIPLE
COMPONENTS COMING TOGETHER AND
TAKES MORE THAN WHAT MY MAC
LAPTOP CAN DO AND USE THE
DEPARTMENT OF ENERGY TO USE
THEIR SUPER COMPUTER.
WE HAVE A WHOLE PROJECT.
I WILL SAY THE MOONSHOT FUNDED
WE SCRAPED TOGETHER FOR THE
PROJECT THIS YEAR AND IT'S
EXPENSIVE AND HARD TO PAY FOR IN
THE CURRENT BUDGET SITUATION.
TO KEEP PAYING FOR IT SOMETHING
ELSE WILL HAVE TO GO AND WE HAVE
IT COVERED FOR '25 AND '26 BUT
WE NEED TO WORK WITH THE
DEPARTMENT OF ENERGY AND NEED TO
BE ABLE TO USE THAT SUPER
COMPUTING POWER.
AS WE LEARN HOW TO DO IT LIKE
EVERYTHING ELSE IT WILL
EVENTUALLY PEEL BACK THE THINGS
YOU CAN DO AT A NORMAL COMPUTER.
>> TO THE FIRST POINT OF EARLY
ONSET CANCERS IT GOES BACK TO
WHERE YOU STARTED IN THE SUMMER
ABOUT MISINFORMATION AND THIS
COULD BE THAT QUESTION BUT AS
ADVOCATES AND WE INTERACT AND WE
HAVE MEETINGS OR SYMPOSIA WHAT
FORCES ARE THERE TO BRING TO
BEAR TO EDUCATE AND HELP YOUNGER
PEOPLE WHO ARE NOT LOOKING TO
EXPLAIN WHAT'S HAPPENING AND
THEY MAY TURN AND HOW CAN WE BE
THE BEST ADVOCATES AND EXPLAIN
TO OUR COMMUNITIES.
>> THAT'S A GREAT QUESTION.
THAT'S ONE OF THE THINGS WE
REALIZE WAS A GAP.
THERE'S NOT A COMPREHENSIVE
GREAT RESOURCE.
WE'RE MAKING SURE OUR
INFORMATION IS COHESIVE AND TO
THE RIGHT PLACE BUT THAT'S JUST
OUR WEBSITE.
>> IT WOULD BE GREAT TO HAVE A
SPEAKER BUREAU TO COME AND TALK
TO US ABOUT WHAT WE COULD PUT IN
A REQUEST TO HAVE A SPEAKER TO
COME AND TALK ABOUT FIGHTING
DISINFORMATION.
THAT'S A GREAT QUESTION FOR
PIERRE WHEN HE COMES TO SPEAK TO
YOU.
PATS PART OF OUR INITIATIVE.
WE WANT TO MOVE BEYOND OUR
STATIC THINGS ARE AVAILABLE YOU
CAN FIND THEM AND THIS IS OFF
TOPIC BUT I HAVE AN EXTRA
TWITTER PAGE AND WE PUT A LOT OF
CONTENT OUT THERE AND THEY TOLD
ME I HAVE TO START DOING VIDEOS
WHICH I HATE SO MUCH BUT I'M
BETTER.
WHEN I PUT A VIDEO OUT THERE I
GET FIVE TIMES MORE ENGAGEMENT.
IT'S AMAZING.
SO WE'LL PROBABLY HAVE TO FIGURE
OUT HOW TO GET SOME OF THE
INFORMATION OUT THERE IN WAYS
PEOPLE DIGEST TODAY.
SOME VIDEO CONTENT AND --
>> IF YOU DON'T THEY'LL GET
INFORMATION SOME PLACE ELSE.
>> YEAH.
>> I THINK NCI PUTS A LOT INTO
EXCHANGE OF INFORMATION AND IT'S
ABOUT PACKAGING THAT IN
DIFFERENT WAYS AND THE EXPERTISE
AND CONTENT IS THERE.
>> I AGREE 100% AND KNOW I'VE
BUGGED YOU ABOUT THIS FOR YEARS
AND YOU'VE RESPONDED EVERY TIME.
IT'S GREAT AND I CAN FIND THINGS
BUT IF YOU DIDN'T HAVE A
SPEAKER --
>> WE'RE OPEN TO SUGGESTIONS AND
HEARING THE NEEDS.
>> AND A FOLLOW-UP TO WHAT VICKY
SAID BUT AMANDA AND THEN BOB TO
MAKE SURE TO GET EVERYONE WE
CAN.
>> I THINK YOU'RE SPOT ON IN
EXACTLY WHAT YOU JUST SAID.
YOU HAVE THE INFORMATION.
IT'S JUST A MATTER OF THE MEDIUM
AND I THINK THERE'S A CONNECTION
BETWEEN EARLY INVESTIGATORS
FOCUSSED ON COMMUNICATION AND
WHAT IS CLEARLY A HOT TOPIC
RIGHT NOW OF EARLY ONSET CANCER
I THINK IS LARGELY DRIVEN BY
COMMUNICATIVE PRESS AROUND THE
SUBJECT.
AND SO I WONDER IF THERE'S A
CONNECTING PIECE INVOLVING YOUNG
INVESTIGATORS THAT WOULD
IDENTIFY WITHIN THE COHORT TO
SPEAK TO ABLE-RELATED EARLY
ONSET CANCERS AND I THINK YOU'RE
SPOT ON IN SAYING AYS OUR
TRADITIONAL DEFINITION DOESN'T
FIT IN TALKING ABOUT ADULT
CANCERS NO LONGER BEING IN THE
OLDER ADULT COHORT OF
INDIVIDUALS.
OFFERING PERSPECTIVE AND I THINK
IT WOULD BE INCORRECT TO SAY OH,
THEY'LL GET IT FROM TIKTOK.
YOU DON'T THINK THAT'S THE
CORRECT APPROACH BECAUSE IT'S
REGARDED AS A TRUE SOURCE NOW
AND IT NEEDS TO BE ADDRESSED.
>> MORE OF A QUESTION OF WHAT
NCI IS DOING TO BE DATA READY
BUT MORE IMPORTANTLY I'VE BEEN
HEARING PUSHBACK ABOUT WHAT I
SEE A.I. BEING ABLE TO DO WHICH
IS COMING UP WITH IDEAS TO
STUDY.
WE HAVE DATA AMASSED ON PATIENTS
AND A.I. IS CAPABLE OF LETTING
THE CREAM RISE TO THE TOP AND
THESE ARE THE THINGS WE NEED TO
LOOK AT.
THIS IS A GENE WE'RE SEEING A
LOT OF ISSUES WITH OR WHATEVER.
AND TO THE PUSHBACK I'VE BEEN
HEARING IS THAT'S A BIASSED
STUDY.
LIKE THEY'RE ALMOST AFRAID TO
LET THE DATA LEAD AND THAT'S
CONCERN FOR ME AND WHY WE'RE
AMASSING THE DATA AND LET THE
DATA SHOW US WHERE WE SHOULD BE
GOING AND STUDYING.
INTERESTED IN YOUR THOUGHTS ON
THAT.
DO YOU TRUST THE A.I. HAS ALL
THE INFORMATION IT NEEDS AND NOT
AGGREGATING SOMETHING BUT NOT
INFLUENCED BY SOME COMPONENT I
CAN'T SEE AND TO ANSWER THE
QUESTION A LITTLE BIT MORE
CLEARLY I'M NOT A DATA
SCIENTIST.
I HAVE TO WONDER BUT THERE ARE
THINGS A.I. CAN DO THAT WE JUST
CAN'T THINK IN THAT DIMENSIONS
AT THE A GREAT TIME.
A GREAT EXAMPLE IS AROUND
RADIOLOGY AND USING A.I. TO
PREDICT WHAT'S GOING ON.
THERE'S THINGS THAT IT WILL PICK
UP THAT ARE WRONG AND WE HAVE TO
LEARN HOW TO KNOW WHAT IS WRONG.
AND WE HAVE TO RE-LEARN HOW TO
INTERACTION WITH THE MACHINE.
THE MACHINE CAN BE A TOOL TO SEE
WHAT WE CAN'T SEE AND THE
PATTERN WE'RE SEEING IS KICKING
UP DUST IN THE AREA.
IT'S A LEARNING PROCESS FOR
EVERYBODY.
>> IN TERMS OF BIG DATA AND
GOING BACK TO THE ANALOGY OF THE
WEATHER SERVICE AND WE HAVE A
NATIONAL WEATHER SERVICE WITH
DATA WE ALL TRUST.
THE CANCER DATA SEEMS SILE SILO.
IS THERE A WAY TO SHARE IT AND
COMPILE IT?
>> I'M WITH YOU.
PATIENT INFORMATION IS PRETTY
PROTECTED.
SOME IS MORE COMPLICATED.
FOR EXAMPLE LIKE OUR INCIDENTS
AND MORTALITY WHICH FEEDS INTO
THE CANCER FACTS AND FIGURES
EVERY YEAR IS A PRETTY RELIABLE
CENSUS OF WHAT'S GOING ON
GENERALLY AROUND THE COUNTRY.
THERE'S BEEN A CHALLENGE ABOUT
THREE YEARS FOLD WAY TOO SLOW.
WE'VE DROPPED IT DOWN AND KEEP
PUSHING IT.
IT WILL BE NEVER LIKE I HAVE
CANCER AND CAN SEE IT IN THE
DATABASE TOMORROW.
BUT TO MAKE IT REALISTIC IS VERY
MUCH ON THE HORIZON.
SOPHISTICATED VERSIONS ARE
ACCEPTABLE TO INVESTIGATORS BUT
THINGS PEOPLE CAN LOOK AT.
I AGREE, I FEEL LIKE CANCER IS
AT A PLACE WHERE HAVING THOSE
KINDS OF DATA FEEDS IT WOULD
HELP TO BE ABLE TO WHERE THEY'RE
CHANGING FASTER AND SLOWER AND
WHAT REAL RISKS ARE.
>> WE'RE AT TIME BUT WE'LL TAKE
ONE MORE QUESTION BECAUSE ANDREA
HAD HER HAND UP.
>> I APPRECIATE IT.
I'LL SPEAK QUICKLY.
ONE OF THE THINGS WE HAVE TO BE
CAREFUL OF IS THE INHERENT BIAS
WE CURRENTLY HAVE IN DIVERSITY
ISSUES.
LIKE ALL DATA INFORMATION,
GARBAGE IN, GARBAGE OUT.
WE WORRY ABOUT INCREASING THAT
ISSUE BY RELYING TOO HEAVILY ON
ESPECIALLY OLD INFORMATION AS WE
TRY ENGAGE FURTHER IN DIVERSE
COMMUNITIES.
I HAVE CONCERNS ABOUT THAT.
AND LIFESTYLE ISSUES INCLUDING
ALCOHOL HAVE ALWAYS BEEN A
QUESTION AND IT'S HARDER TO GET
DATA WHEN IT'S LIFESTYLE
INFLUENCES.
>> SO DATA SOURCES LIKE THE "ALL
OF US" PROGRAM IT'S AN PROGRAM
WE PARTNER WITH TAKING REAL
WORLD INFORMATION AND HOPEFULLY
HONESTLY SUPPLIES BECAUSE IT'S
PATIENT INPUT ON SOCIAL FACTORS
OR THINGS LIKE ALCOHOL INTAKE.
IT WILL BE A MILLION PEOPLE AND
IT IS GEOGRAPHICALLY AND
ETHNICALLY DIVERSE AND IT WILL
TAKE TIME BEFORE IT HAS THE
CANCER INFORMATION BECAUSE
CANCER HAS A LONGER LEAD TIME
THAN OTHER THINGS THEY STUDIED
BUT IT WILL BE ONE EXAMPLE OF A
GREAT RESOURCE FOR THAT.
SO I THINK OF THIS AS NO STONE
UNTURNED AND THE INFORMATION IS
BIASSED AND THE PATIENTS IN
THEM.
>> THANK YOU FOR THE AMAZING
DIALOGUE WITH DR. RATHMELL AND
THANK YOU FOR THIS BEAUTIFUL
COMPREHENSIVE REPORT ABOUT
WHAT'S GOING ON AND WHEN WE NEED
FOR THE FUTURE.
NEXT UP DR. KW KIBBE APOLOGIES R
GOING A LITTLE BIT OVER.
>> UME HERE, CAN YOU SEE ME?
>> IT'S GOOD TO SEE YOU.
DR. RATHMELL TALKED ABOUT YOUR
JOURNEY AND WELCOME AND WE'RE
EXCITED TO HEAR MORE.
WE'RE POISED TO HAVE DIALOGUE
AFTER YOUR PRESENTATION ON DATA.
>> IT'S A PLEASURE AND I WAS
LISTENING THROUGH THE EARLIER
SESSION AND I HEARD LOTS OF
GREAT QUESTIONS ON DATA SCIENCE.
I'LL ASK YOU TO BRING THIS UP TO
ME AGAIN AND HAPPY TO TRY TO
DIVE DEEPER ON THEM.
SO I'M JUST GOING TO GIVE A
BRIEF INTRODUCTION.
I WANT TO TALK ABOUT CCDI.
AND YOU THINK THOSE OF US ON THE
PHONE OR ZOOM ARE GETTING A
LITTLE BIT OF ECHO.
I DON'T KNOW IF YOU CAN REDUCE
THAT SO IF YOU NEED TO INTERRUPT
OR ASK A QUESTION, IF YOU RAISE
YOUR HANDS MAYBE I'LL BE ABLE TO
SEE THAT.
I'LL TALK ABOUT USING DATA AND
HOW WE'RE THINKING ABOUT THAT IN
GENERAL WITH CANCER RESEARCH.
TALK ABOUT A.I. WHICH SOUNDS
LIKE THERE'S A LOT OF INTEREST
IN.
AND THEN OPEN IT UP FOR FOR
STUGS.
-- DISCUSSION.
IT'S CREATE TO BE HERE.
JUST ABOUT MY ROLE AS
DR. RATHMELL MENTIONED I'M THE
INAUGURAL DEPUTY DIRECTOR FOR
DATA SCIENCE AND STRATEGY.
I STARTED BACK AT THE END OF
JUNE.
MY ROLE REALLY IS TO TRY TO
PROVIDE SOME LEADERSHIP AND
STRATEGIC DIRECTION FOR NCI IN
THINKING ABOUT DATA, DATA
SCIENCE AND NOW OF COURSE A.I.
THAT CAN'T BE OUT OF THE PICTURE
ANYMORE.
I'LL BE THINKING ABOUT HOW WE
IMPLEMENT A STRATEGIC PLAN FOR
DATA SCIENCE AND OUT OF THE
OFFICE OF DATA SCIENCE STRATEGY
BY DR. SUSAN GREGURICK.
THINK HOW WE EMBED OURSELVES
MORE ACROSS NIH AND DIGGING ALL
THE THINGS IN CANCER RESEARCH
THAT HAPPEN BOTH INSIDE NCI AND
OUTSIDE.
SO JUST TO TELL YOU A LITTLE BIT
ABOUT MYSELF, I WAS THE DIRECTOR
FOR BIO INFORMATICS AND
TECHNOLOGY FOR 2013 TO 2017 AND
THEN DEPUTY DIRECTOR AND THEN
MOVED TO DUKE AS THE CHIEF DATA
OFFICER FOR THE DUKE CANCER
INSTITUTE AND HAD AN OPPORTUNITY
TO WORK IN A LOT OF DIFFERENT
AREAS AND WITH A LOT OF
DIFFERENT PEOPLE INCLUDING
THINKING ABOUT HEALTH EQUITY AND
HOW INDIVIDUAL CANCER CENTERS
ARE TRYING TO IMPROVE HEALTH
EQUITY FOR CANCER PATIENTS AND
OF COURSE COME BACK NOW TO
KNICK.
I'LL TALK ABOUT CHILDHOOD CANCER
DATA INITIATIVE.
SOMETHING I'VE BEEN INVOLVED
WITH SINCE THE START.
I HAD THE PRIVILEGE TO BE ON THE
BSA WORKING GROUP THAT CREATED
THE REPORT THAT DEFINED WHAT
CCDI'S KEY GOALS WERE.
AND WHAT I WANT TO HIGHLIGHT
IT'S PEDIATRIC CANCER INTO
ADOLESCENCE AND YOUNG ADULTS AND
THE DIFFERENCE AS SAID AND EARLY
ONSET CANCERS IS THE CONCERN
WITH EARLY ONSET CANCERS IS IT
APPEARS TO BE MORE ADULT CANCERS
HAPPENING EARLIER VERSUS
PEDIATRIC CANCERS HAPPENING
LATER IN LIFE.
SO THERE'S AN OVERLAP BETWEEN
THE TWO AND CCDI IS INTERESTED
IN THE CHILDHOOD CANCER SIDE
INCLUDING ALL THE WAY UP TO AGE
39 MAKING SURE TO PROVIDE TOOLS
FOR YOUNG ADULTS WHO HAVE BEEN
DIAGNOSED WITH A PEDIATRIC
CANCER AND HOW THEY GET THE
RIGHT CARE.
THE IDEAS IS TO TRY TO LEARN
FROM EVERY SINGLE PATIENT THAT
HAS A PEDIATRIC CANCER AND I'LL
TALK ABOUT WHAT THAT MEANS IN A
LITTLE BIT ABOUT.
HAVE A NATIONAL STRATEGY FOR
MOLECULAR CHARACTERIZATION TO
INFORM DIAGNOSIS AND TREATMENT
AND TALK ABOUT NCI AND THE
STATISTICS WE'RE CURRENTLY AT
AND DEVELOP THE DATA PLATFORM
FOR A PLACE FOR ALL THESE
DIFFERENT KINDS OF DATA TO GO
AND I THINK THERE'S AN
OPPORTUNITY THERE TO THINK ABOUT
THAT DATA PLATFORM AS SOMETHING
WE CAN USE FOR ALL CANCER
PATIE
PATIENTS NOT JUST CHILDHOOD
CANCER PATIENTS AND YOUNG ADULTS
AND GET THE WHOLE CHILDHOOD
CANCER COMMUNITY AND RESEARCH
COMMUNITY WORKING TOGETHER IN
PERHAPS MORE DATA CENTRIC WAYS
THAN THEY ARE HAVE HISTORICALLY.
WITH THAT AS A BIT OF A
BACKGROUND WE'RE CURRENTLY IN
THE FIFTH YEAR FOR CCDI.
IT'S A 10-YEAR PROJECT.
WE HAVE A CHILD CANCER DATA
CATALOG WITH PEDIATRIC AND AYA
DATA SETS.
WE HAVE MORE THAN 4,000 PATIENTS
GET MOLECULARLY CHARACTERIZED.
I'LL TALK BRIEFLY ABOUT THAT AND
OF THOSE 4,000, ALMOST 3,000
PATIENTS THEIR DATA HAS BEEN
RELEASED PUBLICALLY.
SO THE REASON IT'S NOT ALL 4,000
IT TAKES A WHILE TO PROFESSOR IT
AND ANNOTATE AND RELEASE IT.
EVERYONE'S DATA WILL BE RELEASED
WHO GETS CHARACTERIZED THROUGH
THE INITIATIVE.
WE HAVE THIS MOLECULAR TARGETS
PLATFORM CALLED THE OPEN TARGETS
INITIATIVE THAT'S A GLOBAL
INITIATIVE.
THE POINT OF THE OPEN TARGETS
INITIATIVE IS TARGETS FOR
DIFFERENT KINDS OF MUTATIONS AND
ABNORMALITIES THAT HAPPEN IN
CANCER AND TRY TO BRING KNOWN
COMPOUNDS IN TO TARGET THE
SIGNATURES.
WE RELEASED THE MOLECULAR
TARGETS PLATFORM AND HAS IT
ALMOST 60,000 MOLECULAR TARGETS
AND WE THINK THAT'S GOING TO BE
IMPORTANT BECAUSE AS WE'RE
CHARACTERIZED MORE PATIENTS
WE'LL HAVE THE OPPORTUNITY WHEN
WE IDENTIFY A NEW MUTATIONAL
PROFILE TO SEE IF THERE A KNOWN
THERAPY, A KNOWN WAY TO TRY TO
INTERVENE IN THAT PARTICULAR
CANCER.
ALSO IMPORTANT AND RELATED TO
SERE IS OUR NATIONAL CANCER
REGISTRY EXPLORER.
IT HAS 1.7 MILLION CASES BETWEEN
1995 AND 2020.
AND REPRESENTS 70% OF ALL CASES
WE KNOW ABOUT IN THE COUNTRY ARE
AVAILABLE IN THE NATIONAL
CHILDHOOD CANCER REGISTRY.
WE THINK THEY'RE IMPORTANT AN
ONE WAY TO GET DATA AVAILABLE TO
RESEARCHERS TO THE CARE TEAMS
INVOLVED IN PROVIDING CARE TO
THESE CHILDREN AND YOUNG ADULTS.
AND THERE'S ALL KINDS OF
RESEARCHERS IN THESE AREAS TO
TALK ABOUT THE MOLECULAR
CHARACTERIZATION INITIATIVE, IT
IS THE DESIGN BEHIND IT IS THE
CONSISTENT SET OF DIAGNOSTICS.
WE THINK EVERY PATIENT SHOULD
GET ACCESS TO AND IDENTIFY THE
CANCERS WE THINK THOSE
DIAGNOSTICS WILL HAVE THE MOST
VALUE.
WE HAVE THE CAPABILITY OF GOING
UP TO 3,000 PATIENTS A YEAR
RUNNING THEM THROUGH THE
DIAGNOSTIC PIPELINE.
AND AGAIN WE THINK IT'S GOING TO
BE REALLY IMPORTANT AND WE'RE
BUILDING A CLINICALLY ANNOTATED
BIO BANK THAT WILL BE ACCESSIBLE
FOR RESEARCHERS IN THE FUTURE AS
OF THE BEGINNING OF SEPTEMBER WE
HAD OVER 3,000 NEWLY DIAGNOSED
CNS TUMORS.
THEY STARTED IN MARCH OF 2022.
THAT'S BEEN RAPIDLY ACCRUING FOR
THE PAST TWO AND A HALF YEARS.
WE ALSO HAVE ALMOST 1,000
PATIENTS WITH SOFT TISSUE
SARCOMA PART OF THIS.
WE STARTED LATER WITH RARE
TUMORS.
THEY'RE BY DEFINITION ULTRARARE
CANCERS AND WE HAD MORE THAN 400
OF THEM AND STARTING EARLIER
THIS YEAR WE OPENED UP THE
CHARACTERIZATION INITIATIVE TO
NEUROBLASTOMA PATIENTS AND HAVE
OVER 400 PATIENTS CARED FOR AND
EXPANDING TO DOING SARCOMAS AND
PLANNING ON ADDRESSING RELAPSE
TUMORS.
THESE ARE PATIENTS THAT ARE
ALREADY BEEN ON -- HAD A TUMOR
THAT WENT THROUGH MCI AND
THEY'LL HAVE RELAPSE AT SOME
POINT IN THE FUTURE AND WILL BE
CHARACTERIZING THEM AGAIN TO SEE
WHAT'S CHANGED.
MAKING PART OF THE INITIATIVE IS
IT'S IN A CLIA CERTIFIED
ENVIRONMENT AND IT CAN TO RIGHT
TO THE CLINIC AND BE USED IN
CLINICAL CARE.
DATA COMMONS WHERE THE DATA
COMING FROM NCI AND CCDI WILL BE
MADE AVAILABLE.
WE JUST HAD OUR THIRD RELEASE OF
THE DIFFERENT DATA SETS END OF
JULY.
WE'RE GOING TO TO BE DOING TWO
RELEASES A YEAR AND ALL
AVAILABLE PUBLICALLY.
THAT WAS A QUICK HIGHLIGHT AND
RUN THROUGH OF CCDI.
IF ANYONE HAS A QUESTION ABOUT
IT RIGHT NOW THAT I CAN ANSWER
EASILY I'M HAPPY TO DO THAT
OTHERWISE I'LL KEEP GOING AND
TALK ABOUT THE USE OF DATA IN
CANCER RESEARCH.
WE DEVELOPED THIS FOR CCDI.
IT'S NOT JUST ABOUT CHILDHOOD
CANCER BUT ABOUT EVERY CANCER.
UNDERSTANDING THE TOUCH POINTS
IN A PATIENT'S JOURNEY FROM
DIAGNOSIS TO CONFIRMATION
GETTING MOLECULAR
CHARACTERIZATION OCCURRING AND
SMALL MOLECULES, PROTEOMICS.
IMMUNOHISTO CHEMISTRY AND THE
OPTIMAL THERAPY FOR A PATIENT TO
GO IN.
YOU HAVE THE CANCER HOPEFULLY
ERADICATED AND FOLLOW-UP
LONGITUDELY -- LONGITUDINALLY
OVER TIME AND EACH IS A CHANCE
TO LEARN FROM THE DATA BEING
GENERATED IN ALL KINDS OF CANCER
S ACROSS THE AGE GROUPS AND A
WAY TO LEARN TO HAVE AN
OPPORTUNITY TO LEARN FROM OTHER
PATIENTS.
AND THERE'S SOURCES OF DATA.
MOLECULAR DATA INCLUDING GENOMIC
PATHOLOGY AND IMAGES AND
ULTRASOUNDS LAB DATA, THE
CLINICAL NOTES THAT SURROUND A
PATIENT AND THINGS NOW GETTING
INTO THE INTERNET OF THINGS AND
BEING ABLE TO DIRECTLY SENSOR
PEOPLE AND UNDERSTAND THEIR
JOURNEY MORE DIRECTLY.
WE SEE THESE ARE ALL
OPPORTUNITIES TO COLLECT A MUCH
RICHER VIEW OF INDIVIDUALS AND
THEREFORE A RICHER VIEW OF WHAT
CANCER MEANS.
THIS IS A SLIDE IN THE LAST
MEETING TALKING ABOUT A.I.
WE CAN APPLY A.I. TO ALL THESE
THINGS BUT IT'S REALLY
GENERATING HIGH QUALITY DATA AND
DATA THAT IS CAPTURED IN A WAY
FREE FROM BIAS EVERYTHING FROM
CANCER SCREENING AND DIAGNOSIS
THROUGH TO HEALTH CARE DELIVERY
AND SURVIVORSHIP AND ALL THE
DATA THAT GETS GENERATED IN
BASIC SCIENCE AND MECHANISTIC
STUDIES.
UME RUNNING A LITTLE BIT BEHIND
SO I'LL TRY TO RUN QUICKER.
ONE OF THESE I WANT TO HIGHLIGHT
AND THINKING ABOUT DATA SCIENCE
IS THE OPPORTUNITY TO DO
TRAINING AND SOME OF THAT IS
GEKT OUR DATA A.I. READY FOR
LOTS OF TALK ABOUT A.I. READY
AND HEARD MENTION OF IT THIS
MORNING.
TO ME IT'S REALLY AN OPPORTUNITY
TO UNDERSTAND QUALITY OF THE
DATA AND FIT FOR PURPOSE AND
WHAT IT'S FIT TO DO AND GET IT
IN THE RIGHT FORMAT TO REALLY
LEATHER OF LEARN FROM AN A.I.
PERSPECTIVE AND APPLY DIFFERENT
METHODOLOGIES NOT JUST A.I.
THERE'S AN OPPORTUNITY TO BRING
LOTS OF PEOPLE TO THE TRAINING
AND TRAIN SO THEY CAN BECOME
DATA SCIENTISTS.
JUST AS IMPORTANTLY, TRAINING
FOR CANCER RESEARCHERS IN
GENERAL AND INCLUDING CLINICIANS
TO LET THEM UNDER THE WHAT
POSSIBILITIES ARE AND HOW TO BE
A GOOD PARTNER WITH DATA
SCIENTISTS.
AND THE THIRD POINT WHICH IS
SOMETHING DR. RATHMELL
HIGHLIGHTED THE IMPORTANCE OF
HAVING A DIVERSE WORKFORCE IN
ALL ASPECTS OF WHAT WARE DOING
IN DATA SCIENCE AND CANCER
RESEARCH.
>> JUST TO TALK BRIEFLY ABOUT
A.I. PIECES.
WE HAVE ALL THIS NEW METHODOLOGY
AND MOST BEING DRIVEN IN
INDUSTRY.
IT'S IMPORTANT WE PARTNER TO
BRING IN THE GOOGLES AND MIC
MICROSOFTS INTO THESE PROBLEMS
AND DRIVE ALL THIS WITH DATA.
HOW DO WE TRANSFORM CARE AND
TRANSFORM UNDERSTANDING OF
CANCER?
AND A BRIEF HISTORY OF ART
OFFICIAL INTELLIGENCE IN THE
THOUGHT OF ARTIFICIAL
INTELLIGENCE AND WHAT IT IS GOES
BACK PROBABLY SINCE PEOPLE FIRST
HAD LANGUAGE I'LL GO BACK TO THE
1800 MATHEMATICIANS WERE FIRST
COMING UP WITH WAYS TO THINK
FROM A LOGIC STANDPOINT OF
REPRESENTING WHAT HUMAN THOUGHT
AND HUMAN DECISION MAKING WAS.
FAST FORWARD TO 1960s TO THE
BEGINNINGS OF MODERN COMPUTERS.
AND THERE AGAIN A REAL
THEORETICAL DRIVE TOWARDS
COGNITION AND ARTIFICIAL
INTELLIGENCE BUT COMPUTERS
WEREN'T POWERFUL INFORM.
WHEN WE WERE TRAINING IN THE
'80s, I HAD A CHANCE TO WORK
WITH SELF-ORGANIZING NAPS AND
EARLY VERSIONS OF NEURAL NETS
AND THEY WERE GREAT BUT THE
COMPUTING POWER WASN'T THERE TO
DO SOMETHING USEFUL WITH.
STARTING IN 2018 THERE WERE
REPRESENTATIONS FROM
TRANSFORMERS AND THIS SET THE
STAGE FOR A WHOLE NEW REVOLUTION
OF A.I.
AND THEN OF COURSE CHAT GPT WAS
JUST RELEASED TWO YEARS AGO.
AND ANOTHER TYPE OF A.I. MODEL
LARGE LANGUAGE MODELS ARE BEHIND
CHAT GPT.
SO THAT'S REALLY CHANGED THE
VIEW AND ACCESS TO THESE KIND OF
A.I. TOOLS.
SO I THINK IT'S REALLY IMPORTANT
WHEN WE'RE THINKING ABOUT A.I.
TO THERE'S SEVERAL THINGS WE
HAVE TO THINK ABOUT.
ONE IS HOW DO WE GET THE DATA TO
BE A.I. READY AND AN IMPORTANT
PART AND I THINK IT WAS
MENTIONED IT'S IMPORTANT TO
THINK ABOUT THE BIASES THAT ARE
PRESENT IN THE DATA MAKING SURE
WE CHARACTERIZE THAT AND
UNDERSTAND WHAT THE DATA ITSELF
IS GOOD FOR.
IT'S IMPORTANT IN USING THE A.I.
TOOLS UP A TRUSTWORTHY AND
ETHICAL WAY AND DRIVE THE WHOLE
ECO SYSTEM OF A.I. TO WOULD BE
ARE YOU ABOUT SOME OF THOSE.
IF WE HAVE TIME WE'LL TALK ABOUT
THE NEW STRAWBERRY MODEL COMING
OUT OF OPEN A.I. IN CHAT GPT.
AND AGAIN, THE DIVERSE WORKFORCE
PIECE.
WE THINK IT'S REALLY IMPORTANT
THAT EVERYBODY IS PART OF THIS
BECAUSE IF IT'S NOT WE'RE GOING
TO INTRODUCE A WHOLE SET OF
BIASES.
WITH THAT, THANK YOU AND I'D
LOVE TO TAKE YOUR QUESTIONS.
>> THANK YOU DR. KIBBE.
WE'RE GOING TO ALLOW OURSELVES
TO GO A TINY BIT OVER.
WE DON'T WANT TO GO TOO MUCH
INTO THE NEXT REPORT BUT WANT AN
OPPORTUNITY TO ENGAGE.
I HAVE A TWO-PART QUESTION.
THE FIRST PART IS HU DO YOU SEE
YOUR RESEARCH ADVOCATES ENGAGING
WITH THE WORKFORCE AND
DEVELOPMENT OF THE A.I. TOOLS
AND SECONDLY CAN WE JUST ASK THE
A.I. WHAT'S MISSING AND WOULD IT
TELL US HOW TO GET THAT?
>> FOR THE FIRST QUESTION I'M
NOT SURE WHAT THE RIGHT ROLE IS
FOR THE ADVOCATES OTHER THAN TO
GET YOU INVOLVED IN THE
CONVERSATIONS TO THE EXTENT
YOU'RE WILLING TO.
AS FAR AS ASKING WHAT'S MISSING,
THAT IS THE HARDEST THING TO DO
JUST LIKE FOR HUMAN BEINGS.
IT REQUIRES KNOWING WHAT'S
POSSIBLE AND UNDERSTANDING
WHAT'S POSSIBLE AND BEING ABLE
TO LOOK AT BLAZE BEEN DONE AND
THAT'S DIFFICULT.
MAYBE AN EASIER PART OF THAT
QUESTION IS LOOKING AT WHAT'S
ALREADY BEEN DONE AND WHERE ARE
THERE HOLES IN THE EXISTING WORK
TO COMPARE IT WITH OTHER AREAS
AND SAYING SHE'S SHOULD HAVE
HAPPENED BUT HAVEN'T.
A SIMPLE EXAMPLE IS ARE WE
GETTING GOOD DISTRIBUTION OF
RURAL VERSUS URBAN RACES AND
ETHNICITIES INTO CLINICAL
TRIALS?
WE DON'T NEED A.I. TO TELL US WE
STILL HAVE A WAY TO GO THERE.
AND THEY'VE DONE A GOOD JOB IN
ALL OF US AND ARE THERE THINGS
WE CAN LEARN.
THAT WAS RAY LONGER ANSWER THAN
I MEANT TO GIVE.
>> I'M READING A BOOK THAT
INCLUDES THE DEVELOPMENT OF GPT
4.0 RAND HEALTH CARE AND IT'S
WILD.
GO AHEAD KATIE.
ONE IS ON PATIENT ADVOCATES.
I'M A SOFTWARE ENGINEER AS WELL
AND CANCER SURVIVOR MYSELF.
ONE WAY IS TO VALIDATE THE
MODELS.
ONE THING IS CHECKING TO MAKE
SURE THAT IT APPEARS TO BE
CORRECT AND SO CHECKING WITH
PATIENT ADVOCATES TO CHECK WITH
THEIR COMMUNITIES WHEN YOU HAVE
DATA COMING OUT SAYING DOES THIS
FEEL LIKE IT'S MASK WHAT YOU'RE
SAYING AS A GUT CHECK?
IT'S IMPORTANT TO HAVE GUT
CHECKS AT ALL LEVELS.
KIND OF GOING ALONG WITH THAT
THE QUESTION I HAVE IS ABOUT
OPEN ACCESS TO DATA.
THERE'S A PRIVACY CONCERN TOO.
FULL OPEN ACCESS.
TO INVOLVE EVERYONE AND SOFTWARE
SCIENTISTS CAN PARTICIPATE IN
CREATING SOME OF THESE SOLUTIONS
BUT MAY NOT HAVE ACCESS TO THE
DATA CURRENTLY.
>> QUESTION --
>> YES TO ALL OF THAT.
THINGS LIKE TCGA AND GENOMIC
DATA IS A GOOD EXAMPLE WHERE WE
DON'T MAKE THE RAW SEQUENCE
AVAILABLE WITHOUT HAVING DATA
ACCESS REQUEST BUT THE RESULTS
OF ALL THAT SO WHICH MUTATIONS
ARE PRESENT WE DO MAKE THAT
COMPLETELY OPEN.
THE PRIVACY CONCERNS ARE SMALL.
UNDERSTANDING THAT AND PUSHING
ON WHAT CAN WE MAKE AVAILABLE
THAT THERE AREN'T PRIVACY
CONCERNS AROUND IS REALLY
IMPORTANT.
I'LL POINT OUT AND I'VE HAD THE
OPPORTUNITY TO WORK WITH AMANDA
A LONG TIME AT THIS POINT AND
SHE'S BEEN AN OUTSPOKEN ADVOCATE
FOR HOW IMPORTANT DATA SHARING
IS AND I WOULD HAP HAPPILY TALK
ABOUT HOW DO WE ENCOURAGE MORE
DATA SHARING AND WHY IS IT
IMPORTANT.
IT'S INCREDIBLY IMPORTANT TO
GIVE DATA SHARING TO HAPPEN
BECAUSE PARTICULARLY IF IT'S
FUNDED EITHER BY FOUNDATIONS OR
BY PUBLIC DATA OR PUBLIC MONEY
RATHER IT DOES BELONG TO
EVERYONE.
AND IT NEEDS TO BE AS ACCESSIBLE
AS POSSIBLE AND THAT'S HOW WE
ACCELERATE SCIENCE.
>> SPEAKING OF AMANDA, WHY DON'T
YOU GO NEXT.
>> I'M CURIOUS AS WE'RE
DEVELOPING THE NEW INITIATIVES
NCDI AND CCDI IF THERE WILL BE
ANN OPPORTUNITY TO AGGREGATE
DATA ACROSS DISPARATE DISEASES
WE'RE TALKING ABOUT CANCER
RESEARCH BUT WE KNOW MUTATIONS
ARE HAPPENING IN OTHER DISEASES
AND RARE DISEASES.
WILL WE POSITION ITS IN A WAY TO
AGGREGATE THE DATA SET AND DO
MORE WITH THE ANALYSIS?
>> THAT'S A TIMELY QUESTION.
I WAS JUST TALKING WITH FOLKS AT
NCBI THE NATIONAL CENTER FOR BIO
TECHNOLOGY INFORMATION I THINK
IT'S AN OLD TITLE THERE.
THEY HOLD SHORT READS AND WORK
WITH THE NCI INSTITUTES THAT
COVER A LOT OF DISEASE.
AND ALLOW TO SHARE DATA WITH NCI
MORE EFFECTIVELY.
HOW DO WE BRING DIFFERENT VIEW
POINTS TOGETHER.
WE WANT TO FOCUS ON THE WHOLE
HUMAN AND WE'RE' COLLECTION OF
ORGAN SYSTEMS AND DIFFERENT
THINGS.
WE THINK THAT BEING ABLE TO
ACROSS THE WAY THE WAY DISEASE
GROUPS THINK OF THEIR DISEASE
WILL BE TRANSFORMATIVE FOR
EVERYBODY.
THAT GETS AT YOUR QUESTION ABOUT
HOW DO WE BUILD THE BIGGER VIEW
OF DATA TO USE A.I. TOOLS MORE
EFFECTIVELY.
THEY'RE TIED TOGETHER.
DID I ANSWER YOUR QUESTION?
>> KIND OF.
>> IT'S NICE IT'S BEING
DISCUSSED.
>> YOU DID AIN'T EXCELLENT JOB
OF DESCRIBING THE BIO MEDICAL
DATA THAT IS NECESSARY TO BE
COLLECTED FROM EACH PATIENT AND
TUMOR.
TUMORS WITHIN A PATIENT CAN BE
HETEROGENEOUS.
IN ORDER TO USE THAT TO DRIVE A
PRECISION ONCOLOGY FRAMEWORK WE
NEED TO ASSOCIATE THE DATA WITH
WITH TREATMENT AND OUTCOME AND
GENDER AND RACE AND
COMORBIDITIES.
THE MORE YOU DO THAT THE GREATER
THE OPPORTUNITY TO PERSONALLY
IDENTIFY THE PATIENT AND TO
VIOLENCE THE PRIVACY FRAMEWORK
YOU'VE DESCRIBED.
MY QUESTION IS HOW DO YOU
RECONCILE THE TENSION BETWEEN
MAINTAINING PRIVACY AND
ACCUMULATING THE DATA THAT'S
NECESSARY FOR PRECISION ONCOLOGY
DIRECTION.
>> FIRST, I AGREE WE NEED THE
DATA AVAILABLE TO MAKE THEM AS
USEFUL AS POSSIBLE.
IT'S IMPORTANT TO IDENTIFY
INDIVIDUALS IN A PROTECTED
ENVIRONMENT AND PEOPLE HAVE TO
AGREE TO THOSE PROTECTIONS AN
THAT AFWREEMENT.
I ALSO THINK IT'S REALLY
IMPORTANT WE MAKE SURE AS WE'RE
PULLING THE DATA TOGETHER
PATIENTS HAVE CONSENTED
APPROPRIATELY TO IT AND AGREE
THE USE OF THEIR DATA AND ALL
THOSE THINGS COME TOGETHER
UNIMPORTANT WAYS AS WE'RE
BUILDING OUT A DATA ECO SYSTEM
FOR CANCER.
>> THANK YOU SO MUCH.
NATHANIEL.
>> YOU HAD A COMMENT ON RURAL
PATIENTS AND I WANT TO HARKEN ON
THAT QUICKLY BECAUSE IT'S AN
IMPORTANT SUBSET OF THE
POPULATION TO KNOW IT
ENCOMPASSES THIS IN THE UNITED
STATES AND OFTEN TIMES THE
MECHANISMS THAT YOU MENTIONED
FOR GATHERING THE DATA ARE NOT
QUITE AS EQUALLY DISTRIBUTED TO
RURAL COMMUNITIES.
THEY OFTEN TIMES DON'T GET THE
OUTPUT NOR THE INPUT OF THE
DATA.
I THINK THERE'S SOME MORE
DILIGENCE TO BE DONE THERE AND I
JUST WANT TO SUPPORT YOUR VIEW
POINT THERE OF THINKING OF
INNOVATIVE WAYS IN WHICH TO
REACH THE COMMUNITIES FOR THAT
INPUT PIECE OF THINGS TO BETTER
INFORM THE DATA SETS.
THAT'S MY COMMENT.
LEADING INTO MY QUESTION WHICH
IS SOMEWHAT UNRELATED, I THINK
AS WE THINK ABOUT DATA AND A.I.
TOOLS AND KATIE BROUGHT UP A
GOOD PERSPECTIVE HOW TO INVOLVE
RESEARCH ADVOCATES, I CONTINUE
TO THINK ABOUT WHEN IS IT
APPROPRIATE TO HAVE THE HUMAN
ELEMENT OF CARE AND WHEN IS IT
APPROPRIATE TO HAVE A MORE DATA
BACKED OR SCIENCY TYPE
PERSPECTIVE ON THINGS.
THAT DELINEATION AS YOU THINK
ABOUT THIS ARE YOU THINKING WHEN
IS THE APPROPRIATE WAY AND TIME
TO APPLY DATA.
IS IT TALK TO THE A.I. AND
THEY'LL TELL YOU MORE ABOUT THE
CANCER DIAGNOSIS OR A.I. SPEAKS
TO THE POSITION TO HAVE A MORE
HUMAN ELEMENT.
I WANT YOUR PERSPECTIVES ON HOW
YOU'RE THINKING ABOUT
APPLICABILITY MUCH THE A.I.
TOOLS RATHER THAN REPLACING THE
CARE TEAM.
>> THANK YOU.
>> THANK YOU FOR SAYING THAT THE
A.I. CAPABILITIES ARE JUST TOOLS
AND REQUIRE PEOPLE TO USE THEM.
ONE OF THE PHRASES I DIDN'T
MENTION IS YOU NEED TO HAVE A
HUMAN IN THE LOOP.
THERE ALWAYS HAS TO BE SOMEBODY
THERE TO MAKE SURE THE A.I.
TOOL'S NOT GETTING OFF THE
RAILS, I WOULD SAY.
I THINK THE OPPORTUNITIES FOR
A.I. IN SEVERAL PLACES I FEEL
LESS PUTTING THEM INTO A PLACE
WHERE THEY CONVERSE WITH THE
CARE TEAM OR PATIENTS.
I THINK THE OPPORTUNITY THAT I
FEEL THE MOST COMFORTABLE WITH
RIGHT NOW IS HOW DO WE USE IT TO
IDENTIFY EITHER SIGNALS IN THE
DATA WE'RE GENERATING OR DO A
BETTER JOB OF ANALYZING AND
COMING UP WITH REALLY
DISCOVERIES FROM THE DATA WE'RE
GENERATING.
THERE I FEEL PRETTY COMFORTABLE
BUT WE CAN INCORPORATE THE TOOLS
BECAUSE THEY'RE FEEDING INTO
THIS EXISTING RESEARCH
FRAMEWORK.
BUT YOU'RE RIGHT, PEOPLE ARE
ASKING CHAT GPT AND FEEDING IT
THEIR RECORD AND SAYING HOW DO I
THINK ABOUT THIS.
I DON'T THINK THE TOOLS ARE
READY YET.
I'M NOT SURE HOW TO ANSWER THAT
QUESTION.
>> DR. KIBBE SO MUCH.
I CAN'T WAIT UNTIL WE GET CLOSER
AND SEEING WHAT ADVOCATES CAN DO
TO HELP THINGS GET READY AND
MAKE SURE THAT NOT ONLY THERE'S
HUMAN INVOLVEMENT AND PEOPLE
WITH LIVED EXPERIENCE ARE ALSO
IN THE MIX WHEN THINGS ARE BEING
DEVELOPED.
THANK YOU SO MUCH FOR SPENDING
TIME WITH US AND FOR THE GREAT
DIALOGUE.
>> YOU'RE WELCOME I HOPE NEXT
TIME I'LL BE IN THE ROOM WITH
YOU.
>> WE WOULD LOVE THAT SO MUCH.
LOOKING FORWARD TO IT.
NEXT UP WE HAVE MS. HOLLY
GIBBONS OUR DEPUTY DIRECTOR OF
THE NCI OFFICE OF GOVERNMENT AND
CONGRESSIONAL RELATIONS.
THANK YOU SO MUCH FOR HANGING
OUT WITH US AND YOUR PATIENCE
AND WE ARE ACTUALLY GOING TO NOT
TAKE OUR LUNCH BREAK UNTIL NOON
SO WE GOT FIVE EXTRA MINUTES.
THANK YOU SO MUCH.
>>
[NO AUDIO]
>> WE'RE SEEING RESOLUTION
PROPOSALS I'LL TALK MORE ABOUT
BUT NOT SURE WHEN THE FEDERAL
FUNDING WILL BE EXTENDED
THROUGH.
SO WE DON'T KNOW WHETHER BE A
CONTINUING RESOLUTION AND WANT
TO START WHERE WE ENDED UP FOR
THE PROPOSALS.
THE HOUSE STARTED WRITING THEIR
LEVELS TO ENACTED LEVELS BELOW
'24 AND SENATE ABOVE FY24 AND
THE HOUSE PROPOSED KEEPING NIH
FLAT.
YOU MIGHT WONDER WHY IS THE
HOUSE PROPOSING THE INCREASE FOR
NCI WHEN THE SENATE IS PROPOSING
A $266 INCREASE AND THAT'S
BECAUSE THERE'S PROPOSALS ON THE
HOUSE SIDE TO RESTRUCTURE NIH TO
COMBINE CERTAIN INSTITUTES AND
SHIFTING RESOURCES BETWEEN
INSTITUTES.
SO WITH DO NOT EXPECT TO SEE
$651 MILLION UNFORTUNATELY.
THERE ISN'T BIPARTISAN SUPPORT
FOR THAT APPROACH AND NOT A LOT
OF SUPPORT IN THE SENATE.
WE'RE GLAD TO SEE PROPOSED
INCREASES ON BOTH SIDES BUT
WE'LL HAVE TO SEE WHERE FINAL
NEGOTIATIONS LAND.
ON THE SENATE SIDE IT WAS A
BIPARTISAN PROPOSAL AND PASSED
25-3 WHEREAS THE HOUSE PROPOSAL
PASSED ALONG PARTY LINES.
THE GOOD NEWS IS THERE IS STILL
STRONG BIPARTISAN SUPPORT FOR
CANCER RESEARCH ACROSS THE
AISLE.
YOU SEE TOM COLE FROM OKLAHOMA
AND THE COMMITTEE CHAIR PATTY
MUR RAY WITH STRONG SUPPORT FOR
BIOMEDICAL RESEARCH.
STRONG SUPPORT AND GREAT
CONVERSATIONS ACROSS THE BOARD
WITH LEADERS OF OUR
SUBCOMMITTEES.
DR. RATHMELL HAS BEEN A GREAT
CHAMPION FOR INCREASED
INVESTMENT IN NCI AND MET WITH
RANKING MEMBERS OF THE FULL AND
SUBCOMMITTEE CONGRESS DELAURO
PICTURED THERE WITH DR
DR. BERTAGNOLLI AND ALL THESE
PEOPLE ARE INCREDIBLY SUPPORTIVE
OF NCI.
QUICK LOOK AT THE CALENDAR.
I ALWAYS LIKE IT SHARE THE
CALENDAR THERE'S A LOT GOING ON
IN THE NEXT FEW MONTHS.
FEDERAL FUNDING RUNS OUT
SEPTEMBER 30.
THERE'S ONLY SEVEN DAYS AFTER
TODAY WHERE BOTH THE HOUSE AND
SENATE ARE IN SESSION TO FIGURE
OUT THE FIRST CONTINUING
RESOLUTION.
OCTOBER LOOKS CLEAR PAUSE THE
HOUSE AND SENATE ARE ON RECESS
AHEAD OF THE ELECTION AND RETURN
TO SESSION NOVEMBER 12 FOR THE
LAME DUCK SESSION.
THAT SHORT PERIOD OF NOVEMBER
AND DECEMBER BEFORE THE NEW
CONGRESS IS SWORN IN.
ALSO IN JANUARY WE HAVE THE
EXPIRATION LOOMING JANUARY 2 AND
DEPENDING ON WHAT MEASURES THE
TREASURY IS ABLE TO TAKE IT MAY
SHIFT BUT A LOT OF ALIGNS WITH
EARLY SEPTEMBER AND JANUARY AND
PRESSURE ON CONGRESS TO FIGURE
OUT THE FUNDING AND DEBT LIMIT
EXTENSION.
SPEAKER JOHNSON IN THE HOUSE IS
BRINGING A CR THROUGH MARCH
TAKING THINGS INTO THE NEW
CONSIDERATION.
THE 119th CONGRESS.
HE IS PAIRING THAT WITH ANOTHER
BILL WHICH WOULD PROHIBIT NON
CITIZENS FROM VOTING ALREADY
ILLEGAL.
THERE'S ALREADY CONTROVERSY AND
OPPOSITION TO THE BILL AND IT'S
NOT EXPECTED TO PASS.
THAT WILL BE HAPPENING LATER
DATA AND THEN WE'LL SEE WHAT IS
THE NEXT POSITION.
WE HAVE SEEN REPORTING THAT THE
SENATE IS DEVELOPING A C.R.
PROPOSAL THROUGH MID DECEMBER.
TYPICALLY THESE FUNDING BILLS
ORIGINATE IN THE HOUSE BUT
EVERYONE IS GETTING IMPATIENT TO
FIGURE OUT FEDERAL FUNDING AND
MAY SEE THE SENATE MOVE NEXT.
QUICKLY ON THE ELECTION I'M SURE
YOU'VE BEEN READING YOUR OWN
REPORTING.
I WANTED TO HIGHLIGHT POTENTIAL
FOR CHANGE IN BOTH THE HOUSE AND
SENATE.
THERE HAVE BEEN A LOT OF
REQUIREMENTS AND I COVERED THAT
IN ONE OF OUR LAST MEETINGS.
WE SEE IN THE HOUSE THERE ARE 24
SEATS AND SO THE DEMOCRATS HAVE
AN OPPORTUNITY TO FLIP THE
HOUSE.
ON THE SENATE THERE'S
OPPORTUNITIES AND DON'T KNOW
WHERE THEY'LL LAND.
WE KNOW WE'LL HAVE A DIFFERENT
MAKE UP OF CONGRESS EITHER WAY
IN JANUARY BECAUSE OF ALL THE
RETIREMENTS.
SEVERAL CANCER CHAMPIONS HAVE
RETIRED AS WELL SO WE'RE ALL
INTERESTED TO SEE THE NEW
CONGRESS.
THESE ARE JUST A LOOK BACK AT
RECENT LAME DUCK SESSIONS AT
EACH ELECTION AND PRESIDENTIAL
ELECTION YEARS.
SPOILER ALERT THERE'S BEEN NO
PATTERNS AND DIFFERENT APPROACH
EVERY YEAR.
WE'RE HOPE UNTIL WE'LL SEE C.R.
THROUGH DECEMBER AND FINAL
FUNDING FOR FY25 TO MOVE AHEAD
FOR FY26 BUT NOT SURE HOW THINGS
WILL LAND.
UNFORTUNATELY SOME YEARS WE SAW
PARTIAL GOVERNMENT SHUTDOWN IN
2018.
NCI AND THE BILLS UNDER THE HHS
ACCOUNT WERE PAIRED WITH THE
DEPARTMENT OF DEFENSE AND THE
FIRST YEAR SINCE THE MID '90s WE
RECEIVED OUR APPROPRIATION ON
TIME AND THERE WAS A SHUTDOWN
FOR OTHER GOVERNMENT AGENCIES
AND THAT'S NOT WHAT WE WANT
EITHER AND WE DIDN'T RECEIVE A
FINAL BUDGET UNTIL PLAY AND
THAT'S DISRUPTIVE AND WE'LL BE
THAT CLOSELY.
OTHER LEGISLATIVE ACTIVITY.
THERE'S OTHER MUST PASS BILLS
BEFORE THE END OF DECEMBER.
OTHER AUTHORIZATIONS, OTHER
FUNDING EXPIRING SO THE NATIONAL
DEFENSE AUTHORIZATION, THE FARM
BILL AND OTHER MEASURES.
THERE ARE ALSO A LOT OF OTHER
LEGISLATIVE PROPOSALS NOT UP
AGAINST DEADLINES OF INTEREST.
HERE I'VE HIGHLIGHTED SEVERAL OF
INTEREST TO NCI AND THE
BIOMEDICAL RESEARCH COMMUNITY
BUT IT'S HARD TO TELL WHETHER
CONGRESS WILL HAVE THE TIME OR
THE ENERGY TO GET TO THINGS THAT
ARE PASSED.
I WILL HIGHLIGHT QUICKLY I THINK
I SHARED AN INTRODUCTION TO THIS
PROPOSAL AT OUR LAST MEETING BUT
WANTED TO BRING IT UP BECAUSE
PIECES WERE INCORPORATED IN THE
HOUSE APPROPRIATIONS PROPOSAL.
THIS IS FROM THE HOUSE ENERGY
AND COMMERCE COMMITTEE AND AGAIN
PROPOSING CHANGING AND REFORMS
TO NIH AND RESTRUCTURING.
HOWEVER, NCI WILL NOT BE
RESTRUCTURED.
THIS IS SLOW TO GET STRONG
SUPPORT IN THE SENATE AND SLOW
TO GET BIPARTISAN SUPPORT AND
WATCHING IT BUT SHE'S NOT
INTRODUCED THE STAND ALONE BILL.
ALSO WANTED TO MENTION THE
ENERGY AND COMMERCE COMMITTEE IS
MARKING UP 16 BILLS THAT ARE OF
INTEREST AND ONE ACT FOCUSES ON
FDA AND POTENTIAL NEW REGULATORY
AUTHORITY AROUND COMBINATION OF
TARGETED THERAPIES FOR CHILDHOOD
CANCER AS WELL AS THE TELEHEALTH
MODERNIZATION ACT WHICH FOCUSES
ON TELEHEALTH EXTENSIONS UNDER
MEDICARE.
RECENT CONGRESSIONAL ENGAGEMENT.
DR. RATHMELL IS PICTURED AT THE
NATIONAL BRAIN TUMOR SOCIETY
ANNUAL CONGRESSIONAL RECEPTION
FOR BLASTOMA AWARENESS AND
CONGRESSWOMAN WILD AND WILLIAMS
SPOKE ON THEIR EXPERIENCE AND
CONGRESS WOMAN WILD LOST HER MOM
TO BLASTOMA.
AND THERE WAS A VISIT AND WANTED
TO EMPHASIZE SENATOR MORAN AND
SENATOR DURBIN WERE TWO MEMBERS
OF OUR SENATE APPROPRIATIONS
SUBCOMMITTEE TWO HUGE CHAMPIONS
FOR NCI FOR CANCER RESEARCH FOR
BIOMEDICAL RESEARCH OVER ALL AND
GREAT OPPORTUNITIES TO ENGAGE
AND ALSO TO ENGAGE WITH THE
COMMUNITIES AT THEIR
INSTITUTIONS AND THAT'S A
PICTURE IN THE BOTTOM RIGHT
CORNER, DR. RATHMELL AND SENATOR
MORAN AND TRAINING WITH LOCAL
ADVOCATES AND IT WAS A GREAT
OPPORTUNITY TO HEAR EVERYONE'S
PERSPECTIVE.
MOST RECENTLY LAST FRIDAY
SENATOR JACK REED ANOTHER MEMBER
OF THE LABOR HHS COMMITTEE AND
THE SPONSOR OF THIS CANCER STAR
ACT MET WITH LEADERS OF OUR
PEDIATRIC ONCOLOGY BRANCH AND
PICTURED HERE WELCOME BACK THE
CHIEF OF THE ONCOLOGY BRANCH AND
THE CLINICAL DIRECTOR AND
TOMORROW THE CONGRESSIONAL
CHILDHOOD CANCER CAUCUS IS
HOSTING THEIR ANNUAL SUBMIT AND
HERE AN OPENING MESSAGE FROM
DR. RATHMELL I CAN'T MAKE THE
MEETING BUT WE'RE EXCITED TO
HAVE TWO NCI SUPPORTED
INVESTIGATORS AND LEADERS IN THE
FIELD DR. HAWKINS AND
DR. PARSONS WILL BOTH SPEAK AT
THE SUMMIT.
NEXT WEEK, TUESDAY, DR. KIBBE
WILL BE PART OF A CONGRESSIONAL
BRIEFING.
I WANTED TO END HERE WITH A
PIECE OF ARTWORK FROM THE BOOK
SWIM
SWIMMY.
IT'S A CHILDREN'S BOOK I DIDN'T
DISCOVER IT AS A CHILD BUT AT A
TRAINING AND HAS ALWAYS SPOKEN
TO ME ABOUT THE POWER OF
SWIMMING TOGETHER AND IN
RECOGNITION OF THE WORK YOU DO
AND THINK WE CAN BE POWERFUL IN
EXPRESSING THE URGENCY OF THE
WORK AND RETURN ON INVESTMENT
AND THANK YOU FOR ALL YOU DO AND
SWIMMY IS THE LITTLE BLACK FISH
AND THE LEADER OF THE SCHOOL.
SOMETIMES SWIMMY IS NCI,
SOMETIMES IT'S YOUR ORGANIZATION
OR YOU AS AN INDIVIDUAL ADVOCATE
AND ALL THOSE ARE INCREDIBLY
IMPORTANT ROLES.
WE LOOK FORWARD TO WORKING WITH
YOU IF YOU'RE PLANNING ANY
CONGRESSIONAL BRIEFING OR EVENTS
WHERE NCI CAN BE HELPFUL AND
WOULD LIKE A SUBJECT MATTER
EXPERT INVOLVED, REACH OUT,
WE'RE HAPPY TO HELP AND MY
CONTACT INFORMATION.
REACH OUT ANY TIME.
THANK YOU.
>> THANK YOU SO MUCH, HOLLY.
YOUR REPORTS ARE ALWAYS
COMPREHENSIVE, HOPEFUL AND
TERRIFYING.
WE APPRECIATE THE HARD WORK YOU
AND YOUR TEAM TO STAY ON TOP OF
EVERYTHING AND THANK YOU FOR
THAT INTRODUCTION TO SWIMMY.
I CAN'T WAIT TO GET MY HANDS ON
THE BOOK.
I HAD A QUESTION IF NO ONE ELSE
HAS A QUESTION ABOUT YOU
MENTIONED POSSIBLY SOME OF THE
LEGISLATION THAT MAY PASS IN THE
COMING MONTHS AND I'M CURIOUS
ABOUT THE DRUG SHORTAGES.
WE HEAR THAT SOME THINGS ARE
RESOLVED AND IT FEELS LIKE IT'S
AN ONGOING THREAT DO WE KNOW IF
ANY OF THE NCI TRIALS OR
RESEARCH HAVE BEEN IMPACTED BY
THE SHORTAGES?
PROBABLY NOT YOUR QUESTION.
>> I HAVE NOTE CHECKED RECENTLY.
AT CERTAIN POINTS IN TIME WE DID
RECEIVE SOME QUESTIONS ABOUT AND
NCI TRIALS AT THE CLINICAL
CENTER AND THE NETWORK HAD NOT
BEEN DIRECTLY EFFECTED.
SOME INSTITUTIONS HAD BEEN
HEARING FROM PATIENTS SO I DON'T
KNOW IF DR. RATHMELL HAS
ANYTHING ADDITIONAL IT SAY.
>> THAT'S CORRECT.
THIS IS AN ISSUE THAT KEEPS
COMING UP AND COMES UP IN ALL
DIFFERENT DRUGS AND HARD TO
ANTICIPATE.
I DON'T KNOW WE CAN POINT TO
SOMEONE WHO DIDN'T GET TREATMENT
AROUND CONTINGENCY PLANS OR
TRYING TO KEEP UP WITH WHERE
THINGS ARE GOING ON.
IT CONTINUES TO BE AREAL ISSUE.
>> THOSE ARE PROPOSALS WE EXPECT
TO SEE RE-INTRODUCED IN THE
CONGRESS IF THEY DON'T MOVE IN
THE NEXT COUPLE OF MONTHS.
>> I SEE HUNGRY FACES SO THANK
YOU AGAIN FOR ALWAYS COMING AND
INFORMING US.
WE APPRECIATE IT, HOLLY.
AND WITH THAT WE WILL TAKE A
BREAK FOR LUNCH.
DO YOU HAVE THE ANNOUNCEMENTS?
AND WE'LL RECONVENE AT 1:00.
>> I WOULD LIKE TO CALL THE
MEETING BACK TO ORDER AND THANK
YOU FOR RETURNING BACK ON TIME.
I'D LIKE TO WELCOME THE OF
OPERATIONS FOR THE NIH
COMMUNITIES ADVANCING RESEARCH
FOR HEALTH NETWORK, MS. AJAZI.
SHE JOINED IN 2004 AND WAS CHIEF
OPERATING OFFICER AND CHIEF
ADMINISTRATIVE OFFICER FOR THE
CLINICAL ALLIANCE AND WE LOOK
FORWARD TO YOUR PRESENTATION.
>> THANK YOU.
>> GOOD AFTERNOON.
THANK YOU FORE INVITING ME ON TE
INITIATIVE.
AS NETTED I'M THE OPERATIONS
DIRECTOR FOR THIS PROGRAM.
I ALSO WOULD LIKE TO NOTE AMY
PATTERSON IS ON THE ZOOM LINE.
AMY IS THERE.
THERE'S AMY.
SO IN TODAY'S TALK I'LL PROVIDER
AN OVERVIEW AND THE COMPONENTS
OF THE PROGRAM WE'RE PLANNING
AND THEN I AM LOOKING FORWARD TO
AN OPEN DISCUSSION WITH YOU AT
THE END OF MY TALK.
SO WHY CARE FOR HEALTH?
THE HEALTH OF THE
U.S. POPULATION IS DECLINING.
AND THIS DECLINE IS STEEPEST
AMONG THE UNDER SERVED AND UNDER
REPRESENTED POPULATIONS.
AND U.S. LIFE EXPECTANCY RANKS
LOW AMONG PEERS AS YOU'LL SEE
DEPICTED ON THE SLIDE HERE.
IT DROPS SIGNIFICANTLY BY 2.4
YEARS BETWEEN 2019 AND 2021 AND
THE INCREASES IN 2022 DOES NOT
MAKE UP FOR THE PANDEMIC LOSSES.
SO THIS PROGRAM LAUNCHED IN JUNE
OF 2024 ONE A $30 MILLION PILOT
TO TEST THE FEASIBILITY OF A
NATIONAL PRIMARY CARE RESEARCH
NETWORK.
AND I WILL NOTE THAT THE FIRST
SET OF AWARDS THAT WE WILL BE
PROVIDING FOR THE PROGRAM IS FOR
RESEARCH IN THE RURAL HEALTH
COMMUNITIES.
THIS SLIDE GOES OVER THE AIMS OF
THE PROGRAM WHICH INCLUDE THE
AIM TO INTEGRATE RESEARCH INTO
THE CLINICAL CARE ENVIRONMENTS.
WE WANT TO ENGENDER TRUST IN
SCIENCE BY ADDRESSING THE
COMMUNITY NEEDS, CONDUCT
RESEARCH ADDRESSING ISSUES
IMPORTANT TO DIVERSE
COMMUNITIES, PARTICULARLY THOSE
UNDER REPRESENTS BIO MEDICAL
RESEARCH AND TO REDUCE BURDEN ON
PROVIDERS USING INNOVATIVE DATA
COLLECTION METHODS, INCREASE
ADHERENCE OF EVIDENCE-BASED
CARE, IMPROVE EFFICIENCY OF CARE
DELIVERY AND LAST BUT NOT LEAST
TO ACHIEVE THE LONGITUDINAL
COLLECTION OF CLINICAL DATA TO
ADDRESS HEALTH ACROSS THE LIFE
SPAN.
SO IN ORDER TO ESTABLISH THIS
NIH NETWORK WE ARE GOING TO HAVE
A COORDINATED INFRASTRUCTURE FOR
INNOVATIVE RESEARCH INTO ROUTINE
CLINICAL CARE IN THE PRIMARY
CARE SETTING BY SUPPORTING
PRIMARY CARE BASED CLINICAL BASE
IN MISSION AREAS, PREVENTION AND
TREATMENT WITH A FOCUS ON HEALTH
EQUITY AND WHOLE PERSON HEALTH.
WE SEEK TO ESTABLISH A
FOUNDATION FOR SUSTAINED
ENGAGEMENT WITH COMMUNITIES
UNDER REPRESENTED IN RESEARCH
AND DO AIM TO ESTABLISH
INFRASTRUCTURE FOR IMPLEMENTING
INNOVATIVE STUDY DESIGNS
SUITABLE TO PRIMARY CARE STUDIES
AND ENHANCE DISSEMINATION AND
IMPLEMENTATION THEREBY ADVANCING
HEALTH EQUITY FOR ALL.
IN ADVANCE OF THE LAUNCH FOR
THIS PROGRAM AND ALSO TO INFORM
THE PLANNING, NIH DID HAVE
SEVERAL LISTENING SESSIONS ALONG
THE FOLLOWING THEMES INCLUDING
SUSTAINED ENGAGEMENT OF PATIENTS
AND COMMUNITY ORGANIZATIONS,
CLINICAL RESEARCH NETWORK
CAPABILITIES, THE NEEDS OF
PROVIDERS AND HEALTH CARE
SYSTEMS FOR RESEARCH PART
PASSION AND CLINICAL RESEARCH
INNOVATIONS TO REDUCE SITE AND
PROVIDER BURDEN.
SO WE DID CATEGORIZE AND
SUMMARIZE THE RESULTS OF THE
LISTENING SESSIONS INTO THREE
MAJOR CATEGORIES INCLUDING
BRIDGING GAPS AND BUILDING
CONNECTION.
I'M GOING TO HIGHLIGHT NOT GOING
TO GO THROUGH EVERY POINT ON THE
SLIDE BUT HIGHLIGHT A FEW
POINTS.
IN ORDER TO BUILD SUSTAINABILITY
AND EFFECTIVE PARTNERSHIP IT'S
IMPORTANT THE ENGAGEMENT IS
CONTINUOUS AND NOT EPISODIC AND
THAT WE DO MAINTAIN THESE
RELATIONSHIPS WITH THE LOCAL
COMMUNITY PARTNERS.
IT'S IMPORTANT TO DEVELOP AND
DEMONSTRATE WE ARE TRUST WORTHY
AND THAT INCLUDES CO-DEVELOPMENT
IN ORDER TO SHAPE THE RESEARCH
AGENDA.
AND NEED BETTER APPROACHES TO
UNDERSTAND THE DIVERSE NEEDS OF
COMMUNITIES.
IN TERMS OF PROVIDER NEEDS, WE
DO NEED TO ACCOUNT FOR THE NEEDS
OF THE PROVIDERS BY ALIGNING THE
PRACTICE NEEDS AND RESEARCH
STRUCTURES.
IT'S IMPORTANT TO CONSIDER THE
WORK LOAD OF HEALTH CARE
PROVIDERS ESPECIALLY IN THE
PRIMARY CARE SETTING WHERE THERE
IS NOT MUCH ROOM OR RESOURCES
FOR THE RESEARCH.
IT'S IMPORTANT TO REDUCE THEIR
BURDEN BY DEVELOPING INNOVATIVE
STUDY DESIGN AND TECHNOLOGY.
YOU'LL NOTE ONE POINT NOTED IS
HOW DO WE UTILIZE THE I IN THESE
DESIGNS, COMMON DATA MODELS AN
DATA TOKENS IN ORDER TO SIMPLIFY
THE RESEARCH PROCESS.
IT'S IMPORTANT TO CONSULT WITH
THE PROVIDERS TO INFORM HOW
TECHNOLOGY CAN BE INTEGRATED
INTO RESEARCH.
AND LAST BUT NOT LEAST WE ALL
KNOW THERE'S ALWAYS A NEED FOR
RESEARCH FUNDING AND IT'S
IMPORTANT TO BALANCE THE
FINANCIAL IMPLICATIONS OF
RESEARCH.
TO ADDRESS PATIENT
SUSTAINABILITY AND VALUE AND
EQUITABLY COMPENSATE THE
COMMUNITY AND INDIVIDUALS AND
COMMUNITIES PARTICIPATING IN OUR
RESEARCH.
ONE THING THAT I WANT TO NOTE
THROUGHOUT ALL OF THE LISTENING
SESSIONS IS THAT THE
PARTICIPANTS EMPHASIZE THE NEED
TO INCLUDE THEM IN THE DECISION
MAKING PROCESS, THE PROVIDERS,
PATIENTS AND COMMUNITIES AND
THAT IT WAS NOT ENOUGH FOR THEM
TO JUST BE ADVISORY.
SO I'M GOING TO BUILD THE
APPROACH OF BUILDING NETWORKS.
IN ORDER TO HAVE A QUICKER
LAUNCH WE ARE IN THE PROCESS OF
EXPANDING ENROLLMENT EFFORTS OF
EXISTING NIH STUDIES AND THEN
GOING TO TURN OUR ATTENTION TO
DEVELOP NEW STUDIES AS THE
INFRASTRUCTURE IS ESTABLISHED.
THIS INCLUDES PARTNERING WITH
EXISTING CLINICAL RESEARCH
NETWORKS AND RESOURCES AND WE
ARE ENGAGING THE NIH CENTERS AND
OFFICES AS WELL AS COMMUNITY
NETWORK PARTNERS AS A WAY TO
PRIORITIZE AND APPLY FOR THE
RESEARCH FOR THE WE'RE TO
CONDUCT.
THIS INCLUDES IMPLEMENTING STUDY
DESIGNS ACROSS THE LANDSCAPE OF
CLINICAL TRIAL INNOVATIONS TO
REEMPHASIZE THE POINT OF
MINIMIZING THE BURDEN ON
PATIENTS AND PROVIDERS.
THE COMPONENTS OF THIS
INFRASTRUCTURE INCLUDE EMBEDDED
IN THE INFRASTRUCTURE IS THE
COMMUNITY ENGAGEMENT ACTIVITIES
AS WELL AS THE INDUSTRY
PARTNERSHIPS WOULD BE PART OF
THIS AS WE MOVE ALONG.
AND THEN AS PART OF THE NIH WE
ARE GOING TO CENTRALIZE THE
CLINICAL AND OPERATION CENTER
WITHIN THE PROGRAM.
AND THIS INCLUDES ALSO PROVIDING
FOR THE INDEPENDENT REVIEW AND
MONITORING BOARDS.
ONE KEY TO THUS INFRASTRUCTURE
ARE THE NETWORK RESEARCH HUBS
THAT WILL CONDUCT THE RESEARCH
AT THE PRIMARY CARE SETTINGS.
THIS SLIDE INCLUDES ENTITIES
IDENTIFIED FOR SYNERGISTIC
PARTNERSHIPS.
OBVIOUSLY NOT ALL INCLUSIVE HERE
AND THAT INCLUDES PARTNERING
WITH FEDERAL AGENCIES, FQHCs AND
HCHs, PROFESSIONAL SOCIETIES AND
OUR NETWORKS AND INDUSTRY
PARTNERS.
SO, WE DID ISSUE A ROA OVER THE
SUMMER AND WE'RE ON THE VERGE OF
AWARDING A FEW.
SO THE PURPOSE OF THE ROLE WAS
FOR APPLICATIONS FOR
ORGANIZATIONS TO SERVE AS
NETWORK RESEARCH HUBS TO
ESTABLISH AN INFRASTRUCTURE TO
CONDUCT RESEARCH IN RURAL
PRIMARY CARE SETTINGS AS A
TWO-YEAR PILOT.
THESE HUBS NEEDED TO BE LOCATED
IN STATES WITH AT LEAST 25% OF
CENSUS DEFINED AS RURAL USING
CODES.
SO THE TIME LINE FOR THIS
INITIATIVE IS TO AS NOTED
EARLIER LAUNCH IN 2024 TO EXPAND
STUDIES TO INCREASE ENGAGEMENT
WITH UNDER REPRESENTED RURAL
POPULATIONS AND ENHANCE AACCRUAL
ACCRUAL AND ADMINISTRATION AND
IT'S ADMINISTERED BY THE NIH
ECONOMIST AND THE RESEARCH
OPPORTUNITY WAS ANNOUNCED IN MAY
AND WILL AWARD 5.4 AND 5.6 IN A
COUPLE WEEKS THE AWARDS WILL BE
OUT BY THEN.
IN 2025 AND BEYOND WE'RE GOING
TO LAUNCH ADDITIONAL STUDIES AND
ESTABLISH THE NETWORK
INFRASTRUCTURE.
AND HOPE TO RAMP UP FOR THE
FUNDING FOR THE PROGRAM WITH THE
EXPECTATION THE PILOT WILL BE
SUCCESSFUL.
AS A PHASED APPROACH OF OUR TIME
LINE WE'RE LAUNCHING THESE
NETWORK RESEARCH HUBS TO
PARTICIPATE IN EXISTING STUDIES
AND PLAN FOR NEW STUDIES
INTERVENTIONAL AND OBSERVATIONAL
AND THEN YEAR TWO WE'RE GOING TO
BUILD UP THE INFRASTRUCTURE WITH
AN EVALUATION POINT AT THE END
OF YEAR TWO.
AND THEN BEYOND WE DO NOTE WE DO
EXPECT TO EXPAND THE FOCUS
BEYOND RURAL COMMUNITIES IN
OTHER POPULATIONS AND SITUATIONS
WHERE WE HAVE UNDER SERVED AND
UNDER REPRESENTED POPULATIONS IN
CLINICAL RESEARCH.
EVEN MORE THAN WHAT'S DEPICTED
ON THE SLIDE.
THAT WAS THE PROGRAM OVERVIEW
AND OUR CURRENT STATUS.
I'D LIKE TO TURN A LITTLE BIT OF
ATTENTION BACK TO THE COMMUNITY
ENGAGEMENT COMPONENTS OF THE
PROGRAM.
I WANT TO NOTE THAT WE'RE EARLY
IN THE PLANNING.
IN FACT OUR FIRST COMMUNITY
ENGAGEMENT SPECIALIST MANAGER IS
ONLY STARTING IN THE NEXT FEW
WEEKS TO HELP US PLAN OUT OUR
COMMUNITY ENGAGEMENT COMPONENTS
FROM A CENTRALIZED STANDPOINT.
AND CARE FOR HEALTH.
AND THAT WILL INCLUDE OBVIOUSLY
LOCAL ENGAGEMENT THROUGH OUR
LOCAL RESEARCH HUBS.
WE'RE PLANNING FOR A COMMUNITY
ENGAGEMENT COMMUNITY THAT
INCLUDES PARTICIPATION AND
REALLY WE EXPECT THEM TO DO SOME
DRIVING FROM THE PATIENT
REPRESENTATIVES.
AND COMMUNITY REPRESENTATIVES,
SORRY.
AS PART OF OUR COORDINATION
EFFORTS WE EXPECT TO BE ABLE TO
PROVIDE WORKSHOPS, TOOL KITS
INCLUDING LEARNING AS PART OF
THESE COMPONENTS.
SO THAT BRINGS US TO DISCUSSION.
YOU'D LIKE TO OPEN IT UP FOR
QUESTIONS ON WHAT WAS PRESENTED
AND THEN AMY AND I WOULD LIKE TO
HEAR FROM YOU LESSONS LEARNED
FROM THE NCI COUNCIL ON ADVOCACY
EXPERIENCE AND SOME ADVICE HOW
TO PROMOTE EFFECTIVE STRATEGIES
TO THE PATIENT COMMUNITY AND HOW
TO INCORPORATE RESEARCH EFFICACY
AT THE RESEARCH NETWORK LEVEL.
SO THANK YOU.
>> THANK YOU SO MUCH FOR THIS
WONDERFUL PRESENTATION AND AMY
FOR BEING ONLINE.
IS THIS PRESENTATION FROM ASCO
WHERE YOU AND DR. BERTAGNOLLI
WERE ON STAGE?
OKAY.
THIS WAS EXCITING TO SEE
DR. RATHMELL AND DR. BERTAGNOLLI
ON STAGE TALKING ABOUT THIS AND
TO SEE HOW THINGS ARE COMING
TOGETHER AND JUST RESEARCH
HELPING EVERYBODY BEING ON
CANCER.
I KNOW MANY OF US HERE WITH OUR
FAMILY MEMBERS OR OURSELVES
THERE ARE ISSUES THAT ARE IN
NEED OF RESEARCH AND HEART
DISEASE AND SO MUCH OUT THERE
AND MAKING CLINICAL TRIALS AND
CONTRIBUTING TO RESEARCH MAKING
IT PART OF LIFE AND THE IMPACT
OF CANCER AND IF SOMEBODY HAS TO
DEAL WITH THAT RESEARCH IS PART
OF WHAT HAS TO HAP VPEN.
YOU MENTIONED THE COMMUNITY
ENGAGEMENT AND IT DOESN'T LOOK
AS THOUGH THERE HAVE BEEN
PATIENT OR COMMUNITY INPUT IN
PLANNING STAGES.
AND THAT YOU'RE GEARING UP FOR
THAT RIGHT NOW.
CAN WE GO BACK TO YOUR QUESTION
BECAUSE I WANT TO MAKE SURE WE
CAN DISCUSS THAT.
I'M WONDERING IF YOU'RE
LEVERAGING -- THE FIRST THING
THAT COME WILLS TO MIND IS THE
NCORP NETWORK AND CLINICAL
TRIALS OUT IN THE COMMUNITIES
AND CAN YOU LEVERAGE SOME OF THE
THINGS THAT HAVE BEEN LEARNED
AND ARE IN PLACE FROM HERE IN
REACHING COMMUNITIES UNDER
REPRESENTED AND GETTING PEOPLE
ENROLLED AND INTERESTED IN
CLINICAL TRIALS.
WELL, I DO COME FROM THE NCI EQ
SCRO SYSTEM, SHALL WE SAY.
-- ECO SYSTEM, SHALL WE SAY.
I DO VERY MUCHEN JOY WORKING
WITH THE NCORP FOLKS AND WOULD
BE HAPPY TO ENGAGE THEM IN
HELPING PLAN AND PROVIDE ADVICE
IN HOW TO DO THIS.
I KNOW ALSO AMY HAS BEEN WITH
NIH IN VARIOUS PROGRAMS AND ALSO
HAVE SOME EXPERIENCE IN THIS AND
HAVE SOME CONTEXT IN OTHER PARTS
OF THE NIH THAT WE HOPE TO
LEVERAGE SO SHORT ANSWER IS YES.
>> I WANT TO CHIME IN ON THIS A
LITTLE BIT TOO.
YOU MADE ONE POINT I WAS GOING
TO MAKE WHICH IS WE'RE REALLY
FORTUNATE TO HAVE A CANCER
PERSON IN THIS ROLE SO TRAINING
THE CANCER RESEARCH BACKWARDS
AND FORWARDS AND FOR ME THE
EXCITING THING ABOUT THIS IS
PREVENTION AND EARLY DETECTION
HAPPEN OUT IN PRIMARY CARE AND
THAT'S NOT BEEN A PART OF OUR
ECO SYSTEM AND IT SHOULD HAVE
BEEN.
NCORP WAS DESIGN TO HELP WITH
THIS BUT IT'S MEDICAL
ONCOLOGISTS BY AND LARGE.
BEING ABLE TO ENGAGE PRIMARY
CARE DOCTORS THERE WILL BE ALL
KINDS OF RESEARCH VALUABLE THERE
AND DOING GOOD PREVENTION AND
EARLY DETECTION WORK IT WILL BE
VERY EXCITING FOR US.
>> I WILL CONFESS THAT WAS PART
OF THE TRANSACTION IN THE
POSITION.
>> I WASN'T MESSENGER TO REACH
OUT AND LEVERAGING THE DOCTORS
LIKE THE PEOPLE WHO ARE DOING
THE CONSENTING AND PARTICIPATING
IN CLINICAL TRIALS AND HAVE
RELATIONSHIPS WITH THESE SITES
BECAUSE A LOT OF COMMUNITY
BUILDING GOES INTO THAT.
THAT WAS THE ASPECT I WAS
REFERRING TO AS FAR AS
LEVERAGING FOR THIS USE.
THE PRIMARY CARE DOCTORS DO
UNDERSTAND THEY'RE NOT
ADVOCATING BUT GOING TO DOCTORS
AND ASKING FOR MEASURES IN THE
NETWORKS AND IN THE A QUESTION
JUST AN AFFIRMATION.
>> THANK YOU.
>> I LOVE THE CONCEPT HERE.
MY QUESTION ACTUALLY IS I WORKED
WITH A COUPLE SITES IN A COUPLE
CIRCUMSTANCES TO TRY AND DO A
SIMILAR THING AND SAYING HOW CAN
WE GET RESEARCH IN THE PRIMARY
CARE AND PRACTICES IN CLINICS.
ONE THING I'M NOTICING THAT IS
MISSING THAT HASN'T BEEN
DISCUSSED AS A BARRIER IS HOW
PROVIDERS ARE COMPENSATED FOR
THEIR TIME IN ORDER TO DO THIS.
IT'S A CRITICAL PIECE OFTEN NOT
DISCUSSED.
IN THE CURRENT STRUCTURE WITH
FEE FOR SERVICE MEDICINE THERE'S
NO INCENTIVES TO DO CLINICAL
TRIALS OR RESEARCH.
WITHOUT THAT INCENTIVE OFTEN
TIMES IT'S JUST MORE WORK FOR
THE PHYSICIANS IN RURAL
COMMUNITIES ALREADY BURDENED TO
DO SO I'M WONDERING IF THERE'S A
COMPONENT TO MAYBE ADDRESS OR
BEGIN TO HAVE A CONVERSATION
WITH PROVIDERS ON HOW TO
APPROPRIATELY COMPENSATE THEM
FOR THE RIGHT AMOUNT OF TIME.
>> THAT'S PART OF THE
CONVERSATION AND WE ARE HAVING
NETWORK RESEARCH HUBS AWARDING
FUNDING TO IN ORDER TO
PARTICIPATE IN THE PROGRAM.
AND PART OF IT IS HOW DO WE
PROVIDE THE FINANCIAL RESOURCES
TO THE NETWORKS AND TO THESE
SITES THAT WILL COMPENSATE THEM
FOR THE WORK AND ACTUALLY ALSO
IN SOME OF OUR DESIGNS REDUCE
THE BURDEN SO THE BURDEN FOR
THEM TO CONDUCT RESEARCH IS NOT
SO HIGH.
>> AMY, DID YOU WANT TO COMMENT?
>> IT'S AN EXCELLENT POINT AND
IS A VERY DIFFICULT ONE TO
TACKING.
TRINI TOUCHED ON ADEQUATE
COMPENSATION AND PROVIDING
ADDITIONAL BOOTS ON THE GROUND
SUPPORT TO SOME OF THE
ADMINISTRATIVE TASKS PART AND
PARCEL OF RESEARCH AND THE
CLINICAL CARE TEAMS AND OTHERS
TO KEEP THEIR EYES ON THE
CLINICAL CARE DUTIES AND
MINIMIZING THE BURDEN OF DOING
THAT BY INNOVATIVE TRIAL
DESIGNS, LEVERAGING TECHNOLOGY
THAT'S WORKABLE WITHIN THE
CONTEXT OF THE PRIMARY CARE
SETTING AND MAKING THIS AS
STREAMLINED AND PRACTICAL AS
POSSIBLE AND THAT REQUIRES
WORKING WITH PROVIDERS TO
UNDERSTAND DAY TO DAY OPERATIONS
AND WORK FLOWS.
IT WILL BE A CRITICAL COMPONENT
AND THERE'S ONLY 24 HOURS IN A
DAY SO TIME FROM RESEARCH IS
AWAY FROM CARE DELIVERY AND
THAT'S A SOURCE OF REVENUE.
WE HAVE TO TAKE INTO ACCOUNT THE
COST OF PARTICIPATING IN
RESEARCH FROM THAT PERSPECTIVE.
SO THANKS FOR BRINGING IT UP.
I WANT TO ACKNOWLEDGE I THINK
IT'S A TOUGH NUT TO CRACK BUT
ONE WE HAVE TO CRACK.
WE'LL DO THAT IN PARTNERSHIP
WITH OUR RESEARCH NETWORK AND
PRACTICE COMMUNITIES AND WELCOME
YOUR THOUGHTS IN HOW TO GO ABOUT
THIS?
>> THANK YOU FOR THAT.
KATIE, DID YOU HAVE SOMETHING TO
ASK?
>> YEAH, JUST A QUESTION ALONG
THE SAME LINES OF FUNDING IS ONE
MECHANISM TO HELP ALLEVIATE SOME
ISSUES BUT I ALSO THINK AN
IMPORTANT KEY PART OF SUCCESS
MAY ALSO BE NETWORKING AND
SUPPORT AS PART OF THE RESEARCH
HUB DO THESE PRIMARY CARE
PHYSICIANS OR PEOPLE
PARTICIPATING HAVE ACCESS TO
THAT NETWORK OF SUPPORT TO
CONNECT WITH OTHER COMMUNITIES
PARTICIPATING IN THE SAME
PROGRAMS TO EXCHANGE IDEAS
BEYOND JUST HAVING THE FUNDING
SUPPORT?
>> THERE ARE PRIMARY CARE
RESEARCH ASSOCIATIONS AND THINGS
LIKE THAT THEY'RE CONNECTING
THROUGH.
>> IN BUILDING THE NETWORK OF
NETWORKS WE'RE TRYING TO HABE
ESTABLISH A VERY STRONG
FOUNDATION FOR A LEARNING
COMMUNITY THAT SUPPORTS ONE
ANOTHER AND SO VENE WITH THE
FIRST STUDIES THE NETWORKS THAT
WE'RE FUNDING NOT ALL THEIR
SITES WILL INITIALLY BE
PARTICIPATING IN THEIR STUDIES
BUT WORK WITH OTHER SITES TO
BRING THEM ON BOARD TO BUILD
CAPACITY LEARNING FROM ONE
ANOTHER WE'LL BE BRINGING THE
NETWORK RESEARCH HUBS TOGETHER
TO THEY'RE BEST PRACTICES AND
INNOVATIVE APPROACHES.
WE'RE VERY MUCH TRYING TO CREATE
A SUPPORTIVE COMMUNITY FOR THESE
PRACTI
PRACTICES.
>> YOU SHOULD BE VERY INSENSUAL
ABOUT THAT AND NOT JUST ASSUME
THEY'RE GOING TO NETWORK WITHIN
THEMSELVES AND CREATE A SPACE
AND IN THE MOUNTAIN WEST REGION
WE BROUGHT TOGETHER ASSOCIATIONS
OF FIVE DIFFERENT STATES.
LEARNING BETWEEN THEM WAS OF
GREAT VALUE.
YOU HAVE A CAPTIVE AUDIENCE WITH
FUND
FUNDING YOU HAVE THAT CARROT AND
FORCE THEM INTO THE NETWORKING
AND YOU'LL REAP THE BENEFITS IS
A GREAT COMMENT.
>> ONE THING WE'LL BE ASKING
THEM TO DO IS TO WORK TOGETHER
AND CREATE REPORTS THAT WILL BE
FOUNDATIONAL REPORTS THAT AS THE
NETWORK OF NETWORKS WILL BE
AUGMENTED BUT WILL BE SHARED
LESSONS LEARNED AND EXPERIENCES
IN ENGAGING COMMUNITY
ORGANIZATIONS AND PATIENTS AND
ANOTHER WILL BE A TOOL KIT FOR
CAPACITY, READINESS AND HOW CAN
PRACTICES OF PARTICIPATING
RESEARCH AND WORKING ON THAT
TOGETHER AND ALSO HAVING THEIR
OWN SORT OF CASE EXEMPLAR
SPECIFIC ADDITIONS TO THAT
REPORT IS VERY CON SPECIFIC.
OTHER IDEAS ABOUT HOW TO DO THIS
VERY INTENTIONALLY WILL BE
WELCOME.
>> IF THERE ARE NO FURTHER
QUESTIONS, TRINI AND AMY, THANK
YOU SO MUCH FOR COMING AND
TELLING US ABOUT THE EXCITING
GROUNDBREAKING ENDEAVOR AND
CAN'T CAN'T WAIT TO HEAR ABOUT
OUT WHEN IT'S OFF THE GROUND.
>> THANK YOU FOR HAVING US.
>> GREAT.
>> VERY HELPFUL.
>> NEXT WE'LL HEAR ABOUT THE
CANCER MOONSHOT SCHOLARS PROGRAM
AND INTRODUCE OUR THREE
PRESENTERS WE'LL HEAR FROM.
FIRST WE'LL HEAR FROM DR. BAILEY
THE BRANCH DIRECTOR WITH THE NCI
CENTER FOR CANCER HEALTH EQUITY
AND LATER WE'LL HEAR FROM TWO
CANCER MOONSHOT SCHOLARS.
DR. DANG AND DR. McLOUTH.
DR. BAILEY OVERSEES THE CANCER
MOONSHOT SCHOLARS PROGRAM AND
THE RO1 GRANT APPLICATIONS FOR
THE PORTFOLIO BY ENHANCING THE
NUMBER OF APPLICATIONS SUBMITTED
BY EARLY STAGE INVESTIGATORS
FROM DIVERSE BACKGROUNDS AND
WE'LL HEAR MORE ABOUT THE WORK
OF DR. DANG AND DR. McLOUTH
LATER IN THE PRESENTATION.
DR. BAILEY WE'RE EXCITED TO HEAR
FROM YOU.
>> THANK YOU FOR THE KIND
INTRODUCTION AND THE OPPORTUNITY
TO SHARE THE CANCER MOONSHOT
SCHOLARS PROGRAM WITH YOU TODAY.
BEFORE I BEGIN SPEAKING ABOUT
THE CANCER MOON SHOT SCHOLARS
PROGRAM I'D LIKE TO SAY A BIT OF
BACKGROUND INFORMATION ABOUT THE
NCI EQUITY AND INCLUSION PROGRAM
WE HAVE AT NCI.
THIS IS RESPONSIBLE FOR THE MOON
SHOT SCHOLARS PROGRAM AND THE
NCI EQUITY AND INCLUSION PROGRAM
IS COMMITTED TO ENDING
STRUCTURAL RACISM AND SUPPORTS
THE NIH OVER ALL INITIATIVE
CALLED UNITE YOU MAY BE FAMILIAR
WITH.
EQUITY AND INCLUSION ARE NOT
ISSUES THAT EXIST IN ISOLATION
AND TRULY DOES REQUIRE THE
ENGAGE.
OF THE ENTIRE ENTERPRISE TO
ADDRESS IT.
TREMENDOUS PROGRESS HAS BEEN
MADE TO RETALIATE AGAINST CANCER
THANKS TO DECADES OF INVESTMENT
UP CANCER RESEARCH HOWEVER,
THERE ARE GROUPS THAT BEAR
DISPROPORTIONATE BURDEN OF
CANCER IN COMPARISON WITH
OTHERS.
NCI IS COMMITTED TO ADDRESSING
INEQUITY AND BUILD AN INCLUSIVE
COMMUNITY AND INCREASE THE
DIVERSITY OF THE CANCER RESEARCH
WORKFORCE.
WE SEEK TO ADDRESS THE CANCER
DISPARITIES AND ADVANCE HEALTH
EQUITY.
WE HAVE A LEADERSHIP BODY CALLED
THE EQUITY COUNCIL THAT GOVERNS
AND ADVISES THE EIP.
EACH HAD A DIFFERENT GROUP.
THE FIRST IS ADDRESSING RESEARCH
ON CANCER HEALTH DISPARITIES AND
THE SECOND IS TO ENSURE
WORKFORCE DIVERSITY IN THE RO1
POOL SPECIFICALLY.
THE THIRD PROMOTES AN EQUITABLE
AND INCLUSIVE COMMUNITY
INTERNALLY.
THE FOURTH IS REALLY ABOUT DATA
ANALYTICS, TRACKING AND
EVALUATION OF THE ACTIVITIES OF
THE EIP.
AND THEN LASTLY COMMUNITY AND
COMMUNICATION OUTREACH AND
STRATEGIES FOR ALL OF OUR EQUITY
ACTIVITIES.
THE CO-CHAIRS ARE LISTED HERE
ALONG WITH THE MEMBERS OF THE
EQUITY COUNCIL.
I AM THE WORK GROUP CO-CHAIR FOR
WORK GROUP 2.
AND THE CANCER MOONSH SHOT
SCHOLARS PROGRAM WAS BORN FROM
THIS.
THE APPROACHES TO CANCER
RESEARCH FUNDS WAS TO DIVERSE
AND DIVERSIFY IN THE ONLY THE
THOUGHT BUT APPROACH AND AWARE
THE DIVERSE WORKFORCE IS
ESSENTIAL FOR COMPLEX HEALTH
CHALLENGES AND WE UNDERSTAND
MULTIDISCIPLINARY SCIENCE AND
THE ABILITY OF GENERATING
DIVERSE APPROACHES REALLY
SUPPORTS THE ADVANCEMENT OF
RESEARCH.
DESPITE CONTRIBUTIONS OF A
VARIETY OF PROGRAMS AT NIH AND
BEYOND, SEVERAL GROUPS STILL
REMAIN UNDER REPRESENTS IN THE
BIO MEDICAL AND BEHAVIORAL
SCIENCES.
SO THIS PROGRAM WAS DEVELOPED
ALSO AT THE SAME TIME THE CANCER
MOONSHOT 2.0 WAS SHARED WITH THE
PUBLIC.
THE GOAL WAS TO INSPIRE AND
SUPPORT THE NEXT GENERATION OF
DIVERSE, INNOVATE YOU HAVE
CANCER RESEARCHERS.
AND ALSO TO INCREASE THE
DIVERSITY OF CANCER RESEARCH AND
THE CANCER CARE WORKFORCE TO
BETTER RESEMBLE THE COMMUNITIES
WE SEEM TO SUPPORT.
THERE HAVE BEEN SEVERAL NOT ONLY
PUBLIC FORUMS AND PRESS RELEASES
AND MEDIA EVENTS THAT HIGHLIGHT
THE GOAL FOR THE CANCER MOON
SHOT.
AT THE SAME TIME THE NATIONAL
CANCER PLAN WAS LAUNCHED AT NCI
AND DRIVING INNOVATION AND
CANCER RESEARCH AND WITH THE
GOAL OF ENDING CANCER AS WE KNOW
IT.
THE SCHOLARS PROGRAM IS ALIGNED
WITH THE GOALS YOU SEE LISTED
HERE.
THE RFA SUPPORTS THE PRIORITIES
IDENTIFIED BY THE NATIONAL
CANCER PLAN AS WELL AS THE
CANCER MOONSHOT 2.0 EFFORT AND
TO PROMOTE THE SCIENTIFIC
ADVANCES IN CANCER RESEARCH BY
INCREASING THE DIVERSITY OF
THOUGHT AND PERSPECTIVE IN NCI'S
FUNDED PORTFOLIO AND TO SUPPORT
EARLY STAGE INVESTIGATORS OR
THOSE WHO HAVE YET TO ATTAIN
THEIR FIRST RO1.
WE ULTIMATELY WANT TO INCREASE
THE NUMBER OF RO1 INVESTIGATORS
FROM UNDER REPRESENTED GROUPS
THE CANCER RESEARCH.
THE RESEARCH SCOPE ALIGNS WITH
THE NCI MISSION AND YOU CAN SEE
IT'S QUITE BROAD.
IT ENCOMPASSES ALL AREA OF
CANCER RESEARCH INCLUDING
BIOLOGY, PREVENTION, DIAGNOSIS,
AND CONTROL.
IT ENCOMPASSES ALL RESEARCH
DISCIPLINES INCLUDING ALL THOSE
LISTED HERE AND THE SCOPE IS
SIMILAR TO THE PARENT RO1 WITH
THE RESEARCH PROPOSAL INTENDED
TO BE INVESTIGATOR INITIATED.
WE'RE PLEASED TO SHARE THE
SCHOLARS PROGRAM FROM 2023 AND
THE 11 GRANTEES ARE DEPICTED
HERE.
THE RESEARCH PROJECTS SPAN A
VARIETY OF INTERESTS.
THEY'RE ALL LISTED ON THE SLIDE
BUT THE OTHER THING TOO THAT'S
FANTASTIC IS THAT THERE ARE
APPROACHES SPAN THE ENTIRE
CANCER CONTINUUM.
THAT'S ALSO EXCITING.
CREDENTIALS FROM PHYSICIAN
SCIENTISTS TO A VARIETY OF
DISCIPLINES AND ALL VERY
EXCITING SCIENCES I'M SURE
YOU'LL HEAR IN MOMENTS.
THE 2024 AND 2025 COHORTS WILL
BE ANNOUNCED SOON.
THE RESULTS AND RECIPIENTS ARE
RELEASED WITH THE WHITE HOUSE SO
THERE'S COORDINATION BUT BE
ADVISED THEY'RE COMING SOON TO
COMMUNICATION PORTAL NEAR YOU.
LASTLY I'D LIKE TO END WITH
ACKNOWLEDGEMENT AND THANKS.
AN EFFORT LIKE THIS DOES NOT
BEGIN DE NOVO IN SUCH A SHORT
PERIOD OF TIME.
THIS IS AN EFFORT THAT'S BEEN
OVER 20 YEARS IN THE MAKING
WHILE I HAD THE OPPORTUNITY TO
GIVE IT VOICE IT'S BEEN FROM NCI
LEADERSHIP AND SPECIFICALLY
DR. SPRINGFIELD TO DIVERSIFY AND
SUSTAIN A WORKFORCE.
AGAIN, I'D LIKE TO THANK THE
TIMES SQUARE PROGRAM AND THEY
SUPPORT AND QUESTIONS AND THE
MANAGEMENT OF THE AWARDS AFTER
MADE AND THE TEAM.
THIS PROGRAM IS CO-LED BY MYSELF
AND DR. TIFFANY WALLACE JOINING
US TODAY AS WELL THE SUPPORT
TEAM AND OUR COLLABORATORS.
MY CO-CHAIR FOR WORK GROUP 2 AND
THOSE INSTRUMENTAL IN HELPING
WITH THE DATA.
WITH THAT I'M HAPPY TO TAKE ANY
QUESTIONS BEFORE DR. McLOUTH AND
DR. DANG PRESENT.
>> I THINK WE'RE READY TOHEAR
FROM YOUR SCHOLARS.
>> WONDERFUL.
>> I WANT TO MAKE SURE EVERYBODY
CAN HEAR ME.
>> WE CAN HEAR YOU.
>> IT'S A PLEASURE TO BE HERE
AND THANK YOU SO MUCH FOR
INVITING AND HAVING AND
LISTENING TO WHAT WE HAVE TO
OFFER IN TERMS OF OUR RESEARCH
AND PROGRAM.
A QUICK OUTLINE OF MY TALK.
A QUICK BACKGROUND OF ME AS A
P.I. IN LIVER CANCER AND THE
RESEARCH PROJECTS AND THE
FUNDING GRANT AS WELL AS THE
FUTURE PROGRAMS THAT WE'RE
THINKING ABOUT THAT'S GOING TO
BOUNCE OFFER THIS GRANT.
BOUNCE OFF THIS GRANT.
THIS IS A NICE MILESTONE IN
SUMMARY.
MY FAMILY MIGRATED IN 1988 TO
THE PHILIPPINES REFUGEE
PROCESSING CAMP FROM VIETNAM AND
A CHURCH SPONSORED OUR FAMILY
FROM GRAND RAPIDS, MICHIGAN AND
DURING 2001 AND 2000 I WAS
INTRODUCED TO CANCER RESEARCH
FROM THE VANNENDAL INSTITUTE AND
IT WAS THEN I APPRECIATED AND
UNDERSTAND RESEARCH WAS
SOMETHING YOU CAN DO AS A CAREER
OPPOSED TO SOMETHING OF A DREAM.
THEN I LEFT AND MAJORED IN BIO
INFORMATICS AND GRADUATED IN
2006 AND I WAS NOMINATED AND
BECAME A SEE CHANGE CANCER
RESEARCH FELLOW.
A PROGRAM ESTABLISHED BY FORMER
PRESIDENT GEORGE W. BUSH AND
FIRST LADY BARBARA BUSH TO
PROMOTE CANCER RESEARCH AS WELL
AS DECREASE CANCER BURDEN
WORLDWIDE.
I MET AND INTRODUCED TO THE
CONCEPT OF DOING RESEARCH IN A
Ph.D. PROGRAM.
I WENT THERE AND AND DID A
FELLOWSHIP AND USED MY BIO
INFORMATICS AND BENCH RESEARCH
BACKGROUND TO UNDERSTAND COLON
CANCER.
AND A POST-BAC FELLOW WAS THIS
AMAZING EXPERIENCE TO GET ALL
THESE GREAT PEOPLE WHO SHARED
THE SAME VISION.
IT WAS AMAZING.
THAT MADE ME WANT TO DO A Ph.D.
AND I WENT TO PENN STATE AND
THAT WAS ANOTHER EXPERIENCE
WHERE I SAW WHAT IT MEANS TO DO
RESEARCH AND THE IMPACT ON
PATIENT CARE AND WE HAD AN
OPPORTUNITY TO FOLLOW
ONCOLOGISTS AS WELL AS THE
MEDICAL ONCOLOGISTS TO SEE AND
CAME BACK TO THE NCI TO DO A
POSTDOC FELLOWSHIP IN THE
LABORATORY OF HUMAN
CARCINOGENESIS AND HE THOUGHT I
COULD RAN MY OWN LAB AND I
THOUGHT SO TOO AND I WORKED HARD
AND IN 2018 I LANDED A POSITION
AS A TENURE TRACK ASSISTANT
PROFESSOR IN THE DEPARTMENT OF
SURGERY AT THOMAS JEFFERSON.
AT THAT TIME COVID HIT AND OUR
LAB GOT DERAILED A LITTLE BIT
AND THAT'S OKAY AND WE LANDED
THE CANCER MOONSHOT AWARD AND
WORKING ON THAT PROJECT AND
HOPING TO MAKE PROGRESS.
LIVER CANCER OR SPECIFICALLY
HEPA
HEPATIC CARCINOMA MAKES UP ABOUT
90% OF ALL LIVER CANCERS.
IN THE UNITED STATES ABOUT 70%
OF ALL CASES ARE FOUND IN
SOUTHEAST ASIA BUT IN THE UNITED
STATES NOT AS COMMON THOUGH IT'S
INCREASING IN THE NEXT 10 YEARS
PROJECTED TO INCREASE BY 40% DUE
TO THE OBESITY EPIDEMIC.
AND LIVER CANCER OR HCC STARTS
WITH A NORMAL HEALTHY LIVER AND
UNDERLYING LIVER DISEASES OR
CAUSES OF LIVER DISEASE
INCLUDING FROM MOLD ON PEANUTS
OR ALCOHOL AND OBESITY THAT CAN
LEAD TO FATTY LIVER DISEASE AND
INFECTION CAN LEAD TO FATTY
LIVER OR HEPATITIS AND
CIRRHOSIS.
CIRRHOSIS IS END STAGE LIVER
FAILURE THAT CAN LEAD TO HCC.
WHAT'S OF NOTE IS THE MAJORITY
HAVE CIRRHOSIS OR NOT ALL THESE
PATIENTS GET THIS BUT IN FACT
DIE BEFORE THEY GET HCC.
BECAUSE OF THE ETIOLOGIES
ASSOCIATED IT'S A DIFFICULT
TREATMENT OF HCC.
IT'S HARD TO TARGET AND BECAUSE
AND A SMALL NUMBER ARE PRESENTED
EARLY.
THEY'RE MOSTLY CURATIVE.
THE MAJORITY ARE EITHER ADVANCED
STAGE OR TERMINAL TREATMENT.
IMMUNOTHERAPY SEEMS TO BE
BENEFI
BENEFICIAL AND PROTEINS AND THE
HYPOTHESIS IS THERE'S SMALL
THINGS THAT CAN OCCUR THAT WE
DON'T SEE OR OFTEN OBSERVE IN
THE VAST CHANGES OF CANCER
BIOLOGY BUT THEY CAN DRIVE THE
BIG CHANGES AND THAT'S HOW
CANCER CAN PROGRESS.
SO THE CANCER IN THE LAB IS HOW
DO WE IDENTIFY THE SMALL THINGS
OR CHANGES AND HOW DO WE TARGET
TO MAKE AN IMPACT IN DECREASING
TUMOR BURDEN.
AND WE SELECTED THIS GENE
NEGATIVE ELONGATION FACTOR E
THROUGH AN INTEGRATIVE ANALYSIS
LOOKING AT CHAIN COPY
ALTERATIONS IN mRNA IT MUST BE
IMPORTANT TO BE SELECTED AND
IT'S A FWEEN GENE THAT WAS SELE
AND SEEMED TO BE STATISTICALLY
IMPORTANT.
THERE'S A PROTEIN PART OF THE
COMPLEX OF DIFFERENT PROTEINS
THAT REGULATE TRANSCRIPTION SO
IT HELPS RNA GET TRANSCRIBED BUT
MOST IMPORTANTLY IT'S IMPORTANT
FOR PAUSING.
TRANSCRIPTION OCCURS BUT
SOMETIMES PAUSES AND ALLOWS THE
OPEN ACCESSIBLE CHROMATIN AND
ALLOWS STRESS OR STIMULI TO
RELEASE THE PAUSING AND HAVE AN
ACTIVE TRANSCRIPTION.
SO YOU'RE ABLE TO REACT FAST AND
TRAN SCRIBE THE GENES FAST TO
HAVE FAST AND EFFECTIVE RESPONSE
TO THE STRESS.
IN ADDITION THE PROTEINS IS
KNOWN TO BE IMPORTANT IN FORMING
THE COMPLEX TO UNDER GO LIPID
LIPID PHASE SEPARATION.
THIS IS A NEW CONCEPT THAT'S
BLOWN UP IN THE LAST FIVE, 10
YEARS AND LITTLE KNOWN IS CANCER
BIOLOGY FIELD.
A CONCEPT OF DIFFERENT PROTEINS
INTERACTING WITH EACH OTHER AS
WELL AS NUCLEIC ACIDS AND FORM
NICE ROUND ORGANELLES OR
CONDENSATES.
WHEN THEY'RE FORMED LIKE THIS
THEY CAN ESSENTIALLY HAVE
MULTIPLE DIFFERENT WAYS OF
REGULATING TRANSCRIPTION,
PROTEIN INTERACTIONS AND GENE
SIGNALLING PATHWAYS.
THAT CAN HAVE AN EFFECT ON
CANCER BIOLOGY.
SO IF YOU CAN THINK ABOUT IT
LIKE AN OIL DROPLET IN WATER IF
YOU SHAKE THE BOTTLE WITH OIL IT
WILL SEPARATE PUT OVER TIME WILL
COME BACK AND FORM DROPLETS
AGAIN AND SAME CONCEPT BUT
IMAGINE THAT IN A CELL.
AND IN THE LCI AND THE MAJORITY
HPV OR HEPATITIS B INDUCED HCC
IF YOU HAVE HIGH LEVELS OF THIS
PROTEIN OR GENE, EXCUSE ME,
YOU'RE MORE LIKELY TO HAVE A
POORER OUTCOME AND IN TERMS OF
RNA EXPRESSION DURING TUMOR
PROGRESSION OF HGC IN CIRRHOTIC
NODULES THERE'S INCREASED
EXPRESSION MUCH THE GENE.
WE THOUGHT IT WAS IMPORTANT IN
POTENTIALLY DRIVING HCC.
WE'VE SHOWN IS IN A CANCER CELL
PAPER IN 2017 WHEN WE KNOCK THE
GENE DOWN IN ANIMAL AS WELL AS
CELL MODELS WE SEE A SIGNIFICANT
DES DECREASE IN TUMOR BURDEN AND
WHERE MIK IS A GENE
OVEREXPRESSED IN HCC IN OVER 70%
OF CASES.
WE FOUND WHEN YOU HAVE AN MIC
ONLY GENE YOU FORM TUMORS BUT
WHEN YOU ADD THIS GENE IT
DOUBLES IT SO A HUGE IMPACT.
WHEN WE LOOK AT THE PATHWAYS WE
SEE IT'S ACTIVATED AND IF
PATIENTS HAVE THIS ACTIVE
SIGNALLING PATHWAY ARE THEY MORE
LIKELY TO DO WORSE.
ACROSS VARIOUS ETIOLOGIES AND
POPULATIONS IF YOU HAVE THE GENE
SIGNATURE OR ACTIVE MYC
SIGNALLING YOU'RE MORE LIKELY TO
HAVE A POORER OUTCOME AND IF YOU
HAVE THE SIGNALLING YOU'RE MORE
LIKELY TO HAVE AN INCREASE IN
TUMOR RECURRENCE.
FOR THE GRANT WE'RE ASKING
WHETHER THE PROTEIN IS IMPORTANT
IN THE OPERATION BECAUSE IT'S
CURRENTLY UNKNOWN AND WHETHER
THE SIGNALLING PATHWAY DRIVEN
THROUGH THE LIQUID-LIQUID SPACE
SEPARATION AND IF SO HOW.
WE COLLABORATED WITH A BIO
PHYSICAL CHEMIST AT BROWN
UNIVERSITY AND WE ASKED HIM
WHETHER THE PROTEIN CAN UNDER GO
LIQUID, LIQUID PHASE SEPARATION
AND THE LITMUS TEST IS ADDING
RNA AND LOOKING TO THE TEST TUBE
TO SEE IF THEY ADD THE DROP LETS
AND THEY WERE ABLE TO REPRODUCE
THIS AND WE FOUND WHEN YOU ADD
RNA THE PROTEIN ITSELF CONFORMS
THIS SEPARATED DROPLETS BUT WHEN
YOU CAN SEE A SIGNIFICANT
REDUCTION.
YOU HAVE MODELS TO TEST THIS IN
VITRO BUT ONE IMPORTANT DATA
POINTS I WANTED TO HIGHLIGHT WAS
THAT WHEN YOU KNOCK DOWN THE
PROTEIN YOU DON'T SEE THE TUMORS
FORM.
WHEN YOU RESCUE THE PROTEIN YOU
SEE THEY FORM TUMORS NICELY.
WHEN YOU INHIBIT TO FORM THE
DROPLETS HERE YOU SEE THE TUMORS
DO NOT FORM AS WELL.
CURRENTLY WHAT WE'RE DOING IS
TESTING AND DEFINING THE
MECHANISM OF HOW THIS WHOLE
PROCESS DRIVES CANCER BIOLOGY
AND REGULATES MIXED SIGNALLING.
AND OUR SECOND PART OF THE
PROJECT IS ASKING HOW WE CAN
UTILIZE THE THINGS WE'VE
DEVELOPED OR UNDERSTAND TO
IMPROVE CANCER BURDEN.
AND ONE OF THE THINGS WE WANTED
TO KNOW WAS WHETHER THERE WAS A
SOMATIC MUTATION DRIVING HIS
CANCER ASSOCIATED PHENOTYPE.
WE DID SOME SEQUENCING ON ABOUT
90 OR SO PATIENT SAMPLES AND
FOUND NOTHING BUT WHAT WE DID
FIND WAS THE SINGLE POLY
NUCLEOTIDE MORPHISM IN HCC
PATIENTS.
IF WE LOOK THE DATA WE FOUND
PATIENTS THAT HAVE THIS MUTATION
ACTUALLY DID BETTER.
THEY HAVE A BETTER AND TRENDED
BETTER IN TERMS OF OVER ALL
SURVIVAL.
THEY ARE HAVE A DETAILS OF THE
MUTATION AND 5% OF SOUTHEAST
ASIANS HAD THE MUTATIONS AND
WE'RE RECRUITING PATIENTS AND
ASIAN HCC PATIENTS WITH HIGH
RISK HCC TO DO A PROSPECTIVE
STUDY TO TEST OR DETERMINE
WHETHER THE PATIENTS WITH THE
SNIP FOLLOW THIS.
I HAVE A CLINICAL TRIALS IN DO
THAT RIGHT NOW.
WHY IS THIS MORE ASSOCIATED WITH
BETTER OUTCOMES?
WE THOUGHT MAYBE WHEN HAVE YOU
THE SNIP THERE'S A SPLICING
EVENT OCCURRING.
WE LOOKED AT THE RNA EXPRESSION
OF THE PATIENTS WE DID HAVE RNA
FOR AND FOUND IF PATIENTS HAD
THE SNIP WE WERE ABLE TO
IDENTIFY THAT THIS MUTATION HAD
DECREASED OF AND BECAUSE IT'S
BLOCKING SPLICING AND CAUSING
THIS AXON TO BE EXCLUDED.
YOU GET THE SECOND ISOFORM HERE.
SO OUR GRADUATE STUDENT IS
FIGURING OUT WHETHER IT'S
MEANINGFUL IN PRODUCING A
PROTEIN AND IF IT DOES IS IT
EXPRESSING THE WILD TYPE.
WHAT'S DRIVING THE AIM OR STUDY
IS WHETHER WE CAN IDENTIFY A
SPECIFIC TARGET OR THERAPY THAT
CAN PHENOTYPE OR PHENOCOPY THE
SNIP.
ONE WAY WAS USING THESE OLIGO
NUCLEOTIDES RNA SEQUENCES 25
LONG BINDING TO THE PRE mRNA AND
IT'S BEEN USED IN CLINICAL
TRIALS AND THEY'VE BEEN
ESTABLISHED IN CLINICAL TRIALS
FOR TREATMENTS OF DIFFERENT
DISEASES JUST NOT IN HCC.
WE CAN SHOW THE ASOs WORK AND
MAKE IT SKIP TRANSCRIPTION AND
THEN GENERATE THE SECOND
ISOFORM.
WE PUT THIS IN ACC CELL LINES
AND I'M ONLY SHOWING TWO HERE
AND CAN SEE THERE'S A
SIGNIFICANT REDUCTION IN CELL
GROWTH.
THIS WAS REALLY PROMISING AND
DID A PILOT PROJECT WHERE WE
INJECT TUMOR CELLS TO NON SNP
MICE AND TREAT THE ASO AND
WITHIN FOUR WEEKS POST INJECTION
WE WERE SEEING A SIGNIFICANT
DIFFERENCE BETWEEN THE MICE
TREATED WITH ASOs COMPARED TO
NON-TREATMENT.
THIS IS IN COLLABORATION WITH
THE DEPARTMENT OF RADIOLOGY AT
TJU.
WE WANTED TO FOCUS ON HOW TO
REALLY TARGET THE TUMOR BECAUSE
IT'S IMPORTANT IN TRANSCRIPTION.
IF YOU WERE TO DELIVER THIS, IT
WOULD PROBABLY GO WHERE EVER AND
WANTED TO LOOK AT THE MICRO
BUBBLES TO DIRECT THE DRUG TO
ONLY THE TUMORS.
AND THE GAS MICRO BUBBLES ARE
REALLY SMALL.
THEY'RE VERY POSITIVELY CHARGED
AND SO WE CAN LOAD OUR ASO
NEGATIVELY CHARGED ON THIS AND
ESSENTIALLY DELIVER IT INTO THE
LIVER.
YOU SEE THE TUMOR AND THE LIVER
AND THE WITH THE MICRO BUBBLES
WE GO MICRO INJECTION AND POP
THE BUBBLES AND SEE THE BUBBLES
BURSTING AND THEY'RE BROKEN HERE
WHERE THE TUMORS ARE.
THEN YOU HAVE A REFER FUSION AND
WE'LL HAVE MULTIPLE PULSIONS AND
EXPECT TO SEE THE ASOs GET
DELIVERED IN THE TUMOR REGIONS
AND WE'RE DOING STUDIES TO
UNDERSTAND HOW NELFE UNDER GOES
THIS SEPARATION AND DRIVES THE
CHROMATIN IN THE CANCER AND HOW
SNP CAN BE A TUMOR SUPPRESSIVE
TYPE AND LOOKING AT MODELS TO
TEST OUR ASOs TO LOOK FOR AN
IMPROVEMENT IN THERAPY.
WE HAVE A CLINICAL TRIAL OR ON
PANCREATIC CANCER.
WE'RE HOPING TO BE ABLE TO HOP
ON THAT BANDWAGON AND SEE IF IT
WILL MAKE A DIFFERENCE.
IT'S A LONG WAY BUT THERE'S A
PATH ALREADY FOR US.
IN ADDITION WE'RE WORKING WITH
OUR HTC GROUP HERE OUR TUMOR
BOARD AND I GO TO THOSE AND TALK
TO THE CLINICAL ONCOLOGISTS AS
WELL AS THE HEPATOLOGISTS TO SEE
IF THEY HAVE MUTATIONS AND THE
FUTURE IS CAN WE TARGET THESE IN
PANCREATIC CANCER AND THIS WORK
HAS STARTED BY A SMART GRADUATE
STUDENT AND HAVE PRELIMINARY
DATA AND WE'RE TRYING HARD TO
EXPAND THAT INTO MAKING THAT A
PRECLINICAL STUDY ON ORGANOIDS
IN PANCREATIC CANCER TO HELP THE
PATIENT BURDEN.
THE WORK ISN'T DONE ALONE.
THEY'RE BY OUR GRAD STUDENTS AND
TECHNICIANS AND POSTDOC FELLOWS
AND THOSE YOU SEE HERE.
AND OF COURSE OUR COLLABORATE
ERS AND IT'S NOT POSSIBLE WOULD
THE MOONSHOT AWARD.
AND WITH THAT I'LL TAKE ANY
QUESTIONS AND THANK YOU VERY
MUCH FOR YOUR TIME.
>> IN THE INTEREST OF TIME WE'RE
GOING TO HOLD QUESTIONS UNTIL
THE END TO MAKE SURE DR. YOUNG
HAS A CHANCE BECAUSE THEY'LL BE
COMING FROM THE WHITE HOUSE.
I INVITE DR. McLOUTH TO SHARE
AND IF WE CAN WRAP UP, SORRY TO
SAY BY ABOUT 2:20 WE'LL HAVE
TIME FOR A FEW QUESTIONS BEFORE
WE NEED TO MOVE ON.
THANK YOU SO MUCH.
>> I THINK I CAN GET US THERE.
I'M DR. McLOUTH AN ASSISTANT
PROFESSOR AT THE UNIVERSITY OF
KENTUCKY AND HAPPY TO SHARE MY
SCHOLAR'S PROGRAM.
I'M GOING TO SHARE ABOUT MY
PROFESSIONAL BACKGROUND AND TALK
ABOUT THE PROGRAM.
I'M A CLINICAL PSYCHOLOGIST BY
TRAINING AND DESIGNING AND
TESTING INTERVENTIONS FOR
PATIENTS AND FAMILIES AND
PROVIDERS TO TRY TO HELP
PATIENTS AND FAMILIES FROM THE
POINT OF DIAGNOSIS TO END OF
LIFE.
MY RESEARCH FALLS INTO THREE
BUCKETS.
THE FIRST IS SURVIVORSHIP AND
SUPPORTIVE ONCOLOGY.
THIS IS AN AREA WHERE I'M TRYING
TO UNDERSTAND HOW TO INTERVENE
ON QUALITY OF LIFE FOR PATIENTS
AND FAMILY MEMBERS.
THE SECOND IS ABOUT CANCER CARE
DELIVERY.
TRYING TO UNDERSTAND WHAT TO DO
TO IMPROVE CANCER CARE AND
LEVERAGE INFRASTRUCTURE TO TRY
TO IMPROVE PROFESCESSES FOR
PATIENTS AND FAMILIES AND
EQUITY.
AND IT'S ABOUT MAKING SURE
EVERYBODY RECEIVES THE HIGHEST
QUALITY CARE POSSIBLE AND
OUTCOME POSSIBLE.
I HAVE AN EMPHASIS ON ADVANCED
CANCERS AND RURAL COMMUNITIES.
THIS IS A PAPER PEOPLE ESTIMATED
OVER 600,000 PEOPLE IN THE U.S.
LIVING WITH THE DIAGNOSIS OF
ADVANCED LIVER CANCER WHETHER
NEW OR DISEASE THAT HAS
RECURRED.
UNFORTUNATELY, ADVANCED CANCER
DOES BEAR A DISPROPORTIONATE
BURDEN.
KENTUCKY IS A PREDOMINANTLY
RURAL STATE.
PART OF OUR STATE FALLS WITHIN
APPALACHIA AND THERE'S ADVANCED
RATES FOR LUNG CANCER.
TWICE WHAT WE SEE IN THE U.S.
PART OF THIS IS CERTAINLY DRIVEN
BY DISPARITIES IN TOBACCO AND
THERE'S OTHER FACTORS THAT DRIVE
OUTCOMES IN RURAL COMMUNITIES.
NCI HAS A NICE CANCER MAP STORY
RIGHT NOW ON RURAL AND URBAN
CANCER DISPARITY THAT SPEAK TO
WHAT RURAL COMMUNITIES FACE.
PART OF WHY I'M PASSION FLAT
FROM RURAL HEALTH I GREW UP ON A
SMALL WHEAT FARM IN KANSAS,
CALLED CUNNINGHAM.
AND MY FAMILY ARE STILL THERE
AND A LOT OF THE THINGS WE DEALT
WITH ARE THINGS THEY STILL
STRUGGLE WITH DRIVING OVER AN
HOUR FOR HEALTH CARE OR BEING
UNDER INSURED.
OUR COMMUNITY IS ALSO RESILIENT.
THAT'S PART OF WHY I'VE ALWAYS
BEEN INTERESTED IN UNDERSTANDING
PEOPLE'S STRENGTH AND HOW TO
LEVERAGE THEM AND HAVE BEEN
INTERESTED IN STUDYING HOPE.
HOPE IS A TRICKY CONSTRUCT TO
THINK ABOUT AND RESEARCH IT
BECAUSE WE USE IT IN OUR
EVERYDAY LANGUAGE AND MEANS SO
MANY THINGS TO SO MANY PEOPLE.
IF YOU THINK ABOUT WHEN WE NEED
HOPE WE NEED IT WHEN WE DON'T
KNOW AND HOPE FOR SOMETHING
POSITIVE IN THE FUTURE AND IT'S
THREATENED SOMEHOW AND HELPS
WITH OPTIMISM WITH A POSITIVE
EXPECTATION GOOD THINGS WILL
HAPPEN.
A REALLY ROBUST DEFINITION OF
HOPE YOU CAN STUDY IS RICK
SCHNEIDER'S DEFINITION WHERE
IT'S A POSITIVE MOTIVATIONAL
STATE PEOPLE EXPERIENCE WHEN
THEY HAVE GOALS AND HAVE THE
WILL TO WORK TOWARDS THOSE GOALS
AND PERCEIVE THEY HAVE DIFFERENT
WAYS TO WORK TOWARDS THOSE
GOALS.
WHY I'VE BEEN INTERESTED IN THE
IDEA OF HOPE IS THE IDEA OF
PATIENTS WITH ADVANCED DIAGNOSIS
WAS HELPING THEM THINK ABOUT THE
FUTURE THEY ARE CAN SEE THROUGH
THEIR DIAGNOSIS.
HOW CAN WE HELP THEM?
ONE THING I LEARNED WORKING WITH
PEOPLE GOING THROUGH THIS AS
WELL IS THAT AS YOU EXPERIENCE
SETBACKS AND CHALLENGES,
FUNCTIONAL AND PHYSICAL
LIMITATIONS IT'S EITHER A MATTER
OF FINDING A NEW WAY TO GO AFTER
WHAT YOU HAD AND I THINK ALL
THIS IS INTERESTING AND CURRENT
LANDSCAPE AND NOW I KNOW WE HAVE
PEOPLE LIVING LONGER AND PEOPLE
TRYING TO PURSUE A WORK LIFE AND
BALANCE THAT AND MANAGING CANCER
AND A LONGER DISEASE COURSE.
I'VE BEEN STUDYING HOPE SINCE
GRAD SCHOOL AND I DID A SURVEY
STUDY OF PATIENTS UNDERGOING
TREATMENTS FOR LUNG CANCER AND
IDENTIFIED HOPE PREDICTED BETTER
DAILY QUALITY LIFE OF SYMPTOMS
AND TREATMENT SIDE EFFECTS.
ON MY FELLOWSHIP I SURVEYED TO
UNDERSTAND WHAT TYPES OF GOALS
THEY WERE PURSUING AND WERE THEY
ARE INTERESTED IN
S INTERVENTIONS AND HELPED ME
DEVELOP THIS INTERVENTION CALLED
PATHWAYS AND WENT BACK TO
PATIENTS AND PROVIDERS AND
DEFINE THE INTERVENTION AND WHEN
I STARTED MY FACULTY POSITION I
RECEIVED A TWO-YEAR GRANT TO
PILE OAT THE INTERVENTION.
BASICALLY WE GAVE IT 40 PEOPLE
AND LOOKED AT WERE PATIENTS ABLE
TO DO IT AND DID WE SEE CHANGES
WE'D EXPECT IF WE'RE TARGETING
THEM THAT SERVED AS THE EMPHASIS
WHICH IS TESTING THIS FOR
TREATMENT FOR LUNG CANCER.
THE PATHWAY BRIEF AND DID THIS
TO TRY TO REDUCE BURD BURDEN.
THIS HAPPENS WHILE IT'S
DELIVERED BY A NURSE
PRACTITIONER OR NURSE AND THEY
SIT WITH PATIENTS AND GO THROUGH
EXERCISES WITH THEM TRYING
UNDERSTAND WHAT AREAS OF UNDER
-- YOU'RE LIFE ARE MOST
IMPORTANT AND GOALS AND WHAT ARE
POTENTIAL OBSTACLES AND HOW TO
ADDRESS THEM.
PART OF WHAT WE DO IS
FORECASTING.
LOOKING AHEAD TO THE FUTURE AND
WHAT THINGS MIGHT COME UP
RELATED TO YOUR DISEASE OR OTHER
BIG LIFE CHALLENGES YOU MIGHT
EXPERIENCE AND WHAT WOULD YOUR
PLAN BE IF THOSE LAND.
THIS IS ALL SUPPLEMENTED BY WHAT
WE CALL A TOOL KIT WHICH IS A
COMPILATION OF RESOURCES FROM
OUR PSYCHO ONCOLOGY PROGRAM
ABOUT LUNG CANCER SYMPTOM
MANAGEMENT, ADVANCED CARE
PLANNING, CAREGIVER STRESS,
FINANCIAL NAVIGATION AND LOCAL
RESOURCES AVAILABLE TO PEOPLE SO
AS THEY'RE WORKING ON THEIR
GOALS AND EXPERIENCE DIFFERENT
REFLECTION THEY HAVE DIFFERENT
RESOURCES TO LOOK TO.
MY MOON SHOT SCHOLARS GRANT WILL
ANSWER THREE QUESTIONS.
DOES THE INTERVENTION WORK.
THE PRIMARY OUTCOME WE'RE
INTERESTED IN IS REDUCTION IN
DEPRESSION SYMPTOMS.
THE OTHER TWO THINGS WE'RE
INTERESTED IN ARE REALLY
UNDERSTANDING WHY THIS
INTERVENTION WORKS.
I THINK THIS INTERVENTION, IF IT
DOES HAVE THE EFFECTS WE EXPECT
IT'S PARTLY BECAUSE HOW MUCH
CANCER FALLS IN THE WAY OF THEIR
GOALS AND HELPING PEOPLE AT
ADJUSTING THE GOALS AND PIVOTING
WHEN ROAD BLOCKS OCCUR.
THE FINAL AIM I HAVE IS ABOUT
EQUITY.
SO WE HAVE DONE A PRETTY POOR
JOB IN PSYCHOSOCIAL INTERVENTION
RESEARCH IN REACHING PEOPLE WHO
ARE OLDER WHO LIVE IN RURAL
AREAS WHO ARE MEN.
THEY ARE NOT MEN NOT PEOPLE
WE'RE OFTEN INCLUDING IN OUR
TRIALS AND THIS IS A POPULATION
VERY UNDER REPRESENTED AND
SEEING IF PEOPLE ARE WILL TO
PARTICIPATE AND BENEFIT FROM THE
INTERVENTION IN THE SUB GROUPS.
WE'RE RANDOMIZING 234 PEOPLE
WITHIN 12 WEEKS OF STARTING
TREATMENT FOR ADVANCED STAGE
LUNG CANCER FOR ENHANCED USUAL
CARE FOR MEET TO LOOK AT THE
TOOL KIT RESOURCE GUIDE OR THE
FULL PATHWAYS INTERVENTION.
WE'RE COLLECTING DATA BEFORE
THEY START THE INTERVENTION,
PART WAY THROUGH IT AND LOOKING
AT DURATION OF EFFECTS AND THEN
TO UNDERSTAND PEOPLE'S
EXPERIENCES, POTENTIAL
CHALLENGES WITH COMPLETING THE
INTERVENTION AND INTERVIEWING
PATIENT TO MAKE SURE PEOPLE'S
EXPERIENCES ARE POSITIVE ACROSS
DIFFERENT POPULATIONS.
THE GRANT WAS AWARDED AT THE END
OF JULY.
WE ENROLLED OUR FIRST PERSON AT
THE END OF NOVEMBER OF LAST
YEAR.
I WAS GETTING READY TO GO ON
MATERNITY LEAVE AND HAD AN
IMPORTANT WRAP UP AND WE
RANDOMIZED PEOPLE AND WE HAVE
76% OF THE PEOPLE WE APPROACH
SAY YES AND HAVE GOOD COMPLETION
RATES FOR OUR SURVEY DATA SO
FAR.
IN TERMS OF THE PROMISE OF THE
INTERVENTION IF THE INTERVENTION
DOES WORK, IT IS A REALLY BRIEF
INTERVENTION.
SO MOST OF OUR PSYCHOSOCIAL
INTERVENTIONS WE DEVELOPED FOR
PATIENTS ARE ABOUT SIX TO EIGHT
SESSIONS.
THEY'RE LIKE AN HOUR LONG,
YOU'RE MEETING WITH A CLINICAL
PSYCHOLOGIST DPIFT OR SOCIAL
WORKER.
THIS IS SOMETHING WE DESIGNED
INTENTIONALLY FOR DISSEMINATION
AND WANTED IT TO BE SOMETHING
THAT A PERSON WHO WASN'T
SPECIFICALLY TRAINED IN
SPECIALTY MENTAL HEALTH CAN
DELIVER AND NURSE PRACTITIONERS
WE THINK COULD INCREASE REACH
AND WE ALSO THINK THAT TESTING
IT AND OUR POPULATION WHICH IS
PREDOMINANTLY RURAL AND
EXPERIENCES PERSISTENT POVERTY
AND CHALLENGES FOR PEOPLE COMING
IN FOR TREATMENT AND IMPROVING
MENTAL HEALTH BUT THIS COULD
TRANSLATE WELL TO SUCCESS IN
OTHER POPULATIONS AS WELL.
AND FINALLY UNDERSTANDING WHY
THIS WORKS OR DOESN'T WITHIN
CERTAIN POPULATIONS WILL HELP US
KNOW WHAT WE CAN DO TO IMPROVE
IT TO MAKE SURE OVER HAS A
CHANCE TO BENEFIT FROM THIS TYPE
OF INTERVENTION.
IN TERMS OF FUTURE DIRECTIONS, I
RECENTLY SURVEYED 60 ADVANCED
CANCER CAREGIVERS.
NOT JUST BREAST, COLORECTAL,
HEAD AND NECK, MELANOMA, BRAIN
AND SURVEYED THEM TO UNDERSTAND
WHAT TYPES OF GOALS THEY WERE
PURSUING AND HOW TREATMENT WAS
IMPACTING THEIR GOALS.
WE HAD CAREGIVERS PURSUING GOALS
AND PERSONAL GOALS RELATED TO
THEIR SOCIAL RELATIONSHIPS AND
ROLES AND TRYING TO MAKE MAJOR
LIFE DECISIONS.
OVER 60% SAID THEIR LOVED ONE'S
CANCER TREATMENT WAS INTERFERING
WITH THEIR PROGRESS ON IMPORTANT
GOALS AND CAREGIVERS WERE
INTERESTED IN AN INTERVENTION TO
HELP SUPPORT THEM AND PURSUING
THESE TYPES OF GOALS AND THOUGHT
THEY WERE IMPORTANT THINGS TO
STAY ENGAGED WITH.
THIS DATA IS SERVING AS
BACKGROUND FOR AN INTERVENTION
ADAPTATION AND I AM HOPING TO
SUBMIT AT THE END OF OCTOBER.
WITH THAT I'M GOING TO STOP.
I WANTED TO SHARE SOME GOALS
PEOPLE HAVE SHARED WITH US
THEY'RE TRYING TO WORK ON.
YOU CAN SEE A MIX OF THINGS
IMPORTANT TO PEOPLE.
I LOVE I GET TO DO THIS
INTERVENTION.
I WANTED TO DEVELOP HOPE AND
INTERVENTION FOR PATIENTS SINCE
GRADUATE SCHOOL AND TO DO
SOMETHING THAT FEELS PATIENT
CENTERED IN THE CANCER MOONSHOT
PROGRAM ALONGSIDE FABULOUS BASIC
SCIENTISTS.
I'M GRATEFUL FOR THE
OPPORTUNITY.
THANK YOU.
>> THANK YOU FOR YOUR
PRESENTATION AND THIS REALLY
INSIGHTFUL WORK.
IT'S VERY THOUGHTFUL HOW YOU
DESIGNED THE INTERVENTION AS
WELL AS THE NEXT PHASE WITH THE
CAREGIVERS.
I THINK THE LAST SLIDE SHOWS HOW
WE KNOW EVERYONE'S CANCER IS
DIFFERENT BUT JUST REALIZING
DIFFERENT CANCER PATIENTS HAVE
DIFFERENT GOALS AND THEY'RE ALL
DIFFERENT AND WHAT THEY NEED.
THANK YOU SO MUCH AND HOW IT'S
RELATED TO DR. DANG'S WORK WHEN
SOMEBODY WITH AN ADVANCED CANCER
WHO NEEDS TO PLUG IN TO HOPE.
BRAVO CANCER MOONSHOT SCHOLAR
PROGRAM MANY FOR SUPPORTING
THESE WONDERFUL YOUNG
INVESTIGATORS.
DO WE HAVE QUESTIONS FROM THE
BOARD?
YES, MARTY.
>> A QUESTION FOR DR. McLOUTH.
AS A PATIENT AND PATIENT
ADVOCATE I REALLY APPRECIATE THE
PANEL WAY OF THE WORK YOU'RE
DOING.
IT HAS THE POTENTIAL TO HELP
PATIENTS AND CAREGIVERS IN HUGE
WAYS THAT IS UNDER SUPPORTED.
WE LIVE IN A HEALTH CARE FORMED
SOCIETY.
IF THE CANCER PATHWAYS
INTERVENTION PROVES TO BE
SOMETHING WE WANT TO STANDARDIZE
OR INSTITUTIONALIZE GIVE ME
THOUGHTS HOW IT MAY BE PAID FOR.
>> THANK YOU FOR THAT QUESTION.
IT'S A REALLY GOOD ONE.
ONE THING I'M GOING FOR THE
CAREGIVER WORK IS CONVENING THE
PARTNER GROUP AND PART OF THE
PEOPLE I'M INVOLVING IN THAT
GROUP ARE PAYERS AND POLICY
MAKERS BECAUSE THAT'S AN AREA I
DON'T UNDERSTAND AND I DO THINK
WE DESIGN IT TO WHERE IT COULD
BE BUILT WITH THE TYPES OF
PROVIDERS WE WERE DELIVERING
THROUGH BUT I ALSO THINK THERE'S
OPPORTUNITIES TO WEAVE HOPE INTO
OTHER INTERACTIONS IN THE HEALTH
CARE SYSTEM WHETHER THERE'S
TRAINING FOR ONCOLOGISTS OR
SEEING THEM AND I DO THINK
EXTENDING BUILDING PARTNERSHIPS
WITH PAYERS IS PROBABLY
SOMETHING I NEED TO INVEST IN.
I WOULD WELCOME IDEAS IN HOW TO
GET STARTED.
>> DO WE HAVE ANY OTHER
QUESTIONS FROM THE BOARD?
>> WITH THAT WE'RE PRACTICALLY
ON TIME.
THANK YOU SO VERY MUCH,
DR. BAILEY, DR. DANG AND
DR. McLOUTH FOR SPENDING TIME
WITH US AND LETTING US KNOW
ABOUT YOUR WORK AND DIVERSIFYING
THE WORKFORCE IT'S SO VERY
IMPORTANT AND WE'RE SO GRATEFUL
TO HAVE HEARD ABOUT YOUR VERY
IMPORTANT WORK.
THANK YOU VERY MUCH.
WITH THAT IT IS TIME FOR A VERY
QUICK BREAK.
SO WE HAVE JUST UNDER 10 MINUTES
WE'LL RECONVENE AT 2:30 A REAL
2:30.
>> WE'RE CALLING THE MEETING
BACK TO ORDER AND NEXT AN UPDATE
ON THE WHITE HOUSE SCIENCE AND
UPDATE DIRECTOR YOUNG AND WE'RE
EXCITED TO HEAR AN UPDATE ON
WHAT'S GOING ON WITH THE CANCER
MOONSHOT 2.0.
THANK YOU FOR BEING WITH US.
>> AMAZING.
I JOKE THOUGH I WORK FOR THE
WHITE HOUSE OF OFFICE OF SCIENCE
AND TECHNOLOGY IT'S ALWAYS
TECHNOLOGY THAT TRIPS US UP OVER
HERE AND IT'S A PRIVILEGE TO BE
ABLE TO BE HERE WITH YOU TODAY
AND TO PROVIDE AN UPDATE ON THE
CANCER MOONSHOT.
I KNOW MANY OF YOU HAVE
PARTICIPATED IN THIS AND I WAS
LOOKING AT THE FIRST SLIDE THAT
SAID THE 92nd CONVENING OF THIS
AND THANK YOU FOR YOUR EFFORTS
IN SUPPORTING NCI GOING FORWARD.
AS MANY KNOW, THE PRESIDENT
REIGNITED THE CANCER MOONSHOT IN
2022.
THIS IS ONE OF MY FAVORITE
QUOTES FROM HIM.
IT SAYS I COMMITTED TO THIS
FIGHT WHEN I WAS VICE PRESIDENT.
IT'S ONE OF THE REASONS WHY
QUITE FRANKLY I RAN FOR
PRESIDENT.
LET THERE BE NO OUT TO BE NOW
THAT I AM PRESIDENT, THIS IS A
PRESIDENTIAL WHITE HOUSE
PRIORITY, PERIOD.
AND A LITTLE BIT OF BACKGROUND
FROM ME I JOINED THE CANCER
MOONSHOT IN 2022 WHEN IT WAS
REIGNITED AND CAME FROM THE
NON-PROFIT THAT THEN FORMER VICE
PRESIDENT STARTED THE CANCER
MOONSHOT CARRYING THE WORK OF
THE FIRST MOONSHOT IN 2016.
AND THIS WORK HAS BEEN ONGOING
FOR MANY YEARS NOW.
WITH THIS CANCER MOONSHOT
REIGNITION CAME TWO GOALS AND
DOING IT WITH GOVERNMENT AGENCY
PARTNERS AND WITH ALL OF YOU AND
OF THE CANCER COMMUNITY
ALONGSIDE US.
THE TWO GOALS TO REFRESH YOUR
MEMORY IN CASE IT NEEDS
REFRESHING IS TO WHERE HE DEUCE
THE CANCER DEATH RATES IN THE
UNITED STATES BY 50% IN THE NEXT
25 YEARS.
WHEN THINK OF THAT IN TERMS OF
LIVES POSSIBLY SAVED IT'S ABOUT
A MILLION AND IMPROVING THE
EXPERIENCE OF PEOPLE LIVING
THROUGH AND SURVIVING CANCER AND
CAREGIVERS AND THOSE AFFECTED
ONCE ONE INDIVIDUAL RESOURCED A
CANCER DIAGNOSIS.
WE KNOW IT EFFECTS THE ENTIRE
FAMILY AND BEYOND TO END CANCER
AS WE KNOW IT.
THE CANCER MOONSHOT HAS FIVE
SPECIFIC PRIORITY ACTION AREAS.
THESE ARE THE AREAS THAT HELP US
DRIVE AND FOCUS THE WORK AT THE
FROM AGENCY LEVEL AND ALSO
BRINGING COMMUNITY PARTNERS
TOGETHER ALONGSIDE.
AND WHAT I'LL DO IS GO THROUGH
SOME OF THE MAJOR UPDATES ON
EACH OF THESE BUT RUN THROUGH
THESE QUICKLY RIGHT NOW.
THE FIRST IS TO EXPAND ACCESS TO
CANCER SCREENING.
THE SECOND IS TO UNDERSTAND AND
PREVENT TOXIC AND ENVIRONMENTAL
EXPOSURES.
THE THIRD IS TO PREVENT MORE
CANCERS BEFORE THEY START.
THE FOURTH IS TO DRIVE NEW
INNOVATION AND DELIVER THE
LATEST PROGRESS TO PATIENTS AND
COMMUNITIES AND THE FIFTH IS TO
SUPPORT AND CENTER PATIENTS AND
CAREGIVERS.
NOW, WHAT I WANT TO POINT OUT
HERE IS THIS IS A PRETTY
COMPREHENSIVE SET OF ACTION
AREAS AND ALSO IMPORTANTLY THE
ENVIRONMENTAL PART AND THE
CONVENTION PART I WOULD SAY ARE
TWO AREAS THAT HAVE REALLY COME
TO THE FOREFRONT FOR THE CANCER
MOONSHOT REIGNIT-IGNITION.
ON THE GOVERNMENT SIDE IT'S
REALLY IMPORTANT -- I THINK WE
NEEDED SLIDE NUMBER 6.
THANK YOU.
IT'S IMPORTANT TO EXECUTE OUR
WORK BY BRINGING ALL AGENCIES
ALONGSIDE US.
TO DO SO WE ENSURE WE ARE
STUDYING AT THE SAME TABLE, THAT
WE ARE UNDERSTANDING THE WORK
THAT HAS BEEN DONE, THAT IS
BEING UNDERTAKEN AND THAT WILL
BE DONE.
AND BY DOING THIS, BY BRINGING
THESE AGENCIES AND DEPARTMENTS
TOGETHER WE ARE ABLE TO MAKE
SURE THAT FOCUS IS CONTINUED AND
UNIFIED THROUGHOUT THE
GOVERNMENT ITSELF.
THE CANCER CABINET AN IDEA OF
THE PRESIDENT BRINGING PARTNERS
TOGETHER TO DO THIS WORK IS
COMPRISED OF OVER 20 AGENCIES IN
THE GOVERNMENT.
THOUGH WE HAVE THE NATIONAL
CANCER INSTITUTE AS A MAJOR
PLAYER AND PARTNER WITH US IN
THE CANCER MOONSHOT ALONG WITH
OTHER USUAL SUSPECTS LIKE THE
V.A., HHS, CDC, FDA, THERE'S
ALSO A NUMBER THAT ARE KIND OF
THE UNUSUAL SUSPECTS FOR EXAMPLE
NASA, DEPARTMENT OF ENERGY AND
OTHERS THAT SOMETIMES PEOPLE
DON'T ALWAYS ASSOCIATE CANCER
WITH WHEN YOU FIRST THINK ABOUT
IT.
THE REASON WHY WE DO THAT IS
BECAUSE EVERY AGENCY IS GOING TO
BRING WITH THEM THEIR OWN SET OF
TOOLS, RESOURCES AND IDEAS IN
ORDER TO HELP PROVIDER SOLUTIONS
FOR PATIENTS THAT WILL ALLOW US
TO CROSS FROM PREVENTION TO
SURVIVORSHIP.
THAT'S WHY IT'S CRITICAL WE HAVE
THIS VERY UNIFIED AND BROAD SET
OF PARTNERS IN THE
U.S. GOVERNMENT AGENCY.
TO GO TO WHAT YOU MENTIONED
BEFORE IN TERMS OF HIGHLIGHTS
AND ACHIEVEMENTS UNDER EACH
CATEGORIES NOTING THIS IS A
SNAPSHOT BUT NOT EVERYTHING WE
HAVE ACCOMPLISHED SO FAR AND
SOME OF THE BIGGEST PIECES YOU
MAY BE INTERESTED IN.
SO GOING BACK TO FIRST PRIORITY
ACTION, EXPANDING ACCESS TO
CANCER SCREENING.
OF COURSE WHEN THE CANCER
MOONSHOT WAS RE-IGNITED IN 2022
WE WERE COMING TO THE TAIL END
OF THE PANDEMIC OF US ALL BEING
AT HOME AND MOVING ABOUT $10
MILLION SCREENINGS DURING THAT
TIME.
SO IT WAS REALLY IMPERATIVE THIS
BECOME A MAJOR FOCUS AND PUSH AT
THE BEGINNING OF THE CANCER
MOONSHOT.
AND SO WE HAVE RESPONDED IN A
COUPLE OF WAYS THROUGHOUT THE
U.S. GOVERNMENT.
THE FIRST IS THROUGH A $1
MILLION COMMITMENT THROUGH THE
CDC TO EXPAND CANCER SCREENINGS
IN UNDER SERVED COMMUNITIES
THROUGHOUT THE UNITED STATES.
THE SECOND IS THE VETERANS
AFFAIRS HAVE EXPANDED LUNG
CANCER SCREENING AND AT HOME
COLORECTAL SCREENING FOR OVER $1
MILLION VETERANS.
THE THIRD IS NO-COST SCREENING
FOR TENS OF MILLIONS OF
AMERICANS FOR LUNG, COLORECTAL
AND BREAST CANCER.
WHAT WE'RE STARTING TO SEE IS
WE'RE STARTING TO SLOWLY CLOSE
THE GAP WHEN IT COMES TO
SCREENING AND SEE WHAT WE WERE
BEFORE THE PANDEMIC ITSELF AND
MAKE SURE SCREENINGS ARE MADE
ACCESSIBLE TO ALL AMERICANS NOT
JUST THE FEW AROUND THE COUNTRY.
UNDERSTANDING AND PREVENTING
TOXIC AND ENVIRONMENTAL
EXPOSURES IS ONE OF OUR MAJOR
PARTNERS IN THE WORK.
THIS FOCUSES ON PREVENTION AND
ENSURING ALL AMERICANS HAVE
ACCESS TO VERY A CLEAN
ENVIRONMENT WHICH IS SO
IMPORTANT FOR OUR OVER ALL
HEALTH.
A BIG ACHIEVEMENT IS A $3
BILLION INVESTMENT IN CLEANING
UP TOXIC SITES, CONTAMINATED
SITES AROUND THE UNITED STATES.
$20 BILLION TO CLEAN WATER AND
WE KNOW THERE'S BEEN A HUGE
ISSUE IN CLEAN WATER AND WE WANT
TO PROVIDE AMERICANS WITH CHEAP
WATER AND THE FIRST PFAS
STANDARDS AND START TO MAKE SURE
THOSE REGULATIONS ARE IN PLACE.
WE'VE BEEN MOSTLY FOCUSSED ON
SMOKING CESSATION.
IT CAUSES MANY LUNG CANCER
DEATHS AND A PRIORITY FOR THE
ADMINISTRATION AND FOR THE
MOONSHOT WE TACKLE THIS MAJOR
ISSUE.
SO A COUPLE OF THINGS TO
HIGHLIGHT IS THAT HHS HAS
INTRODUCED A FRAMEWORK
SPECIFIC
SPECIFICALLY FOCUSSED ON
ACCELERATING SMOKING CESSATION
FOR AMERICANS AND POPULATIONS
IMPACTED HEAVILY BY SMOKING.
AND THERE'S A COUPLE DIFFERENT
TYPE OF PREVENTION INITIATIVES
AS WELL.
FOR EXAMPLE THE USDA HAS
ACCELERATED RESEARCH ON
NUTRITION AND CHRONIC DISEASES
AND HOW TO PREVENT IT VERSUS
TREAT IT AND THAT LIFESTYLE
PIECE IS VERY IMPORTANT AND THE
NCI HAS PARTNERED WITH PUBLIC
AND PRIVATE ENTITIES TO LAUNCH A
CLINICAL TRIAL METHOD
COLLECTIONS TO IMPROVE
IDENTIFICATION OF AT RISK
POPULATION.
WE KNOW CERVICAL CANCER IS
PREVENTIBLE AND WE BELIEVE IS
IT'S IMPERATIVE WE COME TO GRIPS
WITH THE ABILITY TO SHARE THE
TOOLS AND RESOURCES WE ALREADY
HAVE TO PREVENT CERVICAL CANCER
AND THE HPV VACCINE BEING ONE OF
THEM.
SUPPORTING AND CENTERING
PATIENTS AND FAMILIES IS REALLY
AT THE CORE OF THE CANCER
MOONSHOT.
AND IT IS ALSO BECAUSE OF THE
LEADERSHIP WE'VE BEEN ABLE TO
REALLY ACCOMPLISH MUCH WHEN IT
COMES TO SUPPORTING PATIENTS
GOING FORWARD.
AND MOST OF THE WORK HAS BEEN
FOCUSSED ON PATIENT NAVIGATION.
RECENTLY WITHIN THE PAST FEW
MONTHS STARTING AT THE BEGINNING
OF THE YEAR, HARD TO BELIEVE
WE'RE IN SEPTEMBER ALREADY, THE
CANCER MOONSHOT WITH THE OFFICE
OF THE FIRST LADY HAS BEEN ABLE
TO SECURE MEDICARE COVERAGE FOR
CANCER PATIENT NAVIGATION
SERVICES WHICH NOW COVERS MORE
THAN 150 MILLION AMERICANS AND
PROCURED ABOUT 50 CANCER CENTERS
NOW PROVIDING THESE SERVICES.
WE KNOW WITHOUT A DOUBT PATIENT
NAVIGATION IMPROVES HEALTH
OUTCOMES.
THIS IS A CRITICAL PIECE OF THE
WORK WHEN WE THINK ABOUT THE
PILLAR OF SUPPORTING AND
CENTERING PATIENTS AND THEIR
FAMILIES.
THEN I WANTED TO HIGHLIGHT THE
PACT ACT PASSED MAYBE IN 2022.
THIS IS REALLY HISTORIC
LEGISLATION THAT IS PROVIDING
EXPANDED BENEFITS FOR VETERANS
THAT HAVE BEEN EXPOSED TO TOXIC
SUBSTANCES INCLUDING THOSE
FACING CANCER.
A VERY IMPORTANT COMMUNITY IN
MAKING SURE THE VETERANS RECEIVE
THE CARE THEY DESERVE TO RECEIVE
GIVEN THE SERVICE THEY HAVE
CONTRIBUTED TO THIS COUNTRY.
AND THEN OF COURSE GUIDING
INNOVATION.
SUCH AN IMPORTANT ROLE THE NCI
SPECIFICALLY PLAYED AND A
CRITICAL PARTNER OF OURS IN THE
CANCER MOONSHOT AND YOU HEARD
SOME OF THE SCHOLARS WHICH IS AN
AMAZING PROGRAM THAT HAS BEEN
HIGHLIGHTED TO CREATE THE NEXT
GENERATION OF INNOVATORS AS WELL
WITHIN THE CANCER RESEARCH WORLD
AND WE'VE BEEN SO THRILLED TO
SEE THIS PROGRAM COME TO LIFE.
AND THEN OF COURSE THE THIRD
WITHIN THE INNOVATION IS THE
LAUNCH OF THE NEWEST AGENCY
ARPA-H WHICH REALLY CAME
TOGETHER ON A VERY SECURED AND
BIPARTISAN WAY TO DELIVER THE
PRESIDENT'S VISION OF THE NEW
BIOMEDICAL RESEARCH FUNDING
AGENCY.
AND IT'S HAD AN INITIAL
INVESTMENT OF $4 BILLION TO
DRIVE BREAKTHROUGHS IB HEALTH
AND SPECIFICALLY FOR THAT IN
CANCER.
AND SEE PROGRAMS LAUNCHED BY
ARPA-H INCLUDING THOSE LOOKING
AT NEW mRNA VACCINES FOR CANCER
AND A.I. TOOLS FOR RARE CANCER
MUTATIONS AND RECENTLY A NEW
PRECISION CANCER SURGERY PROGRAM
THAT WAS LAUNCHED IN NEW ORLEANS
A COUPLE WEEKS AGO IN WHICH
ARPA-H HAS CURED ABOUT $150
MILLION GOING TOWARDS THAT.
OF COURSE THE WAY THE CANCER
MOONSHOT ENGAGES AND EXECUTE THE
WORK IS A CRITICAL PART OF HOW
WE THINK OF THE WORK.
WE HAVE TO ENGAGE WITH
COMMUNITIES FROM ALL ANGLES AND
CONSIDER ALL VOICES.
THE FIRST LADY HAS BEEN A HUGE
ADVOCATE IN THE WORK AND HELPED
STEWARD MUCH OF THE PATIENT
SUPPORT WORK GOING FORWARD.
OF COURSE WE ALSO HAVE A DIRECT
LINE TO THE CANCER MOONSHOT
WHERE ANYBODY DOESN'T MATTER WHO
YOU ARE WE'RE NOT A BLACK BOX.
YOU CAN REACH OUT AND PROVIDE
IDEAS FOR POLICIES OR PROJECT OR
COMMITMENTS GOING FORWARD.
WE ALSO PUT OUT MANY CALLS TO
ACTION AND THIS IS REALLY ONE OF
THE WAYS WE GALVANIZE THE PUBLIC
AND PRIVATE SECTOR TOGETHER
AROUND KEY PIECES AND IF YOU
VISIT OUR CANCER MOONSHOT
WEBSITE ON THE WHITE HOUSE
WEBSITE THERE'S A LIST OF
COMMITMENTS THAT ARE FACT SHEETS
THAT CONTAIN COMMITMENTS AROUND
A NUMBER OF DIFFERENT IMPORTANT
AREAS OF CANCER.
WE ALSO ENCOURAGE PUBLIC-PRIVATE
PARTNERSHIPS AND HAVE OVER 100
PLUS FEDERAL ACTIONS SPARK AND
OVER 200 NATIONAL COMMITMENTS
FROM BOTH THE PUBLIC AND PRIVATE
SECTORS.
SO REALLY ENCAPSULATING THE IDEA
OF IT CAN ONLY WORK IF WE'RE ALL
IN THIS TOGETHER.
I WANTED TO MENTION IS THAT A
BIG FOCUS OF THE CANCER MOONSHOT
IN THE LAST YEAR OR SO HAS BEEN
THIS QUESTION ABOUT HOW DO WE
TAKE THE CANCER MOONSHOT GLOBAL.
NOW, WE CERTAINLY BELIEVE THOUGH
THE CANCER MOONSHOT HAS
DOMESTICALLY BEEN A NATIONALLY
FOCUSSED PROGRAM WE BELIEVE
STRONGLY THE MISSION OF THE
CANCER MOONSHOT DESERVES TO BE
BEYOND OUR OWN BORDERS.
SO FOR THE PAST YEAR, YEAR AND A
HALF WE HAVE BEEN INTENTIONAL
ABOUT HOW WE START TO THINK
ABOUT ENGAGING WITH OTHER
COUNTRIES IN CANCER PROBLEMS.
WE'RE ALL IN THIS TOGETHER.
THAT'S TRUE BUT WE CANNOT
DELIVER ON THE PRESIDENT'S GOALS
DOING THIS AS WELL AND WHAT
BETTER AUDIENCE TO ANNOUNCE THIS
AND WE'LL BE ANNOUNCING A
MOONSHOT INITIATIVE TO BRING
TOGETHER THE UNITED STATES,
JAPAN AND INDIA AND COMBAT THIS
IN THE INDO-PACIFIC REGION AND
FOCUSSING ON THE PREVENTIBLE
CANCER THAT WE KNOW HAVE GLOBAL
ELIMINATION GOALS.
WE CAN THINK OF NO BETTER WAY OF
OVERCOME THE CHANCE OF CANCER.
WE ALSO HOSTED FOR THE FIRST
TIME FOR THE DIALOGUE HOSTED IN
NEW DELHI FOR A NEW BILATERAL
RELATIONSHIP BETWEEN THE TWO
COUNTR
COUNTRIES COMMITTED TO DRIVER
-- DRIVE RESEARCH AND THE WHITE
HOUSE HOSTED A WHITE HOUSE
AFRICA CARE FORUM.
WE BROUGHT IN A NUMBER OF
COUNTRIES AT THE MINISTERIAL
LEVEL.
WE TALK ABOUT HOW TO INCLUDE
CANCER AS A NON-COMMUNICABLE
DISEASE ALSO NEGLECTED IN HEALTH
PLANS IN THESE COUNTRIES.
HOW CAN WE HELP SUPPORT THESE
COUNTRIES INCLUDE CANCER AS PART
OF THEIR NATIONAL PLAN AND HAVE
SEEN GREAT WORK COME FROM THAT.
WE ALSO ANNOUNCED $100 MILLION
IN NEW COMMITMENTS FOR AFRICA AT
THAT EVENT AND THAT WAS SPARK
AND CATALYZED IN THE NATIONAL
SPACE AT THE MARGINS OF THE
AFRICAN AMERICAN LEADERS SUMMIT
AND THERE WAS ANNOUNCEMENT OF
$300 MILLION OF NEW COMMITMENTS
TO REDUCE THE BURDEN ON THE
CONTINENT OF AFRICA AS WELL.
I'LL TALK THROUGH THIS ONE.
I DON'T HAVE A SLIDE BUT I DID
WANT TO MENTION THE CANCER
MOONSHOT HAS ALSO -- WE KNOW
THIS IS CHILDHOOD CANCER
AWARENESS MONTH AND IT'S
IMPORTANT TO MAKE SURE TO
CONTINUALLY FOCUS ON CHILDHOOD
CANCER AND TYPICALLY IN THE PAST
WE HAVE HELD FORUMS TO BRING
COMMUNITIES TOGETHER.
THIS YEAR WE TOOK A DIFFERENT
APPROACH AND HAVE HOSTED
FOCUSSED ROUNDTABLES ON PRESSING
ISSUES SO WE CAN REALLY DRIVE
MISSIONS FORWARD TOGETHER IN A
SLIGHTLY DIFFERENT WAY.
I JUST WANTED TO HIGHLIGHT TWO
THINGS WE HAVE DONE FOR
CHILDHOOD CANCER AWARENESS
MONTH.
THE FIRST IS THE CANCER MOONSHOT
AND OSTP CONVENED LEADERS FROM
ACROSS THE GENERIC ONCOLOGY DRUG
SUPPLY CHAIN AND PATIENT
ADVOCATES AND HEALTH CARE
PROVIDERS TO HEAR DIRECTLY FROM
THOSE WORKING ON THE GROUND TO
RESOLVE SUPPLY CHAIN DISRUPTIONS
BECAUSE OF THE DRUG SHORTAGE
MANY CANCER PATIENTS ARE FACING
TO BE ABLE TO GET THE MEDICINES
TO THIS -- THESE PATIENTS AND
SOLUTIONS AROUND THAT AND
FOCUSSED ON PEDIATRIC CANCER.
AND THEN JUST TO FLAG TOMORROW
CANCER MOONSHOT IS HOSTING A
ROUNDTABLE ON STATE ADVOCACY FOR
CHILDHOOD CANCERS.
WE KNOW INCORPORATING PEDIATRIC
CANCER TO MEDICAID POLICIES AND
OTHER LEGISLATION IS REALLY
VITAL AND A MECHANISM THAT WE
CAN PUSH FORWARD TO SUPPORT
THOSE CHILDREN WHO ARE DIAGNOSED
WITH CANCER.
AND SO AT THIS ROUNDTABLE WE'LL
HAVE EXPERTS SUPPORT HOW
STATE-LEVEL ADVOCACY CAN ENSURE
STATE LED PROGRAMS WILL SUPPORT
CHILDREN AND FAMILIES IMPACTED
BY CANCER.
SO WE'RE GOING TO COVER THE
GAMUT ON POLICY RECOMMENDATIONS
AND FUNDING MECHANISMS AND THE
ROLES OF ADVOCACY IN SHAPING
LEGISLATION THAT SUPPORTS
COMPREHENSIVE CARE AND EQUITABLE
ACCESS FOR TREATMENT FOR
PEDIATRIC CANCER PATIENTS AND
THEIR FAMILIES.
AND I THINK MY LAST SLIDE WHICH
ARE PARTING WORDS AND THEN I'LL
LEAVE THE LAST FEW MINUTES FOR
QUESTIONS.
60 YEARS AGO WHEN PRESIDENT
KENNEDY SAID THAT AMERICA CHOSE
TO TWO TO THE MOON NOT BECAUSE
IT WAS EASY BUT BECAUSE IT WAS
HARD AND THE CHALLENGE IS ONE WE
WERE UNWILLING TO POSTPONE AND
PRESIDENT BIDEN MADE IT CLEAR
THIS IS THE NEXT MOONSHOT ENDING
CANCER AS WE KNOW IT AND TO THE
POINT EARLIER THAT IT IS
SOMETHING THAT WE CAN DO
TOGETHER.
AND WE'LL LOOK AT CONVENING THAT
WAS HAD AND ANY FORUMS THAT HAVE
BEEN RECORDED, THEY'RE ALL
AVAILABLE ON OUR CANCER MOONSHOT
WEBSITE A TON OF UPDATES ON
ACHIEVEMENTS WE'VE MADE IN THE
PAST YEAR OR SO.
E-MAIL ME IF YOU HAVE QUESTIONS
OR IDEAS OR PLEASE DO VISIT OUR
WEBSITE AS WELL IN CASE YOU'D
LIKE ANYMORE INFORMATION AND
WITH THAT I WILL COME TO AN END
AND TURN IT OVER TO YOU.
>> THANK YOU TO THE PRESIDENT
AND FIRST LADY FOR THEIR
CONTINUED ONGOING SUPPORT OF
CANCER RESEARCH AND PATIENTS AND
FAMILIES DEALING WITH CANCER.
THE COMMITMENT OF THE AGENCIES
AND RESOURCES TO THIS ENDEAVOR
IS SO HEARTWARMING TO KNOW IT'S
IMPORTANT TO THE PRESIDENT AND
HEARING SOME OF THE THINGS GOING
ON WE THINK CANCER RESEARCH -- I
PERSONALLY SPEAK FOR MYSELF, I
THINK CANCER RESEARCH SHOULD
HAVE NO BOUNDARIES AND THE
WORLDWIDE EFFORTS ARE
ENCOURAGING IN THINKING ABOUT
THE INNOVATION AND HEARING FROM
THE MOONSHOT SCHOLARS WAS A
TREAT AND SO INSPIRING.
AND I CAN'T WAIT TO HEAR MORE
ABOUT ARPA-H WHEN SOME OF THAT
WORK DOES MATURE.
I'LL SEE DOES ANYONE HAVE
QUESTIONS FOR DR. YOUNG?
>> THANK YOU FOR THE UPDATE.
REALLY EXCITING WORK.
I GUESS I HAD A QUESTION LOOKING
TO THE FUTURE I COMMEND
PRESIDENT BIDEN FOR THE WORK
THAT HE'S DONE IN CHAMPIONING
THIS.
AS WE LOOK AHEAD TO AN ELECTION
SEASON AND RECOGNIZING THE WHITE
HOUSE WILL LOOK DIFFERENT IN
SOME REGARD NEXT YEAR IN THE
SUCCESSION PLAN AND MOVING
FORWARD TO ACHIEVE THE GOAL BY
2047 OF THE 50% DECREASE
RECOGNIZING IT'S ONE OF THE
GREAT CHAMPIONS IS THE WHITE
HOUSE.
>> THANK YOU FOR THAT QUESTION.
I'M SURE THIS IS A QUESTION ON
EVERYBODY'S MIND.
I THINK ONE THING TO RECOGNIZE
IS THAT WE HAVE REALLY ENJOYED,
FOR LACK OF A BETTER WORD,
STRONG BIPARTISAN SUPPORT AROUND
CANCER FOR MANY MANY YEARS AND
WE DON'T SEE THAT NECESSARY
CHANGING.
IN TERMS OF WHAT WE HAVE DONE AT
THE CANCER MOONSHOT, THE IDEA OF
WORKING TOGETHER WITH OUR
AGENCIES AS WE HAVE IS TO BE
ABLE TO ENSURE THAT REGARDLESS
OF WHETHER OR NOT THE TEAM AT
THE WHITE HOUSE NO LONGER
EXISTS, THE WORK WILL CONTINUE
AND SO WE HAVE REALLY OVER THE
PAST FEW YEARS MADE A CONCERTED
EFFORT TO MAKE SURE THE GOALS
AND FUNDING LINES ARE THREADED
FOR MANY YEARS FROM THIS POINT
ON AND WORKED CLOSELY WITH
AGENCIES BECAUSE NOW
EVERYBODY -- THE TRAIN IS MOVING
AND IT WILL CONTINUE TO MOVE.
WE'RE EXCITED TO SEE WHAT
HAPPENS EVEN BEYOND THE
BIDEN-HARRIS ADMINISTRATION
BECAUSE WE THOUGH THE WORK WILL
CONTINUE GOING FORWARD AND IT
MAY NOT LOOK EXACTLY THE SAME.
AGAIN, I WISH I HAD A CRYSTAL
BALL TO SHOW YOU WHAT IT MIGHT
LOOK LIKE BUT THE WORK WILL
CONTINUE GOING FORWARD AS WELL.
>> DOES ANYONE ELSE HAVE
QUESTIONS OR COMMENTS?
I GUESS WE CAN'T WAIT TO HEAR
MORE TO SEE HOW THE WORK
CONTINUES AND WHATEVER WAY,
SHAPE OR FORM.
BIGGEST THANKS TO PRESIDENT JEAN
FROM THE FIRST CANCER MOONSHOT
TO WHERE WE ARE NOW AND PLANTING
THE SEED TO BRING US TO THE
FUTURE.
THANK YOU VERY MUCH.
>> THANK YOU TO ALL OF YOU
SITTING IN THE ROOM.
I SEE FAMILIAR FACES AND SO HI
TO ALL OF YOU.
BUT THANK YOU FOR YOUR
DEDICATION TO THIS CAUSE AS WELL
AND LOOKING FORWARD TO SEEING
WHAT COMES OUT OF THIS AS WELL.
THANK YOU FOR YOUR TIME TODAY.
6:
>> MOVING ON.
WE'RE ON TIME.
WE HAVE A COUPLE ITEMS OF
BUSINESS BEFORE WE CAN CONCLUDE
WE NEED TO MOVE ON APPROVAL FOR
THE LAST MEETING THE 92nd
MEETING SUMMARY AND YOU HAVE A
COPY IN YOUR FOLDERS.
I'D LIKE TO CALL FOR A MOTION TO
APPROVE THE MEETING SUMMARY.
ALL IN FAVOR?
ANY OPPOSED?
HEARING NONE OPPOSED WE CARRY
SLY.
AND THE NEXT THING WE NEED TO
VOTE FOR IS FOR OUR 2025 MEETING
DATES.
I BELIEVE WE HAVE A SLIDE.
HERE ARE THE MEETING DATES THAT
ARE SCHEDULED FOR NEXT YEAR,
TUESDAY MARCH 4, 2025, WEDNESDAY
JUNE 18, 2025 AND TUESDAY
SEPTEMBER 16, 2025.
THANK YOU VERY MUCH.
SO TO APPROVE THE MEETING DATES
PLEASE SAY AYE.
ANY OPPOSED?
AND HEARING NONE THESE WILL BE
NEXT DAY YEAR'S MEETING DATES.
SAVE THE DATES IN YOUR CALENDARS
AND INSTRUCTIONS WILL COME OUT
AS WE GET CLOSER.
ANY CONFLICTS YOU HAVE PLEASE
LET OAR KNOW RIGHT AWAY.
DO WE HAVE ANYTHING ELSE, AMY,
WE NEED TO HANDLE?
>> NO.
>> I'LL TURN IT BACK BUT IT'S A
TERRIFIC DISCUSSION ON A VARIETY
OF TOPICS TODAY.
ON PAPER IT LOOKS SHORT BUT I
ALWAYS FEEL LIKE WE COVER SO
MUCH AND BY THE TIME WE FINISH
IT FIELD LIKE WE'VE ACCOMPLISHED
A LOT.
IT'S A PLEASURE TO HAVE YOU AS
PARTNERS AND TALKING ABOUT THE
SCIENCE AND THE WORK IN OUR
PORTFOLIO.
YOU KNOW THE STAFF SITTING
AROUND IN THE ROOM THERE'S WORK
THAT GOES INTO THESE MEETINGS
WITH THE EXTERNAL COMMUNICATION
AND ADVOCATES AND I'M GRATEFUL
TO THEM AS WELL.
>> THANK YOU ALL FOR COMING AND
FOR ALL YOUR QUESTIONS AND FOR
ALL THE DEDICATION AND THE REAL
THOUGHT YOU PUT INTO EVERYTHING.
WE REALLY, REALLY APPRECIATE IT
AND MY FINAL REMINDER IS IT'S
NOT JUST THREE TIMES A YEAR
OPPORTUNITY FOR INTERACTION AND
PLEASE REACH ME ANY TIME AND WE
ALL TALK REGULARLY.
HAPPY TO HEAR FROM YOU AT ANY
TIME.
>> I WAS GOING TO THANK
DR. RATHMELL FOR HANGING OUT
WITH US BECAUSE SHE'S SETTING A
PRECEDENT AND BAR FOR FUTURE
DIRECTORS.
ALSO THANKING THE TEAM AMY
BENSON AS WELL AS THE SUPPORT
STAFF WHO HANDLED THE LOGISTICS
AND COORDINATION.
IT TAKES A VILLAGE TO GET THESE
MEETINGS TOGETHER AND I WANT TO
THANK YOU ALL FOR THE GREAT
DIALOGUE HAD AND THE TIME WE GET
TO SPEND TOGETHER WE LEARN EVERY
TIME WE'RE TOGETHER.
WITH THAT OUR MEETING IS
CONCLUDED AND SAFE TRAVELS HOME
EVERYONE.